Exploring the effects of gestational diabetes on placental membrane derived stem cells

Li-Yun Chen

Ph.D. Thesis
Cell and Tissue Engineering
July 2019

Institute for Science and Technology in Medicine (ISTM)
Keele University
Abstract

The progression of regenerative medicine and advanced cell banking technology provide the hope of using perinatal tissue-derived autologous MSCs for personalised medicine. Mesenchymal stem cells (MSCs) derived from placenta, with the advantages of being non-invasive and having fewer ethical issues, are a promising source for cell therapy. The hyperglycaemic intrauterine environment in pregnancies affected by gestational diabetes mellitus (GDM) alters the development of the placenta and may have impacts on placental MSCs behaviours and functions. Therefore, we aimed to investigate the influence of the GDM on placental MSCs and further explore their therapeutic potential.

Placental MSCs were isolated from amniotic membrane (AMSCs) and chorionic membrane (CMSCs). The biological, functional, and immunological characteristics of healthy- and GDM- AMSCs/CMSCs were examined. Compared with healthy MSCs, the GDM-MSCs displayed some levels of alteration in adipogenic capacities and macrophage immunoregulatory properties while comparable immunophenotypes, osteogenesis, chondrogenesis, and T-cell regulation ability were observed in GDM-MSCs.

As the major adverse consequence of GDM is an increased risk of developing diabetes, these women may benefit from cell therapy for diabetes in the future. We developed a step-wise differentiation approach to generating functional insulin-producing cells through a short-term glucose priming period combined with a 16-day serial stimulation of compounds and growth factors, such as activin A, retinoic acid, EGF, GLP1 across different differentiation stages. This approach successfully generated insulin-producing cells from GDM- and healthy- CMSCs which displayed pancreatic beta-cell properties and functions.
Moreover, with more promising potential of CMSCs in regenerative medicine, DNA microarray was performed to examine their transcriptional profiles. Comprehensive investigation of gene expression by microarray and validation of differences between healthy- and GDM- CMSCs via real-time PCR and functional assays revealed enhanced capacities of GDM-CMSCs in wound healing and cardiogenesis compared to healthy-CMSCs. However, significantly reduced expression in detoxification enzymes belonging to the aldehyde dehydrogenase gene families (ALDH1A1/1A2, ALDH2, ALDH3) accounted for downregulation across several metabolic pathways and oxidative stress dysregulation in GDM-CMSCs.

Taken together, understanding these placental stem cell behaviours provides an insight to developing therapeutic applications of GDM-MSCs and healthy-MSCs for future autologous stem cell therapies.
Contents

ABSTRACT .............................................................................................................I

CONTENTS ....................................................................................................III

FIGURES ........................................................................................................VIII

TABLES ..........................................................................................................IX

ABBREVIATIONS ...........................................................................................X

PUBLICATIONS ...............................................................................................XII

ACKNOWLEDGEMENTS ..................................................................................XIII

CHAPTER 1

INTRODUCTION ...............................................................................................1

1.1 Gestational diabetes mellitus (GDM) .........................................................2

   1.1.1 Clinical manifestation ........................................................................ 2

   1.1.2 Morbidity and mortality for mother and infant ................................. 4

   1.1.3 Gestational diabetes and future risk of diabetes ............................... 5

1.2 Placenta .....................................................................................................9

   1.2.1 Placental structure and function ...................................................... 9

   1.2.2 Anatomy of placental membranes ................................................ 13

   1.2.3 Placental pathology complicated by GDM ..................................... 15

1.3 Mesenchymal stem cells (MSC) ..............................................................18

   1.3.1 Stem cells in birth-associated tissues ........................................... 18

   1.3.2 Characterisation of MSCs in placenta ........................................... 21

   1.3.3 Amnion-derived stem cells ............................................................ 22

   1.3.4 Chorion-derived stem cells ............................................................ 24

   1.3.5 Immunomodulation of amnion-/chorion-derived stem cells .......... 26

1.4 Regenerative medicine ..........................................................................28
1.4.1 Placental membranes in clinical application ................................................................. 28
1.4.2 Placenta-derived MSCs in preclinical/clinical studies ............................................. 29
1.4.3 Banking of neonatal tissues and stem cells ................................................................. 34
1.4.4 MSC therapy in type 2 diabetes ................................................................................. 35

1.5 Introduction to microarray .......................................................................................... 42
1.5.1 Microarray technology ............................................................................................ 42
1.5.2 Applications of microarrays ..................................................................................... 43

1.6 Hypothesis and aims .................................................................................................... 44

CHAPTER 2

MATERIALS AND METHODS ............................................................................................ 46

2.1 Materials ...................................................................................................................... 47

2.2 Placental samples collection ....................................................................................... 51

2.3 Isolation and culture of AMSCs and CMSCs ............................................................... 53

2.4 Cell culture techniques ............................................................................................... 55

2.4.1 Cell passage, cryopreservation, and recovery ........................................................ 55

2.4.2 Morphological observation and measurement ....................................................... 56

2.4.3 Cell counting and doubling time ............................................................................. 57

2.4.4 MTT assay ............................................................................................................... 57

2.4.5 Production of conditioned media ............................................................................ 58

2.5 Flow cytometry ............................................................................................................ 59

2.6 Tri-lineage differentiation and assessment ................................................................... 61

2.6.1 Osteogenesis ........................................................................................................... 61

2.6.2 Adipogenesis ......................................................................................................... 61

2.6.3 Chondrogenesis ..................................................................................................... 62

2.7 RNA extraction and reverse transcription .................................................................... 63

2.8 Real-time polymerase chain reaction (qPCR) ............................................................. 65
2.9 Immunology characterisation ................................................. 70
  2.9.1 Culture and stimulation of Jurkat cells .................................. 70
  2.9.2 Supernatant collection .......................................................... 70
  2.9.3 Culture and stimulation of THP-1 cells .................................... 71
  2.9.4 Co-culture system .................................................................. 71

2.10 Elisa assay .............................................................................. 72
  2.10.1 IL-2, IL-10, TNF-α ............................................................... 72
  2.10.2 Insulin and C-peptide ............................................................ 74

2.11 Live/dead viability assay ........................................................... 77

2.12 Beta-galactosidase senescence assay ......................................... 77

2.13 Immunofluorescence staining .................................................. 78

2.14 Migration assay ...................................................................... 79
  2.14.1 Transwell assay .................................................................... 79
  2.14.2 Wound healing assay ............................................................. 79

2.15 ALDH activity assay ................................................................ 80

2.16 Detection of ROS .................................................................... 81

CHAPTER 3
CHARACTERISATION OF AMSCS/CMSCS FROM GDM AND HEALTHY PREGNANCIES...........83

3.1 Introduction .............................................................................. 84

3.2 Aim ......................................................................................... 86

3.3 Methods .................................................................................. 87

3.4 Results .................................................................................... 89
  3.4.1 Morphological analysis ........................................................... 89
  3.4.2 Cell proliferation and doubling time ......................................... 94
  3.4.3 Cell immunophenotype ........................................................... 97
  3.4.4 Tri-lineage differentiation ....................................................... 99
3.4.5 Effect of conditioned media on Jurkat T cells .......................................................... 107
3.4.6 Co-culture system of CMSCs/AMSCs and macrophage........................................... 110

3.5 Discussion .................................................................................................................. 115
3.6 Summary .................................................................................................................... 123

CHAPTER 4

GENERATION OF INSULIN PRODUCING CELLS FROM HEALTHY-/GDM- AMSCs/CMSCS ...124

4.1 Introduction ................................................................................................................. 125
4.2 Aim .............................................................................................................................. 131
4.3 Methods....................................................................................................................... 132
4.4 Results ......................................................................................................................... 135
  4.4.1 Pluripotent markers expression .............................................................................. 135
  4.4.2 High glucose effect on H-/G- AMSCs/CMSCs ....................................................... 137
  4.4.3 High glucose induces pancreatic lineage markers ................................................ 143
  4.4.4 Stepwise differentiation and IPC morphology ...................................................... 145
  4.4.5 Expression of pancreatic markers expression ....................................................... 148
  4.4.6 Immunofluorescence staining and ELISA ............................................................. 153

4.5 Discussion .................................................................................................................. 160
4.6 Summary .................................................................................................................... 167

CHAPTER 5

MICROARRAY STUDY OF HEALTHY- AND GDM- CMSCS TRANSCRIPTIONAL PROFILE ...168

5.1 Introduction ................................................................................................................. 169
5.2 Aim .............................................................................................................................. 172
5.3 Methods....................................................................................................................... 173
5.4 Results ......................................................................................................................... 177
  5.4.1 Identification of differentially expressed genes ...................................................... 177
  5.4.2 Biological function analysis .................................................................................. 179
5.4.3 Validation of enriched biological functions ................................................................. 186
5.4.4 Canonical pathway analysis ......................................................................................... 194
5.4.5 ALDH expression and function examination ............................................................... 202
5.4.6 ROS and oxidative stress ......................................................................................... 205

5.5 Discussion ..................................................................................................................... 210
5.6 Summary ....................................................................................................................... 215

CHAPTER 6
DISCUSSION, CONCLUSION AND FUTURE WORK ............................................................. 216
6.1 Summative discussion and conclusion ......................................................................... 217
   6.1.1 Human placenta – an attractive source of MSCs ..................................................... 217
   6.1.2 IPC generation – an application of autologous MSCs for diabetes therapy .......... 220
   6.1.3 Microarray – insights of gene profile to functional molecular levels .................. 223

6.2 Future work ................................................................................................................... 228

CHAPTER 7 REFERENCES .................................................................................................. 230
APPENDIX – ETHICAL APPROVAL ................................................................................. 277
**Figures**

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-1</td>
<td>INSULIN SENSITIVITY-SECRETION RELATIONSHIP</td>
<td>8</td>
</tr>
<tr>
<td>1-2</td>
<td>FORMATION OF THE PLACENTA</td>
<td>10</td>
</tr>
<tr>
<td>1-3</td>
<td>SCHEMATIC DRAWING OF THE PLACENTA</td>
<td>12</td>
</tr>
<tr>
<td>1-4</td>
<td>CROSS-SECTION OF PLACENTAL MEMBRANE</td>
<td>14</td>
</tr>
<tr>
<td>1-5</td>
<td>EFFECT OF MATERNAL NUTRIENTS ON FETAL DEVELOPMENT</td>
<td>17</td>
</tr>
<tr>
<td>1-6</td>
<td>STEM CELLS DERIVED FROM PLACENTAL MEMBRANES</td>
<td>23</td>
</tr>
<tr>
<td>1-7</td>
<td>NUMBERS OF CLINICAL TRIALS USING PERINATAL CELLS PER YEAR</td>
<td>34</td>
</tr>
<tr>
<td>1-8</td>
<td>MSC THERAPEUTIC EFFECTS ON TYPE 2 DIABETES</td>
<td>37</td>
</tr>
<tr>
<td>1-9</td>
<td>OVERVIEW OF DNA MICROARRAY</td>
<td>43</td>
</tr>
<tr>
<td>2-1</td>
<td>MSC ISOLATION FROM PLACENTAL MEMBRANES</td>
<td>54</td>
</tr>
<tr>
<td>2-2</td>
<td>CELL MORPHOLOGY ANALYSIS</td>
<td>56</td>
</tr>
<tr>
<td>2-3</td>
<td>FLOW CYTOMETRY TECHNIQUE</td>
<td>60</td>
</tr>
<tr>
<td>2-4</td>
<td>REAL-TIME PCR AMPLIFICATION AND DISSOCIATION CURVE</td>
<td>66</td>
</tr>
<tr>
<td>2-5</td>
<td>ELISA STANDARD CURVES FOR IL-10, TNF-α, AND IL-2</td>
<td>73</td>
</tr>
<tr>
<td>2-6</td>
<td>ELISA STANDARD CURVES FOR INSULIN AND C-PEPTIDE</td>
<td>76</td>
</tr>
<tr>
<td>3-1</td>
<td>SUMMARY OF THE METHODOLOGY IN CHAPTER 3</td>
<td>88</td>
</tr>
<tr>
<td>3-2</td>
<td>OBSERVATION OF CELL MORPHOLOGIES</td>
<td>91</td>
</tr>
<tr>
<td>3-3</td>
<td>CELL LENGTH AND SURFACE AREA ANALYSIS</td>
<td>93</td>
</tr>
<tr>
<td>3-4</td>
<td>GROWTH CURVES AND DOUBLING TIME</td>
<td>95</td>
</tr>
<tr>
<td>3-5</td>
<td>CELL PROLIFERATION ASSESSED BY MTT ASSAY</td>
<td>96</td>
</tr>
<tr>
<td>3-6</td>
<td>IMMUNOPHENOTYPE OF H-/G- AMSCs AND CMSCs</td>
<td>98</td>
</tr>
<tr>
<td>3-7</td>
<td>TRI-LINEAGE DIFFERENTIATION – OSTEOGENESIS, ADIPOGENESIS, CHONDROGENESIS</td>
<td>100</td>
</tr>
<tr>
<td>3-8</td>
<td>OIL-RED-O STAIN AND ELUTION</td>
<td>102</td>
</tr>
<tr>
<td>3-9</td>
<td>BASAL ACTIVITY OF ADIPOGENESIS-REGULATING GENES</td>
<td>103</td>
</tr>
<tr>
<td>3-10</td>
<td>EXAMINATION OF ADIPOGENIC PROGRESSION THROUGH MARKER EXPRESSION</td>
<td>106</td>
</tr>
<tr>
<td>3-11</td>
<td>SUPPRESSION OF T-CELLS PROLIFERATION AND IL-2 SECRETION</td>
<td>109</td>
</tr>
<tr>
<td>3-12</td>
<td>SCHEMATIC REPRESENTATION OF MACROPHAGE POLARISATION</td>
<td>111</td>
</tr>
<tr>
<td>3-13</td>
<td>EXAMINATION OF M1/M2 MARKER EXPRESSION IN THP1</td>
<td>113</td>
</tr>
<tr>
<td>3-14</td>
<td>CYTOKINES RELEASE BY M1/M2 MACROPHAGES</td>
<td>114</td>
</tr>
<tr>
<td>4-1</td>
<td>TIME LINES OF MULTISTEP PROCEDURES FOR IPC DIFFERENTIATION.</td>
<td>127</td>
</tr>
<tr>
<td>4-2</td>
<td>DEFINED TRANSCRIPTION FACTORS FOR PANCREATIC DEVELOPMENT</td>
<td>130</td>
</tr>
<tr>
<td>4-3</td>
<td>SUMMARY OF THE METHODOLOGY IN CHAPTER 4</td>
<td>134</td>
</tr>
<tr>
<td>4-4</td>
<td>PLURIPOTENT MARKER EXPRESSION</td>
<td>136</td>
</tr>
<tr>
<td>4-5</td>
<td>MORPHOLOGICAL CHANGES IN HG CULTURE</td>
<td>138</td>
</tr>
<tr>
<td>4-6</td>
<td>DECREASED CELL VIABILITY IN HG CULTURE</td>
<td>140</td>
</tr>
<tr>
<td>4-7</td>
<td>CELLULAR SENESENCE IN HG CULTURE</td>
<td>142</td>
</tr>
</tbody>
</table>
TABLE 1-1. RECOMMENDED MARKERS FOR PLACENTA-DERIVED MSCS ......................................................... 21
TABLE 1-2. SURFACE MARKERS OF AECs, AMSCs, AND CMSC ................................................................. 25
TABLE 1-3. FACTORS INVOLVED IN IPC DIFFERENTIATION ........................................................................ 39
TABLE 2-1. LIST OF MATERIALS .................................................................................................................. 47
TABLE 2-2. PLACENTA SAMPLE DETAILS .................................................................................................... 52
TABLE 2-3. PRIMER SEQUENCES .................................................................................................................. 68
**Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-ME</td>
<td>2-mercaptoethanol</td>
</tr>
<tr>
<td>ALDH</td>
<td>Aldehyde dehydrogenase</td>
</tr>
<tr>
<td>AMSC</td>
<td>Amniotic mesenchymal stem cell</td>
</tr>
<tr>
<td>AEC</td>
<td>Amniotic epithelial cell</td>
</tr>
<tr>
<td>ADIPOQ</td>
<td>Adiponectin</td>
</tr>
<tr>
<td>AQP1</td>
<td>Aquaporin-1</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>BM-MSC</td>
<td>Bone marrow mesenchymal stem cell</td>
</tr>
<tr>
<td>CCL</td>
<td>Chemokine (C-C motif) ligand</td>
</tr>
<tr>
<td>CELSR1</td>
<td>Cadherin EGF LAG seven-pass G-type receptor 1</td>
</tr>
<tr>
<td>CD</td>
<td>Cluster of differentiation</td>
</tr>
<tr>
<td>CMSC</td>
<td>Chorionic mesenchymal stem cell</td>
</tr>
<tr>
<td>CM</td>
<td>Conditioned media</td>
</tr>
<tr>
<td>CTGF</td>
<td>Connective tissue growth factor</td>
</tr>
<tr>
<td>CXCL</td>
<td>Chemokine (C-X-C motif) ligand</td>
</tr>
<tr>
<td>DAPI</td>
<td>4,6-diamidino-2-phenylindole</td>
</tr>
<tr>
<td>DEAB</td>
<td>N, N-diethylaminobenzaldehyde</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco's Modified Eagle Medium</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethylsulphoxide</td>
</tr>
<tr>
<td>ECM</td>
<td>Extracellular matrix</td>
</tr>
<tr>
<td>EDN1</td>
<td>Endothelin-1</td>
</tr>
<tr>
<td>EGF</td>
<td>Epidermal growth factor</td>
</tr>
<tr>
<td>FGF</td>
<td>Fibroblast growth factor</td>
</tr>
<tr>
<td>FLNB</td>
<td>Filamin B</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Glyceraldehyde 3-phosphate dehydrogenase</td>
</tr>
<tr>
<td>GLUT</td>
<td>Glucose transporter</td>
</tr>
<tr>
<td>GLP-1</td>
<td>Glucagonlike peptide-1</td>
</tr>
<tr>
<td>GSIS</td>
<td>Glucose stimulated insulin secretion</td>
</tr>
<tr>
<td>GDM</td>
<td>Gestational diabetes mellitus</td>
</tr>
<tr>
<td>HBEGF</td>
<td>Heparin Binding EGF like growth factor</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Name</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>HCG</td>
<td>Human chorionic gonadotropin</td>
</tr>
<tr>
<td>HG</td>
<td>High glucose</td>
</tr>
<tr>
<td>HLA</td>
<td>Human leukocyte antigen</td>
</tr>
<tr>
<td>HMOX1</td>
<td>Heme Oxygenase 1</td>
</tr>
<tr>
<td>HPL</td>
<td>Human placental lactogen</td>
</tr>
<tr>
<td>HSC</td>
<td>Haematopoietic stem cell</td>
</tr>
<tr>
<td>IGF</td>
<td>Insulin-like growth factor</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>Interferon gamma</td>
</tr>
<tr>
<td>ISL1</td>
<td>Insulin gene enhancer binding protein-1</td>
</tr>
<tr>
<td>IL</td>
<td>Interleukin</td>
</tr>
<tr>
<td>INS</td>
<td>Insulin</td>
</tr>
<tr>
<td>IPC</td>
<td>Insulin-producing cell</td>
</tr>
<tr>
<td>KGF</td>
<td>Keratinocyte growth factor</td>
</tr>
<tr>
<td>LG</td>
<td>Low glucose</td>
</tr>
<tr>
<td>LPS</td>
<td>Lipopolysaccharide</td>
</tr>
<tr>
<td>MRC1</td>
<td>Mannose receptor C-type 1</td>
</tr>
<tr>
<td>M-CSF</td>
<td>Macrophage colony-stimulating factor</td>
</tr>
<tr>
<td>MSC</td>
<td>Mesenchymal stem cell</td>
</tr>
<tr>
<td>MTT</td>
<td>3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</td>
</tr>
<tr>
<td>NEAA</td>
<td>Non-essential amino acid</td>
</tr>
<tr>
<td>NEUROG3</td>
<td>neurogenin 3</td>
</tr>
<tr>
<td>NKK2.5</td>
<td>NK2 Homeobox 5</td>
</tr>
<tr>
<td>NOG</td>
<td>Noggin</td>
</tr>
<tr>
<td>NQO1</td>
<td>NAD(P)H quinone dehydrogenase 1</td>
</tr>
<tr>
<td>OCT-4</td>
<td>Octamer-binding transcription factor 4</td>
</tr>
<tr>
<td>OGTT</td>
<td>Oral glucose tolerance test</td>
</tr>
<tr>
<td>PAX6</td>
<td>Paired box gene 6</td>
</tr>
<tr>
<td>PDX1</td>
<td>Pancreatic and duodenal homeobox 1</td>
</tr>
<tr>
<td>PDGF</td>
<td>Platelet-derived growth factor</td>
</tr>
<tr>
<td>PPAR-γ</td>
<td>Peroxisome proliferator-activated receptor gamma</td>
</tr>
<tr>
<td>PHA</td>
<td>Phytohaemaglutinin</td>
</tr>
<tr>
<td>PMA</td>
<td>Phorbol 12-myristate 13-acetate</td>
</tr>
<tr>
<td>PDGFA</td>
<td>Platelet derived growth factor receptor alpha</td>
</tr>
<tr>
<td>RASIP1</td>
<td>Ras-interacting protein 1</td>
</tr>
<tr>
<td>RPMI</td>
<td>Roswell Park Memorial Institute medium</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive oxygen species</td>
</tr>
<tr>
<td>RSPO3</td>
<td>R-Spondin 3</td>
</tr>
<tr>
<td>STAT</td>
<td>Signal transducer and activator of transcription</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard error of the mean</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>SOD2</td>
<td>Superoxide dismutase 2</td>
</tr>
<tr>
<td>T2DM</td>
<td>Type 2 diabetes mellitus</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Tumor necrosis factor alpha</td>
</tr>
<tr>
<td>TGF</td>
<td>Transforming growth factor</td>
</tr>
<tr>
<td>TRA</td>
<td>T cell receptor alpha locus</td>
</tr>
<tr>
<td>VEGF</td>
<td>Vascular endothelial growth factor</td>
</tr>
</tbody>
</table>

Publications

Liyun C, Marwan MM, Nicholas RF, and Pensee W. Chorionic and amniotic membrane-derived stem cells have distinct, and gestational diabetes mellitus independent, proliferative, differentiation, and immunomodulatory capacities (Under review, Stem Cell Research)

Liyun C, Nicholas RF, and Pensee W. Insulin secreting cell differentiation of placental chorionic, not amniotic, membrane-derived mesenchymal stem cells from gestational diabetic women (Under review, Journal of Tissue Engineering and Regenerative Medicine)

Liyun C, Chungteng W. Nicholas RF, and Pensee W. Comparative microarray analysis of chorionic stem cells between healthy and gestational diabetes pregnancies identifies genes and regulatory mechanisms associated with regenerative potential (In preparation)
Acknowledgements

I would like to thank my supervisors, Dr. Pensee Wu and Prof. Nicholas Forsyth for their guidance and advice throughout this project and being supportive for every step of me PhD. Their expertise and research experience have helped to keep my project on track. Pensee provided the most wonderful support and help at the early stage of my project as well as my life in the UK. As an overseas student, I am truly grateful for having an amazing supervisor who I can share everything with. Special thanks to Nick for all the helpful and valuable input to my publications and thesis, particularly your tremendous academic support and unending patience when it comes to revising the manuscripts. I would also like to thank my viva examiners, Dr. Vinoj George and Dr. Catriona Kelly, for their very helpful comments and suggestions.

I would like to acknowledge and thank Marwan MM for his contributions to stem cell characterisation experiments and Chung-Teng for his invaluable help with microarray analysis and data interpretation. I would also like to thank Sue for giving me my first human placenta dissection lesson and Jess, who I used to share a short but lovely time together in Pensee’s group, for her help with confocal microscope. Thanks to postdocs and PhDs in Guy Hilton, especially everyone in Nick’s group, it was a pleasure to work with you and you have made every day at work enjoyable.

I would like to express my gratitude to my family who have always supported and believed in me. A great deal of thanks to my parents for encouraging me to pursue a PhD and my sister for always bringing me laughs through the ups and downs of my studies.

Finally, thanks to all of the women who have kindly donated their placentas for this project.
Chapter 1

Introduction
1.1 Gestational diabetes mellitus (GDM)

1.1.1 Clinical manifestation

Pathogenesis

Pregnancy is normally accompanied with progressive insulin resistance beginning at mid-pregnancy and progressing through the third trimester, as the result of maternal hyperglycaemia which is thought to facilitate nutrient flux from the mother to fetus\(^1\). Placental hormones are the major factors that contribute to the disruption of glucose/insulin balance and lead to insulin resistance owing to the fact that insulin resistance rapidly abates following delivery. The secretion of human placental lactogen, human placental growth hormone, oestrogen, and cortisol during pregnancy attenuates the ability of maternal organs that respond to insulin\(^2\). Insulin-desensitising effects along with increased maternal adiposity leading to insulin resistance, the need for maternal insulin is, therefore, increased during pregnancy. Pancreatic beta-cells increase their insulin secretion; however, when insulin secretion is inadequate to compensate for the insulin resistance of pregnancy, the development of gestational diabetes mellitus (GDM) occurs\(^3\).

Diagnosis

GDM is defined as glucose intolerance with onset or first diagnosed during pregnancy, usually beginning at the second trimester\(^4\). The diagnostic thresholds of glucose intolerance for GDM vary from country to country. The criteria recommended by World Health Organization (WHO) are a 75g oral glucose tolerance test (OGTT) with fasting plasma glucose ≥ 5.1 mmol/l, OGTT 1 h ≥ 10.0 mmol/l and OGTT 2 h ≥ 8.5 mmol/l\(^5\). In the UK, the National Institute for Health and Care Excellence (NICE) has published updated guidance...
for the diagnosis of GDM in 2015, involving a fasting plasma glucose concentration above 5.6 mmol/l and 7.8 mmol/l after administration of a 2-hour 75g OGTT⁶. Women with risk factors for GDM, such as obesity, family history of diabetes, glucose intolerance, and past GDM, are provided with OGTT at their first antenatal appointment⁷.

**Prevalence**

The incidence of GDM is increasing worldwide and varies among ethnic groups, which has been reported to be higher among Asian and Hispanic women⁸. The increasing prevalence is positively associated with the growth of advanced maternal age, obesity, and inactivity. Globally, the recently prevalence has increased to approximately 15% compared to the previous 8% in 1998⁹, while in Europe, the prevalence is around 12.6% reported in 2013¹⁰,¹¹. GDM accounts for the majority of pregnancies complicated by diabetes, 87.5%, with the remaining being due to type 1 diabetes (7.5%) and type 2 diabetes (5%)¹². Type 1 diabetes is an autoimmune disease resulting in the destruction of beta-cells and where lifetime insulin replacement is normally required while type 2 diabetes has a pathophysiological similarity with GDM; hyperglycaemia, insufficient insulin production, and insulin resistance¹³. Approximately 3.5% of pregnancy was complicated by GDM in the UK in 2008¹⁴; however, the number is likely to rise with the growing trend in obesity¹⁵. A cohort study published in 2012 measured the frequency of GDM based on various locations, with 2,376 participants in Manchester and 1,671 participants in Belfast indicating that 22.5% and 10.2% of those screened having GDM, respectively¹⁶. A recent report published in 2014 suggested that 7 million women were obese in the UK¹⁷, which is a major risk factor contributing to GDM with a 3 to 5-fold increased likelihood vs. non-obese women¹⁸,¹⁹.

**Treatment**
Diet control and lifestyle modification are generally provided as first-line treatments. Metformin, a common oral hypoglycaemic agent, is also widely prescribed to reduce hyperglycaemia in GDM and T2DM patients. Metformin can exert its function by reducing hepatic glucose production and enhancing insulin sensitivity\textsuperscript{20}. However, some concerns exist regarding the potential adverse effects on fetus due to its ability to pass the placenta have been raised\textsuperscript{21}. Alternatively, insulin therapy has been shown to reverse insulin resistance and improve perinatal outcomes where disadvantages include the need for injection, weight gain, and hypoglycaemia\textsuperscript{22, 23}. The combination of insulin and metformin was proved to have superior glycaemic control and less insulin requirement or weight gain\textsuperscript{24}.

1.1.2 Morbidity and mortality for mother and infant

The risk of antepartum morbidity in women with GDM can be increased when combined with maternal hypertensive disorders, such as gestational hypertension, preeclampsia, and eclampsia\textsuperscript{25, 26}. The biological connection between GDM and hypertension is not fully understood; however, studies have suggested that excessive circulating glucose stimulated intracellular changes in stress signalling pathways and vascular remodelling which might result in the elevated risk of hypertension\textsuperscript{27-29}. It is worth noting that the frequency of stillbirth is higher in GDM than healthy pregnancies, especially when it is complicated by hypertension. Therefore, screening for GDM and careful blood pressure monitoring are important during pregnancy and urinary protein excretion is recommended for GDM women at the second half of gestation\textsuperscript{3}.

Apart from antepartum morbidity, there are many short and long term health concerns rising from GDM pregnancies. Fetuses in GDM pregnancies often have an accelerated growth pattern owing to the maternal hyperglycaemia. When an estimated fetal weight is
in excess of 4000-4500 g, it is considered as macrosomia. Infants with macrosomia have an abnormally low head circumference/abdominal circumference ratio due to the increased adiposity in the body\(^\text{30}\). The excessive growth of fetus also leads to adverse perinatal outcomes, including birth trauma, shoulder dystocia, bone fractures, and nerve palsies. Caesarean section is usually recommended to reduce the risk of birth trauma\(^\text{31}\). Long-term outcomes result from metabolic disorders caused during pregnancy, leaving both mother and infant abnormal glucose tolerance, subsequent obesity, and strong risks for future metabolic syndrome, cardiovascular disease, and diabetes\(^\text{32, 33}\).

1.1.3 Gestational diabetes and future risk of diabetes

**Prevalence**

Although the symptoms of GDM are usually resolved after delivery, GDM is associated with a long-term risk of developing type 2 diabetes mellitus (T2DM) later in life among both mother and their offspring. GDM represents the single largest risk factor for future development of diabetes, where 40-60\% women with a GDM history develop T2DM over subsequent decades and approximately 5-10\% are found to have T2DM immediately after pregnancy\(^\text{34, 35}\). A population-based cohort study of approximately 9,000 women with GDM from 1990 to 2016 in the UK, indicated that women diagnosed with GDM were 20 times more likely to develop T2DM and an over 2.8 times increased incidence of ischemic heart disease later in life\(^\text{36}\). The highest incidence of developing T2DM in women with a previous GDM occurs in the first 5 years after pregnancy\(^\text{37}\). Therefore, postpartum follow-up glucose testing (typically performed 6-12 weeks after delivery) and an annual test are usually encouraged. Moreover, children born from GDM pregnancy have a high tendency of being overweight, obese and displaying abnormal glucose tolerance, resulting in T2DM in their
early adulthood\textsuperscript{38}. Exposure to hyperglycaemia in the uterus has adverse effects on fetal outcomes, from epigenetic modification to physical fetal programming, leading to the development of T2DM\textsuperscript{39}. A study conducted among Caucasian pregnant women, indicated that offspring from GDM women had a higher frequency of impaired glucose tolerance with a prevalence of 11.1\% at 1-4 years and 20.0\% at 5-9 years of age\textsuperscript{40}.

**Implication for the pathogenesis**

The underlying mechanisms of developing T2DM in GDM women have been investigated in various aspects. Physiologically, insulin resistance progresses during pregnancy and the level of insulin resistance almost reach T2DM levels in late pregnancy. Insufficient compensatory insulin secretion by beta-cells in GDM women reveals a deficiency in beta-cell function. The insulin requirement reduces after the delivery and GDM symptoms resolve; however, beta-cell dysfunction remains unsolved. The long-term deterioration of beta-cell function increases the likelihood of T2DM development\textsuperscript{41}. As illustrated in Figure 1-1, insulin secretion is approximately 50\% lower in GDM than healthy pregnancy at 3\textsuperscript{rd} trimester.

At the molecular level; reduced insulin receptors, abnormal localisation of GLUT4 transporters, and impaired glucose transport caused by GDM may have an irreversible impact on insulin sensitivity\textsuperscript{42, 43}. Dysregulation of cytokines, such as increased circulating leptin, inflammatory cytokine tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), and reduced levels of adiponectin all play a role in obesity and the progression to T2DM\textsuperscript{44-46}.

GDM is known for its maternal inheritance transmitting to the next generation a genetic predisposition and permanently impaired glucose homeostasis during fetal growth caused by hyperglycaemic environment. Genetic studies indicated that GDM women carried T2DM
susceptibility genes which were transmitted to their offspring\textsuperscript{47-49}. The increasing interest in epigenetic alternations in fetus where DNA methylation and histone modification of metabolic-associated genes is affected by hyperglycaemia\textsuperscript{50}. Non-genetic evidence has been demonstrated in several \textit{in vivo} models, where, for example, the offspring from diabetic rats were observed to have decreased pancreatic weight, low pancreatic insulin content, and low beta-cell mass\textsuperscript{51,52}. 


The correlation between insulin sensitivity and secretion in GDM and healthy women. Insulin sensitivity index was calculated as the ratio of glucose disposal rate to steady-state plasma insulin concentration. Prehepatic insulin secretion rates were assessed from steady-state plasma insulin and C-peptide concentration. FFM, fat-free mass. Reprinted from Buchanan, 2001\textsuperscript{53}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{insulin_sensitivity_secretion}
\caption{Insulin sensitivity-secretion relationship}
\end{figure}


1.2 Placenta

1.2.1 Placental structure and function

**Placentation**

The development of the placenta begins following on from fertilisation and once the fertilised ovum enters the uterus and becomes blastocyst. Immediately after attachment to the uterine lining, the blastocyst starts to enlarge while cells proliferate and differentiate. The outer layer of the blastocyst (trophoblast) becomes the cytotrophoblast and syncytiotrophoblast which will further develop into the placenta and fetal membranes while the inner cell masses will develop into embryo. The cytotrophoblast is the stem cell source of the placenta, which gives rise to most of the placental cell types while the syncytiotrophoblast is a specialised epithelium, which invades the endometrium (uterine mucosa) and establishes contact with maternal vessels forming a lacunar network. Lacunae is then surrounded by syncytial cells and filled with maternal blood and tissues\(^54,55\) (Figure 1-2). Meanwhile, cytotrophoblastic stem cells penetrate into the syncytiotrophoblast layer and differentiate into the villous cytotrophoblast constituting primary chorionic villi, endovascular cytotrophoblast remodelling maternal spiral arteries, and interstitial cytotrophoblast invading the endometrium and eventually becoming placental-bed giant cells to anchor the growing fetus\(^56,57\).

Primary villi are formed of syncytiotrophoblast underlying cytotrophoblast and following the growth of extraembryonic mesodermal cells to the primary villi core turns them into secondary villi. Secondary villi expand and invade the maternal decidua while soon after vasculogenesis occurs, blood vessels begin to grow, and then differentiate rapidly to form
functional tertiary villi. Maternal and fetal vessels are connected at this stage and the placenta evolves to form a highly branched structure. Fetal and maternal vascularisation is complete by the 17th to 20th day and the thickness and circumference of placenta continues to increase until the fourth month. There is no obvious increase in thickness after the fourth month while circumference usually continues to grow.

![Figure 1-2. Formation of the placenta](image)

(a) Implantation of blastocyst in the endometrium. Apoptotic maternal uterine cells are phagocytised by syncytiotrophoblast cells for proper implantation. (b) Maternal tissue fluid, uterine secretions, and blood from the erosion of the maternal capillaries are forming the lacunae. (c) Formation of primary germ layers and chorionic villi. Reproduced from Pearson Education Inc., publishing as Benjamin Cummings, 2004.
**Structure**

An average term placenta is approximately 22 cm in diameter, 2.5 cm central thickness, and a weight of 400-500 g, with a round disc-like appearance and an inserted umbilical cord\textsuperscript{55}. Figure 1-3 demonstrates the schematic structure of a full-term placenta. The chorionic plate and intervillous space are on the fetal side of placenta which is bathed in maternal blood. Umbilical vessels branch into the chorionic plate and supply the capillaries of chorionic villi forming a highly vascularised central core. Between the chorionic and basal plates is a large cavernous intervillous space, where the villi are in direct contact with maternal blood\textsuperscript{58}. The basal plate is on the maternal side of placenta, composed of fetal trophoblasts and maternal uterine decidua. Maternal arteries penetrate the myometrium (middle layer of the uterine wall) and divide into endometrial spiral arteries, highly coiled within the decidua basalis. The cytotrophoblastic shell is formed on the maternal surface of placenta, attaching firmly to endometrial tissues. A gap in the cytotrophoblast shell allows maternal endometrial arteries to reach the intervillous space and bath the chorionic villi in maternal blood\textsuperscript{59, 60}.

**Function**

Placenta, the interface between maternal and fetus circulation, plays an important role during fetal development by regulating gas exchange, nutrient transport, and waste elimination as well as the secretion of hormones during pregnancy. The fetal lung is filled with fluid in the uterus; therefore, the placenta is responsible for the gas exchange during the entire pregnant period. Oxygen and carbon dioxide can pass through the placenta by passive diffusion\textsuperscript{61}. Nutrient transport is critical for fetal growth and includes, glucose, amino acids, fatty acids, ions, vitamins, and water. Glucose, functioning as the main source of energy, crosses the placenta through passive infusion and several types of glucose transporters. Amino acids and fatty acids are important for fetal proteins, essential fatty
acid, and lipids synthesis which can be transferred to fetus by active transport through various transporter proteins and fatty acid binding proteins. Sodium and chloride are transferred by passive transport while calcium ion, iron, and vitamins are transferred by active carrier-mediated transport\textsuperscript{59,62}.

Figure 1-3. Schematic drawing of the placenta
Transverse section through a placenta illustrating the structure and feto-maternal circulation at term. Reprinted from Moore et al., 2004\textsuperscript{60} and Griffiths et al., 2015\textsuperscript{59}

Besides gas exchange and nutrient transport, another important function of the placenta is endocrine regulation which is involved in mediating placental growth, immune function, and fetal development. The placenta produces steroid hormones – oestrogen, progesterone and several protein hormones. The two major protein hormones secreted by placental trophoblast are human placental lactogen (HPL) and human chorionic gonadotrophin (HCG). The production of HCG peaks at the 10\textsuperscript{th} week of gestation and slowly
decreases until the end of pregnancy, which plays a role in placental angiogenesis, immunotolerance, endometrial receptivity, and embryo implantation\textsuperscript{63}. HPL has both insulin-like and anti-insulin effects, which regulates maternal lipolysis, carbohydrate metabolism, and glucose homeostasis. Through the reduction of maternal insulin sensitivity, HPL promotes maternal body to use fatty acid and induces maternal insulin resistance in order to facilitate the mobilisation of nutrients and glucose for the fetus\textsuperscript{64}. In transgenic mice overexpressing HPL, the proliferation of pancreatic beta-cells showed significantly enhanced leading to an increased in insulin production. The enhanced secretion of HPL during pregnancy is associated with insulin resistance and contributing to the hyperglycaemia and hyperinsulinaemia in the maternal body\textsuperscript{65}. Steroid hormones are produced by ovaries until the 8\textsuperscript{th} week of gestation and the placenta then takes over production of oestrogen and progesterone producing an increasing amount until before labour. Major functions of oestrogen and progesterone include stimulating uterine growth, promoting mammary gland development, preventing uterine contractions, and the onset of labour\textsuperscript{59,65}.

\subsection*{1.2.2 Anatomy of placental membranes}

The placental membrane is a bilayer structure composed of amniotic and chorionic membranes. During placental development, the amnion and chorion fuse early in the second trimester\textsuperscript{66}. The bilayer membrane migrates outwards from the placenta and encloses the amniotic cavity, where the fetus is growing and protected within the amniotic fluid\textsuperscript{67}.

The amnion is an avascular membrane, consisting of an epithelial monolayer, basement membrane, and amniotic mesoderm layer\textsuperscript{68,69} (Figure 1-4). Nutrients and gas diffuse freely
from amniotic fluid and underlining decidua. The epithelial monolayer, also called amniotic epithelium, is a single layer of epithelial cells directly in contact with amniotic fluid and uniformly resting on the basement membrane. The basal membrane is composed of collagens secreted by mesenchymal cells situated beneath the basement membrane in the amniotic mesoderm. Interstitial collagens (type I and III) form parallel bundles for maintaining the mechanical integrity of the amnion. Filamentous connections between interstitial collagens and the epithelial membrane are formed by collagens type V and VI\textsuperscript{69}. Connecting between the amnion and chorion are formed via a spongy layer (intermediate layer) of loosely arranged glycoproteins and collagen fibres, mostly type III collagen\textsuperscript{70}.

The chorion is composed of a chorionic mesoderm and trophoblastic region (Figure 1-4). The former has a similar composition to the amniotic mesoderm, containing collagens and mesenchymal cells; the latter contains extravillous trophoblast cells. In between the chorionic mesoderm and trophoblast region is a basal membrane\textsuperscript{68, 71}.

**Figure 1-4. Cross-section of placental membrane**

(A) Schematic presentation of the amniotic and chorionic membrane structure. (B) Layers of human placental membrane visualised by histology. AE, amniotic epithelium; AM, amniotic mesoderm; CM, chorionic mesoderm; CT, chorionic trophoblast. Reproduced from Baergen et al., 2005\textsuperscript{72} and Parolini et al., 2008\textsuperscript{68}
1.2.3 Placental pathology complicated by GDM

Structure and morphology

The composition of a healthy term placenta is 80-88% water, 10% protein, and 1% fat while diabetic placentas are found to have increased mass, DNA, glycogen, and lipids. The increase of glycogen and fat exceeds the relative amount of placental DNA, suggesting that each placental cell contains a higher level of glycogen and fat than a normal glucose-tolerant placenta. Increased placental weight happens in both GDM women with and without glycaemic control during pregnancy and also shows a positive correlation with fetal weight and fat mass. Two common features of GDM placenta, hyperproliferation and hypervascularisation, lead to an enlarged placental surface and exchange area. Hyperglycaemia in early gestation induces trophoblast proliferation and structure modification. The thickening of the trophoblastic basement membrane results in increased diffusion distances between the maternal and fetal systemic circulations and which may be the consequence of trophoblast hyperproliferation at early gestation. High incidences of abnormal villous development and branching in GDM placenta are observed where the cause and mechanism are still unclear. Low oxygen levels in the diabetic environment are suggested to have a profound influence on the upregulation of proangiogenic factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF)-2 in GDM placenta hence stimulating placental vascularisation. Furthermore, the villous regions are likely to have accumulation of the placental resident macrophages promoting the release of leptin, TNF-α, and interleukins leading to alterations of placental metabolic and endocrine functions.

Nutrient transport
Maternal overweight, obesity, or GDM status all alter maternal circulating levels of glucose, fatty acids/cholesterol, and amino acids to the fetal circulation and ultimately, influence fetal growth and development. Glucose, the principal energy substance for both fetus and placenta, is supplied from the maternal circulation. It is reported that placental explants from GDM pregnancies exhibit 2- to 3-fold higher glucose uptake and a 40-50% reduction in fatty acid oxidation. Increased glucose transporter, GLUT-1, expression and activity affects the amount of glucose transport across the placenta. Some studies indicate that the major mechanism affecting maternal-fetal glucose transport depends on glucose concentration gradient instead of glucose transporter expression. The increased steepness of the glucose concentration gradient results in a higher glucose flux across the placenta. When fetal hyperinsulinaemia happens, glucose gradient will favour a persistently high glucose flux even though maternal blood glucose is under control by GDM treatment. Insulin sensitive glucose transporter, GLUT-4, which promotes glucose utilisation within cells, shows a reduction in activity in GDM women skeletal muscle cells. Since fetal glucose consumption can be modified by maternal glucose concentration, the reduced glucose metabolism in the maternal body and increased uptake of glucose in placenta enhance the risk of excessive glucose transfer to the fetus in GDM pregnancies.

Amino acids are important for the formation of proteins and nucleic acids in the fetus. Most amino acids are transported in both directions between the maternal and fetal circulation. Upregulation of the placental syncytiotrophoblast amino acid transporters has been observed in GDM. These are responsible for alanine, glutamine, and serine transport and are associated with macrosomia. Increased lipid transport has also been noted in GDM pregnancies with the expression of receptors and regulators for fatty acid and cholesterol transport. Maternal lipoprotein transporting fatty acids and cholesterol requires lipoprotein receptors, lipases which are highly expressed in GDM placentas. Moreover,
maternal adipose tissues also play a role in regulating lipid transport and insulin resistance by secreting elevated levels of adipocytokines, such as leptin, adiponectin, and TNF-α⁹⁰.

Studies on the pathophysiology of GDM between maternal and fetus are based on the hypothesis by Pedersen⁹¹ who stated that maternal hyperglycaemia leads to fetal hyperinsulinaemia and increased glucose utilisation, which is responsible for macrosomia and neonatal morbidity. The key features of the hypothesis are showed in Figure 1-5.

Figure 1-5. Effect of maternal nutrients on fetal development
The Pedersen’s hypothesis⁹¹ of hyperglycaemia-hyperinsulinemia has been modified and indicated the contribution of maternal nutrients on fetal growth and development. Reproduced from Clinicalgate (https://clinicalgate.com/).
1.3 Mesenchymal stem cells (MSC)

1.3.1 Stem cells in birth-associated tissues

**Stem cell population**

Mesenchymal stem cells (MSCs) are defined as multipotent cells capable of differentiating into a variety of cell types. Originally, the MSC was referred to solely in respect of mesenchymal cell lineages differentiation ability; however, increasing studies have indicated a trans-differentiation potential in adult tissue-derived MSCs\(^92,93\). MSCs can be isolated from different parts of human placenta, which are thought to have a more primitive property due to their originating from inner cell mass of blastocyst giving them more potential in the three cell germ layer differentiation\(^94\).

Haematopoietic stem cells (HSCs) are involved in haematopoiesis and give rise to many types of blood cells and generate the haematopoietic system. Being a highly vascularised organ mediating fetal-maternal exchanges the placenta and umbilical cord blood contain a large numbers of HSCs\(^95\).

**Umbilical cord and cord blood**

The umbilical cord contains a gelatinous connective tissue used to protect umbilical vessels, which is known as Wharton’s jelly. Several types of progenitor cells can be isolated from different regions of Wharton’s jelly although whether these progenitor populations are equivalent is not yet clear\(^96,97\). Functioning as the connection between the placenta and fetus, when haematopoietic cells and MSCs circulate through the umbilical cord, these cells are likely to migrate and rest in Wharton’s jelly. Migratory perivascular cells may also be
one of the MSC cell types in Wharton's jelly perivascular region\textsuperscript{96, 98}.

Fetal haematopoiesis starts at about 2 weeks after fertilisation in the yolk sac and gradually moves to the liver before moving to the bones and taking place in the bone marrow. Umbilical cord blood is a rich source of HSCs, which are more primitive than bone marrow derived HSCs or their counterparts in peripheral blood. Umbilical cord blood is considered as an effective alternative to bone marrow transplantation\textsuperscript{99}.

**Amniotic fluid**

Fetus is allowed to move freely in amniotic fluid, which acts in a protective and nourishing role during pregnancy. Amniotic fluid starts to appear immediately after the formation of the amniotic cavity and increases in volume through gestation. It contains proteins, carbohydrates, fats, and hormones to support nutrient and waste exchanges. Due to the direct contact with embryonic components, a variety of embryonic cells from three germ layers are present in the amniotic fluid\textsuperscript{100}. Multipotent MSC-like cells have been described within amniotic fluid; however, the characteristics may be various based on gestational ages\textsuperscript{101, 102}.

**Placental membrane**

Soon after the implantation of blastocyst, the inner cells mass (embryoblast) transforms into two distinct layers, epiblast and hypoblast, which is also known as bilaminar embryonic disc. The epiblast constitutes the amniotic epithelium between the outer layer (trophoblast) and embryonic disc. Subsequently, bilaminar embryonic disc develops into three germ layers (ectoderm, mesoderm, and endoderm) and the extraembryonic mesoderm surrounding the amniotic cavity gives rise to amniotic and chorionic mesoderm (Figure 1-
2). Given that the cells constituting amniotic and chorionic membranes are evolved from the embryoblast, it has been suggested that these cells retain a pluripotent phenotype. Studies have shown that these fibroblast-like cells derived from amnion and chorion have MSCs characteristics\textsuperscript{103,104}.

**Decidua and chorionic villi**

The decidua is the maternal part of the placenta, essential for implantation, placenta formation and maintenance of pregnancy. During pregnancy, the placenta undergoes regeneration, differentiation, and shedding while stromal cells in decidua are thought to be responsible for the dynamic remodelling and thus found to have stem cell characteristics\textsuperscript{105,106}. Chorionic villi are composed of syncytiotrophoblast, underlying cytotrophoblast, and a mesenchymal cell-filled central core. Therefore, some studies have successfully isolated MSCs from chorionic villi\textsuperscript{107}. However, extravillous trophoblasts invade into decidual tissue during villi formation. The characterisation of villi-derived MSCs and isolation process need to be further elucidated.
1.3.2 Characterisation of MSCs in placenta

MSCs derived from placenta share common criteria with bone-marrow MSCs and most of the MSCs derived from adult tissues (adipocytes, skin, lung). Most adult organs contain tissue-resident MSCs that contribute to tissue maintenance and repair of trauma, ageing, or disease. Although MSCs phenotypes can be altered due to different MSC niche/microenvironment, some general characteristics have been used to define human MSCs. Placenta-derived MSCs are plastic adherent, form fibroblast colony-forming units, undergo mesenchymal differentiation potential (bone, fat and cartilage), and display an appropriate range of surface antigen expression. Due to the lack of unique markers for the identification of the MSCs, there is an agreed specific panel of surface antigen – cluster of differentiation (CD)-90, CD73, and CD105 concurrent with the absence of CD45, CD34, CD14, and human leukocyte antigen (HLA)-DR (Table 1).

Table 1-1. Recommended markers for placenta-derived MSCs
The signs (+) or (-) indicate the presence or absence of markers respectively.

<table>
<thead>
<tr>
<th>Marker</th>
<th>Description</th>
<th>Expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD90 (+)</td>
<td>Thy-1 cell surface antigen</td>
<td>MSC marker</td>
</tr>
<tr>
<td>CD73 (+)</td>
<td>Ecto-5’-nucleotidase</td>
<td>MSC marker</td>
</tr>
<tr>
<td>CD105 (+)</td>
<td>Endoglin, TGFβ receptor III</td>
<td>MSC marker</td>
</tr>
<tr>
<td>CD45 (-)</td>
<td>Protein tyrosine phosphatase, receptor type, C</td>
<td>Hematopoietic cells</td>
</tr>
<tr>
<td>CD34 (-)</td>
<td>Transmembrane phosphoglycoprotein</td>
<td>Hematopoietic stem cells</td>
</tr>
<tr>
<td>CD14 (-)</td>
<td>Myeloid cell-specific leucine-rich glycoprotein</td>
<td>Monocytes/Macrophages</td>
</tr>
<tr>
<td>HLA-DR</td>
<td>HLA Class II/MHC II receptor</td>
<td>Antigen presenting cells</td>
</tr>
</tbody>
</table>
1.3.3 Amnion-derived stem cells

There are two cell types can be isolated from amniotic membrane – amniotic epithelial cells (AECs) from the innermost layer of the amnion and amniotic mesenchymal stem cells (AMSCs) from mesoderm layer (Figure 1-6). AECs are developed at very early stage of gestation (8 days after fertilisation) and capable of secreting growth factors, such as basic fibroblast growth factor, epidermal growth factor\textsuperscript{110}, keratinocyte growth factor, and hepatocyte growth factor. The epithelial nature of AECs is demonstrated by their ability to undergo epithelisation, their expression of several epithelial markers, and their secretion of growth factors. AECs are also able to regulate angiogenesis, fibroblast activation, and immunosuppression\textsuperscript{111, 112}. Moreover, research has reported stem cell characteristics of AECs, indicated by the expression of stem cell markers and possession of a differentiation ability. Pluripotency of AECs has been suggested following demonstration of pluripotent marker expression and evidence of three germ layers differentiation in mouse models\textsuperscript{113, 114}.

Similarly, AMSCs from the mesoderm layer have MSC characteristics and the capacity to differentiate beyond mesodermal lineages. In addition to skeletal, muscle, and cardiomyocytic differentiation (mesoderm), AMSCs also differentiate into neurogenic lineages\textsuperscript{115} (ectoderm), hepatocytes\textsuperscript{116} (endoderm), and endothelial cells\textsuperscript{117}. Moreover, despite the pluripotent marker expression of AMSCs, including octamer-binding transcription factor 4 (\textit{OCT4}), nanog homeobox (\textit{NANOG}), protein antigens – T cell receptor alpha locus (TRA)-1-60 and TRA-1-81, AMSCs do not display any evidence of teratoma\textsuperscript{114, 115}.

Isolation and separation of AECs and AMSCs can be performed by trypsin digestion. AECs
can be released from the amnion and suspended in trypsin solution while AMSCs need further digestion of the collagen matrix to be isolated from mesoderm layer. Moreover, the cell surface markers are somehow different between AECs and AMSCs, where AECs display epithelial markers which are lacking in AMSCs\textsuperscript{118} (Table 1-2). The yield of AMSCs is approximately 1 million per gram of the placental membrane\textsuperscript{119}.

![Stem cells derived from placental membranes](image.png)

**Figure 1-6. Stem cells derived from placental membranes**

(A) Human placenta and manual separation of amniotic/chorionic membrane (B) Schematic representation of the placental membrane structure and MSCs from different membrane layers. AECs, amniotic epithelial cells; AMSCs, amniotic mesenchymal stem cells, CMSCs, chorionic mesenchymal stem cells.

Reproduced from Tabatabaei et al., 2014\textsuperscript{120}, Parry et al., 1998\textsuperscript{70}, and Humpath (http://www.humpath.com/).
1.3.4 Chorion-derived stem cells.

Chorionic MSCs (CMSCs) are derived from the chorionic mesoderm layer and share common characteristics with AMSCs (Figure 1-6). They both display plastic adherence, a mesodermal differentiation ability, and display MSCs markers (Table 1-2). In an *in vivo* study, CMSCs engrafted in neonatal swine and rats and did not induce a xenogeneic response indicating the immunoprivileged status of CMSCs\textsuperscript{121, 122}. CMSCs can be induced to neuron-like cells that showed comparable or even greater potential than AMSCs\textsuperscript{123, 124}. A studied comparing CMSCs from early and late gestation found similar phenotypes and the expression of pluripotent markers in both stage derived CMSCs. It might indicate the retained pluripotency of CMSCs during gestation but when applying to an *in vivo* skin wound, early gestation-derived CMSCs accelerated the wound repair compared to late gestation-derived CMSCs\textsuperscript{125}. However, the literature on CMSCs is insufficient and limited characterisation of multi-lineage differentiation potential.

In addition, as the outermost layer of highly vascularised placenta lying adjacent to the decidual cells, the chorionic membrane was recently found to contain HSCs which are absent in the amnion. HSCs were observed in chorion at all gestational ages after 5-weeks of pregnancy and HSCs derived from mid-gestation showed superior engraftment potential in an *in vivo* model\textsuperscript{126}. However, if mechanical dissection of decidual tissues is insufficient, cross-contamination with maternal cells, blood cells, and decidual cells may be observed in CMSCs culture\textsuperscript{127}.
Table 1-2. Surface markers of AECs, AMSCs, and CMSC

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AECs</strong></td>
<td>Epithelial and embryonic markers: E-cadherin, CK7, CD49f, EpCAM&lt;br&gt;Mesenchymal and embryonic markers: CD90+, CD105+, CD73+, CD44+, CD166+, CD29+, HLA-A,B,C+/-, CD13+, CD24+, SSEA-3+, SSEA-4+, TRA-1-60+, TRA-1-81+, NANOG+, SOX2+, SSEA-1-, CD117+/-, CD49e-&lt;br&gt;Haematopoietic markers: CD34-, CD45-, CD14-, CD11-, HLA-DR-, CD31-&lt;br&gt;Others: CD324+, CD349-</td>
</tr>
<tr>
<td><strong>AMSCs</strong></td>
<td>Mesenchymal and embryonic markers: CD90+, CD105+, CD73+, CD44+, CD166+, CD29+, HLA-A,B,C+/-, CD13+, CD49d+, CD49e+, CD54+, Oct-3/4+&lt;br&gt;Haematopoietic markers: CD34-, CD45-, CD14-, CD31-, HLA-DR-, CD133-, CD3-&lt;br&gt;Others: CD349+, CD140b+, CD324-</td>
</tr>
<tr>
<td><strong>CMSCs</strong></td>
<td>Mesenchymal and embryonic markers: CD90+, CD105+, CD73+, CD44+, CD166+, CD29+, HLA-A,B,C+/-, CD13+, CD10+, CD49e+, CD54+, SSEA-4-/+&lt;br&gt;NANOG+, SOX+, CD117-&lt;br&gt;Haematopoietic markers: CD34-, CD45-, CD14-, CD31-, HLA-DR-, CD3-, CD133-&lt;br&gt;Others: CD349+, CD140b+, CD324-</td>
</tr>
</tbody>
</table>

surface antigens expressed on AEC, human amniotic epithelial cells; AMSCs, human amniotic mesenchymal stem cells; CMSCs, human chorionic mesenchymal stem cells. Reproduced from Kmiecik et al., 2013124
1.3.5 Immunomodulation of amnion-/chorion- derived stem cells

MSC-modulated immune function can be categorised into immunosuppression and immunoprivilege. The former is defined as the ability to suppress immune cell (T-cells, B-cells, natural killer cells) function, such as proliferation and cytokine secretion while the latter describes that MSCs are able to protect themselves from immunological defence mechanisms.

AECs, AMSCs, and CMSCs lack or present very low expression levels of major histocompatibility complex (MHC) class I antigens (HLA-A, HLA-B, HLA-C) and an absence of MHC class II (HLA-DP, HLA-DQ, and HLA-DR)\textsuperscript{128, 129} in order to avoid immune responses caused by T cells. Hence, placental membrane-derived stem cells (PM-SCs) have the ability to engraft and survive in immunocompetent neonatal swine, rats and rabbits, without a xenogenic response\textsuperscript{122, 130}. In an \textit{in vitro} immune assay of AECs and allogeneic lymphocytes, no cytotoxic responses were observed whereas inhibition of lymphocyte proliferation was observed\textsuperscript{131}. Placental membrane expresses high level of HLA-G, which is important for maternal-fetal tolerance, preventing rejection from the maternal immune system at implantation stage\textsuperscript{132}. One unique characteristics of PM-SCs is the presence of HLA-G\textsuperscript{129, 133} which is mainly expressed in immunoprivileged organs (testis, ovary, and embryonic cells) and shows significantly higher levels in birth-associated MSCs than in adult tissue-derived MSCs\textsuperscript{134, 135}. HLA-G interacts with inhibitory receptors present on all immune cells and exerts its function by inducing apoptosis or arresting immune cells at the G0/G1 phase\textsuperscript{136}. This immunoprivilged status of AECs, AMSCs, and CMSCs may reflect their embryonic origin.

The immunosuppression of placental tissue-derived MSCs involves direct cell-cell contact
and secretory effects. In the presence of PM-SCs, the maturation of monocytes into dendritic cells is suppressed by preventing the expression of CD1a and reducing costimulatory molecules CD40, CD40 ligand, CD80 and CD86 expression for T cell activation\textsuperscript{137}. Without direct contact with PM-SCs in a trans-membrane co-culture system, PM-SCs are able to secrete soluble inhibitors to regulate immune cells\textsuperscript{138} as well as the increased amount of prostaglandin 2 suppressing T cells proliferation\textsuperscript{139}. PM-SCs also secrete cytokines involved in angiogenesis, tissue repair or immune modulation, including VEGF, interleukin (IL)-6, IL-11, macrophage colony-stimulating factor (M-CSF)\textsuperscript{124}. In addition, AMSCs are found to suppress the production of C-X-C motif chemokine (CXCL)-10, CXCL9, and C-C motif chemokine (CCL)-5, demonstrating a significant anti-inflammation capacity\textsuperscript{111}. Immunomodulatory effects of AMSCs have been investigated on various in vitro experiments of natural killer, B cells, CD4\textsuperscript{+} T cells, CD8\textsuperscript{+} T cells regulatory T cells, and dendritic cells\textsuperscript{111} while the understanding of CMSCs immunology is still limited.
1.4 Regenerative medicine

1.4.1 Placental membranes in clinical application

Historical background

Human amniotic membrane has been used for skin transplantation for over a hundred years. The first reported medical use of amniotic membrane dates back to 1910 with its use as a skin graft. Descriptions of amniotic membrane applied to burned and ulcerated skin surfaced was introduced shortly after. They found that the amniotic membrane accelerated epithelialisation and reduced the pain on burned or ulcerated sites. In the 1930s, amniotic membrane was applied in surgical reconstruction of vaginas. The first report of using both amnion and chorion as a biological dressing material for conjunctival defects was described in 1940. Kim et al. further used amniotic membrane for corneal surface reconstruction in a rabbit model. Thereafter, more advanced studies on the clinical applications of placental membrane had begun and biological mechanisms were investigated.

Current application

Currently, placental membrane is used in a broad range of clinical applications due to its ability to reduce scarring and its immunomodulatory effect in suppressing inflammation in the healing process. There are numerous cytokines and growth factors found in the placental membrane making it an advantageous biomaterial for wound healing and regeneration. Epidermal growth factor (EGF), vascular EGF (VEGF), basic fibroblast growth factor (bFGF), transforming growth factors (TGFs), keratinocyte growth factor (KGF), and many chemokines are important for the healing process and are contained within the
placental membrane. The chorion contributes 75% of the growth factor content in a amnion/chorion graft\textsuperscript{148, 149}. The amniotic and chorionic membrane products are commercially available via dehydration or cryopreservation techniques for their preservation and used in clinical practice, including cardiothoracic surgery (mainly for surgical closure)\textsuperscript{150, 151}, ocular surface reconstruction\textsuperscript{152}, wound repair and management, especially for severe burns and chronic skin ulcers\textsuperscript{153, 154}. It is also suggested that stem cells derived from placental membrane retain their wound healing properties\textsuperscript{155}.

In recent years, using amniotic membrane in tissue engineering as a biological supporting matrix (scaffold) has gained increasing interest. It is described as improving cell proliferation, migration, differentiation, and as possessing antimicrobial properties, making amniotic membrane a good prospective scaffolding material\textsuperscript{69, 156}.

1.4.2 Placenta-derived MSCs in preclinical/clinical studies

MSC are a promising source for cell tissue engineering and cell-based therapies due to their ability to proliferate and differentiate into various functional cell types. The placenta is a reservoir of stem cells and due to its low immunogenicity, easy acquisition without invasive procedures and ethical concerns make placenta-derived MSCs an attractive source for regenerative medicine.

**Cardiovascular repair**

Myocardial infarction leads to irreversible damage to myocardial calls and is associated with high morbidity and mortality; therefore, cardiac regeneration has been widely investigated via gene therapy, cell therapy, and growth factors\textsuperscript{157}. MSCs have the ability to differentiate and regulate secretion of multiple growth factors as well as angiogenesis factors
demonstrating great therapeutic potential. AMSCs were induced to differentiate into cardiomyocytes and expressed cardiac-related genes as well as proteins in in vitro experiments\textsuperscript{158}. Human AMSCs labelled with a fluorescent marker and transplanted into rats were found to integrate into the myocardial infarct tissue region and differentiate into cardiomyocyte-like cells. Surprisingly, AMSCs survived for more than 2 months in the rat models, improving ventricular functions and enhancing capillary density\textsuperscript{159}. Another in vivo study evidenced the ability of AMSCs to transdifferentiate into cardiomyocytes in infarcted myocardium rats and indicated a strong association with the expression of HLA-G, IL-10, and progesterone that regulated fetal-maternal tolerance during pregnancy playing an important role in cardiac regeneration\textsuperscript{160}. A mixture of AMSCs and CMSCs expressed increased levels of cardiac-related genes and proteins than bone-marrow MSCs when treated with cardiogenic differentiation inducers\textsuperscript{161}. In a chronic heart failure mouse model, placental MSCs enhanced cardiomyocyte proliferation and improved cardiac performance\textsuperscript{162}. In addition, placental MSCs reduced apoptosis of cardiomyocytes at the infarcted border area and enhanced vascularity in pig models\textsuperscript{163}.

AMSCs and CMSCs are known to secrete angiogenic factors and modulate angiogenesis. Their secretion of HGF, IGF-1, and VEGF promoted blood flow and capillary density in mouse ischemia model\textsuperscript{164}. In particular, the VCAM-1\textsuperscript{+} subpopulation of CMSCs was suggested to have superior angiogenic potential in vitro and in vivo\textsuperscript{165}.

**Neurological disorders**

Owing to their stem cell characteristics, AECs have been studied in many neurological diseases, where AECs have demonstrated neuroprotective and neuroregenerative effects. Through the expression of neural markers - nestin, glial fibrillary acidic protein, and microtubule-associated protein 2 (MAP-2), AECs are inclined towards neuronal lineages\textsuperscript{166}.
Using AECs to treat peripheral nerve injuries in monkeys showed enhanced growth of host neurons and guided regenerative sprouting\textsuperscript{167}. AECs were differentiated into neuronal progenitors and transplanted to traumatic brain injury in rat models, which showed improved neurological function, brain tissue morphology, and elevated levels of neurotrophic factors, such as brain-derived neurotrophic factor and nerve growth factor\textsuperscript{168}.

Parkinson’s disease is associated with the progressive loss of dopaminergic neurons in the brain. In a Parkinson’s disease mice model, AMSCs were transplanted into the brain and the results indicated that AMSCs differentiated into neural progenitor cells and promoted endogenous neurogenesis\textsuperscript{169}. \textit{In vitro} differentiation of placental MSCs into neural precursor cells was followed by transplantation into \textit{in vivo} models. These placental MSC-derived neural precursor cells improved neuronal functions\textsuperscript{170}. Placental MSCs have been investigated for their therapeutic potential in multiple sclerosis and neurodegeneration of the central nervous system\textsuperscript{171, 172}.

**Musculoskeletal diseases**

Myogenic potential has been demonstrated with AECs, AMSCs, CMSCs, umbilical cord-derived MSCs, and placental tissue-derived MSCs. These MSCs differentiated into myogenic lineages \textit{in vitro} and following \textit{in vivo} implantation, showed positive results of treating skeletal muscle degeneration\textsuperscript{173}. Kawamichi \textit{et al.}, (2010) demonstrated the intrinsic differentiation potential of placental MSCs into myotubes improving the efficiency of dystrophin delivery in muscle fibres upon implantation into mice\textsuperscript{174}.

CMSCs displayed therapeutic potential with osteogenesis imperfecta which is characterised by brittle bones in response to abnormal collagen composition and currently has no curable treatment. The intraperitoneal injection of CMSCs in osteogenesis imperfecta mice models
reduced fractures, increased bone ductility and bone volume along with the upregulation of endogenous genes involved in endochondral and intramembranous osteogenesis. Placental MSCs were used in bone tissue engineering, by inducing osteogenic differentiation, seeding on a scaffold, and transplanting to injured radius segmental bone in rabbits, while the results showed markedly enhanced bone repair.

**Hepatic and pulmonary regeneration**

AECs, AMSCs, and placental MSCs are capable of inducing liver regeneration and regulating cytokine expression to decrease inflammation, fibrosis, and hepatocyte apoptosis. AECs have been successfully differentiated to hepatocytes in several studies. The expression of hepatic-specific transcription factors, genes involved in drug metabolism, and functional enzymatic activities for drug degradation (Cytochrome P450 1A and 3A) were detected in AEC-derived hepatic-like cells. It suggested the promising potential of using AEC-derived hepatocytes transplantation for liver disease therapy.

Apart from their differentiation ability, the cytokine regulatory effect of AECs, AMSCs, CMSCs plays a major role in suppressing fibrosis. Fibrosis is normally caused by a progressive accumulation of extracellular matrix (ECM) components resulting in the thickening and scarring of connective tissue and chronic tissue inflammation. The transplanted AECs in a carbon tetrachloride-4-induced liver fibrosis mouse displayed an ability to suppress MMPs that instigated fibrinolysis and to increase IL-10 concentrations. Infusing AMSCs in a carbon tetrachloride-4-treated mouse liver protected it from fibrosis and apoptosis. Amniotic membrane also displayed anti-fibrotic properties with a reduction of ductular reaction and ECM deposition.

Likewise, immune regulatory effect was demonstrated in a lung fibrosis model where AECs,
AMSCs, and CMSCs supressed bleomycin-induced lung fibrosis with significant reductions in neutrophil infiltration\textsuperscript{183, 184}. Moreover, the application extended to cigarette-induced obstructive pulmonary disease. Intravenous injection of AMSCs was associated with a delay of the emphysema progression and alleviated lung damage\textsuperscript{185}. However, the inflammation was not entirely repressed and AMSCs were observed in heart, liver, and kidney. The homing efficiency of AMSCs to the target tissue needs to be further assessed.

**Clinical trials**

Currently, most of the clinical trials using birth-associated tissues are dedicated to cord blood HSCs. The first cord blood HSCs transplant was in 1988; thereafter, over 35,000 transplants have been performed worldwide\textsuperscript{186}. However, since MSCs have been found in various birth-associated tissues, the cell therapy using perinatal MSCs has become a growing field. Figure 1-7 shows the numbers of clinical trials registered worldwide per year by cell type, indicating the significantly increasing numbers in perinatal MSCs vs. cord blood cells transplantation\textsuperscript{187}. Some recent clinical applications using placental MSCs in phase 2 trials include severe aplastic anaemia, haemorrhagic cystitis, hypoxic ischaemic encephalopathy, stroke, rheumatoid arthritis, and graft-versus-host disease. Many clinical studies with placenta- or placental membrane-derived MSCs are still in phase 1 trial with small groups of participants. However, with great differentiation potential and immunomodulatory ability, there has been an increasing interest in regenerative medicine of birth-associated MSCs. Some challenges such as mixed cell populations upon differentiation, insufficient amount and purity of specialised cells, and route and timing of cell administration still need to be overcome to achieve therapeutic outcomes.
Figure 1-7. Numbers of clinical trials using perinatal cells per year

Numbers of cell therapy using perinatal MSCs/HSCs in clinical trials registered per year divided by the type of the cells: cord blood cells/HSCs that are unmanipulated or manipulated (specific cell type), perinatal MSC (Wharton’s jelly, fetal membrane, amniotic fluid, placenta), other perinatal cells, multiple sources. MSC, mesenchymal stem cell; HSCs, haematopoietic stem cells. Reproduced from Couto et al., 2017^{187}

1.4.3 Banking of neonatal tissues and stem cells

Cord blood banking has been a popular option since 1993 when the first cord blood bank established^{188}. Banked cord blood has been successfully applied to clinical research and disease treatments while many biobanks have introduced a new type of service – the storage of birth-associated MSCs and new companies specialised in placental component banking have appeared. Pregnant women can choose to donate their placenta and placenta-derived cells to public banks such as UK Transplant Living Amniotic Membrane/Placenta Donation Programme for research purpose or privately store their own placental cells in commercial biobanks. Biobanking processes are required to follow
the principles and guidelines of good manufacturing practice (GMP) for medicinal products for human use\textsuperscript{189}. Although advancements in isolation and characterisation techniques allow scientists to obtain abundant MSCs from the placenta, the lack of specialised medical trainees in hospitals to ensure the quality and integrity of placenta and high costs ensuing from the import of biobanks using quality assurance system controls (such as International Organization for Standardization (ISO)) remain challenging for placental cell banking\textsuperscript{190,191}. The storage of placental cells or components is also beneficial for discovery and screening of new drugs\textsuperscript{192}. The establishment of placental cell biobanks shows exciting promise for future regenerative medicine and stem cell transplantation therapies.

1.4.4 MSC therapy in type 2 diabetes

Type 2 diabetes is characterised by a combination of a defect in beta-cell function resulting in insulin deficiency and insulin resistance. The frequency of diabetic comorbidities and complications, including cardiovascular disease, neuropathy, infections, and impaired wound healing are high when hyperglycaemia is uncontrolled\textsuperscript{193}. Although diabetes is a treatable disease, the existing therapeutic strategy can neither reverse insulin resistance nor the progression of beta-cell dysfunction\textsuperscript{194}. Lifelong monitoring of glucose level and treatment poses a burden on diabetic patients. Therefore, research is searching for new potentially curative therapies for diabetes.

The whole-pancreas transplant was first performed in 1966\textsuperscript{195} while with the improvement in surgical techniques and immunosuppressive therapy in modern medicine, transplant obviates the need for lifelong insulin treatments and prevents diabetic complications\textsuperscript{196}. The necessity of major surgery and shortage of donors limit the availability of this therapeutic approach. In 1999, the transplantation of islet cells with minimally invasive
procedure was introduced\textsuperscript{197}. Transplanted islet cells successfully enhance insulin production, control blood glucose levels, and reduce the requirement of insulin. However, xenotransplantation of islets can introduce risk of zoonotic infections\textsuperscript{198} while human allotransplantation is limited due to increased recipient demand greater than donor tissue supplies and the complications of immunosuppressive drugs\textsuperscript{199}.

MSCs, possessing immunosuppressive capacity and differentiation potential have generated a great interest in light of diabetic therapy. MSCs transplantation offers several advantages, such as lower risks, less complicated procedures, and abolishing the need for immunosuppressive therapy. Figure 1-8 summarises the potential of MSC-mediated type 2 diabetes therapy.

\textbf{Regeneration and protection of islets}

MSCs have been suggested to have the ability to promote pancreatic islet regeneration and to protect endogenous beta-cells from apoptosis. In streptozocin-induced diabetic mice, MSCs homed to and promoted the repair of pancreatic islets through enhancing endogenous cells to proliferate and regain their function\textsuperscript{200}. MSCs express a set of chemokine receptors (CXCR4, CXCR6, CCR1, CCR7) in response to islet-secreted chemokines and allow them to migrate towards the damaged islet site\textsuperscript{201}. Through their paracrine mechanisms, MSC transplantation can modify the pancreatic microenvironment and thereby allow endogenous beta-cell regeneration.
Figure 1-8. MSC therapeutic effects on type 2 diabetes
MSCs demonstrate beneficial effects through IPCs differentiation while undifferentiated MSCs promote islet cell regeneration, protect endogenous islet cells, and ameliorate insulin resistance. IPCs, insulin-producing cells; IGF-1, insulin-like growth factor-1; VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor; IRS-1, insulin receptor substrate-1; PI3K, phosphoinositide 3-kinase. Reprinted from Zang et al., 2017.

Following MSCs intravenous injection, diabetic mice showed increased EGF expression in plasma and pancreas. The secretion of EGF, insulin-like growth factor (IGF)-1, and platelet-derived growth factor (PDGF) are thought to be beta-cell mitogenic factors and other cytokines such as VEGF-α and angiopoietin-1 play a role in vascularisation. Additionally, different MSC subtypes may have different levels of therapeutic effect. Cell sorting based on aldehyde dehydrogenase (ALDH) activity reveals that bone-marrow MSCs with high ALDH expression have greater potential in improving hyperglycaemia and insulin secretion by increasing islet size, beta-cell mass, and vascularisation. The secretory activity of MSCs induces Wnt signal activation, the expression of matrix metalloproteases and
EGFR-activating ligands, contributing to islet regeneration\textsuperscript{204}.

Increased oxidative stress and hypoxia are strongly associated with the diabetic environment leading to islet apoptosis. MSCs support islet survival and protect islets from oxidative stress-induced injury in order to maintain their normal functions. The increased viability through downregulation of apoptotic regulators (caspase 3, caspase 8, p53) and upregulation of anti-apoptotic genes enhance resistance to oxidative stress-induced apoptosis and dysfunction in islets\textsuperscript{205}. Proinflammatory states of diabetes are characterised by increased levels of proinflammatory cytokines such as TNF-\(\alpha\), IL-6, interferon-\(\gamma\)\textsuperscript{206}. Co-culture of MSCs with pancreatic islets prevents beta-cell apoptosis induced by treatment with proinflammatory cytokines, suggesting the islet-protected role of MSC in inflammatory environment\textsuperscript{207}.

**Insulin-producing cell generation**

Although MSC transplant has the aforementioned advantages, whether residual beta-cells and the remaining endogenous precursors could have enough numbers for regeneration to cope with hyperglycaemia and their regenerative efficiency remains unclear. Therefore, replacing damaged beta-cells by inducing MSC differentiation into insulin-producing cells (IPCs) may be a direct way to restore islet function.

Knowing that pancreatic cells derived from endodermal lineages, many studies have shown the capacity of MSCs to differentiate beyond mesenchymal lineage. Since MSCs do not spontaneously differentiate into pancreatic lineage \textit{in vitro}, delicate reprogramming processes are required\textsuperscript{208}. Particularly as, unlike embryonic stem cells, adult tissue-derived MSCs usually express low levels of pluripotent markers; therefore,MSCs reprogramming, examination of pancreatic markers, and evaluation of functions are important for IPC
differentiation. The differentiation approach for IPC generation can involve treatment with many molecules to induce MSC transdifferentiation into endocrine lineages and maturation of functional insulin-secreting cells. Table 1-3 lists the compounds commonly used in current IPC differentiation protocols. Three major stages of IPC differentiation described – definitive endoderm, pancreatic endoderm, and mature beta-cells are each characterised by lineage-specific gene expression; however, differentiation protocols depend on different MSC types and range from one step to multiple steps.\(^{209}\)

The functions of MSC-generated IPCs have been investigated in many *in vivo* diabetic models. When transplanting IPCs into diabetic mice, hyperglycaemia was under control within two weeks and restored normal glycaemic condition as well as the co-expression of insulin, glucagon, and somatostatin in IPC-treated diabetic mice.\(^{210}\) The transplanted IPCs sustainably expressed insulin, c-peptide, and pancreatic-specific markers without apparent apoptosis *in vivo* for at least three weeks.\(^{211}\) Longer survival time of transplanted IPCs was also reported, which maintained glucose regulatory function up to 5 weeks.\(^{212}\)

However, the challenges are the percentage of mature IPCs is low and in most animal models, IPCs are implanted into the renal capsular space. The homing ability of differentiated MSCs to the injured organ will ease the cell transplant process in clinical practice.

**Table 1-3. Factors involved in IPC differentiation**

<table>
<thead>
<tr>
<th>Compounds</th>
<th>Function in IPC differentiation</th>
</tr>
</thead>
<tbody>
<tr>
<td>High glucose</td>
<td>Increases beta-cell replication</td>
</tr>
<tr>
<td>Activin A</td>
<td>Promotes beta-cell regeneration</td>
</tr>
<tr>
<td></td>
<td>Increases insulin content</td>
</tr>
<tr>
<td>N2 and B27</td>
<td>Serum supplements in serum-free medium</td>
</tr>
<tr>
<td>FGF</td>
<td>Early stage differentiation</td>
</tr>
<tr>
<td></td>
<td>Cluster formation</td>
</tr>
</tbody>
</table>
| **EGF** | Accelerates beta-cell proliferation  
|         | Increases insulin expression |
| **HGF** | Induces beta-cell cluster formation |
| **Retinoic acid** | Induces endocrine and ductal differentiation  
|         | Induces insulin-positive differentiation |
| **Nicotinamide** | Induces insulin gene  
|         | Enhances insulin content, DNA content |
| **β-mercaptoethanol** | Increases the potency of nicotinamide |
| **Betacellulin** | Promotes beta-cell regeneration  
|         | Increases cell mass and maturation |
| **GLP-1** | Accelerates maturation of beta-cells towards glucose responsive insulin secretion |
| **Exendin-4** | Accelerates maturation of beta-cells towards glucose responsive insulin secretion |
| **Pentagastrin** | Expands beta-cell mass in combination with other factors |

FGF, fibroblast growth factor; EGF, epidermal growth factor; HGF, hepatocyte growth factor; GLP-1, glucagon-like peptide-1

**Amelioration of insulin resistance**

In addition to beta-cell dysfunction, insulin resistance usually co-exists in type 2 diabetes which occurs when cells fail to respond normally to insulin and have impaired glucose uptake. MSCs were found to alleviate hyperglycaemia in high-fat diet-induced diabetic rats by activating insulin receptor substrate (IRS)-1 signal and Akt (protein kinase B) phosphorylation. Adipose tissue macrophage-induced chronic low-grade inflammation is also thought to play a role in exacerbating insulin resistance. MSCs infusion promoted insulin sensitivity in diabetic rat through converting inflammatory phenotype macrophages, M1 into anti-inflammatory phenotype M2. The study indicated that MSCs upregulated IL-4R expression and promoted phosphorylation of STAT6 (signal transducer and activator of transcription 6) in macrophage leading to polarisation of macrophage into M2 phenotype. However, the underlying mechanisms of MSC-mediated insulin sensitivity are not yet clear.
1.5 Introduction to microarray

1.5.1 Microarray technology

In the past, researchers used to discover genes based on one gene per experiment principle via mutations, selections, and cloning schemes. In the late 90’s, tens of thousands of human cDNA sequences represented previously unseen genes and brought us to think about the unexplored world of human genome. Thereafter, DNA microarray technology has progressed rapidly and introduced a new tool for genetic study with a slide or chip containing thousands of genes arrayed within a small surface area. Microarray technology provides a systematic and comprehensive way to explore the gene expression on genome-wide level. It has revolutionised biological science research in recent times, for instance, large numbers of publications describing data from microarrays, academia or industrial disease and drug discovery, clinical application for evaluating dosages of drugs.

The principle of microarray technology is based on DNA hybridization, a process in which the DNA strand binds to its unique complementary sequence (Figure 1-9A). The arrayed material (DNA strand) has generally been termed as probe. For DNA array, RNA isolated from two different samples, is converted to complementary DNA (cDNA) and labelled with two distinct fluorescent dyes (such as Cy5 and Cy3). Both samples are mixed in hybridization buffer and hybridized to a microarray chip that carries the probes of each specific gene. Two samples result in competitive binding of differentially labelled cDNA to its corresponding probe and through high-resolution confocal fluorescence scanning, relative signal intensity measured at each probe indicates the expression level of genes on the array (Figure 1-9B). Based on this basic concept of microarray, today’s technology has developed a wide range of DNA microarray platforms including one- and two-channel formats, cDNA and
oligonucleotide microarrays, spotted and in-situ synthesised microarrays, and commercially developed microarrays\textsuperscript{219}.

**Figure 1-9. Overview of DNA microarray**

(A) Hybridization with gene elements on a microarray. (B) Schematic overview of probe microarray with two samples. Fluorescent dye Cy3 (green) and dye Cy5 (red) having the fluorescence emission wavelength of approximately 570 nm and 670 nm, respectively. Reprinted from Quackenbush, 2006\textsuperscript{220}.

**1.5.2 Applications of microarrays**

The predominante application of DNA microarrays has been to measure gene expression levels based on the abundances of RNAs in different tissues. Gene expression provides a key clue to a given alteration in phenotype and by looking at overall patterns of gene expression, helps to understand the genetic regulatory networks in order to identify co-
regulated genes with related functions. One of analytical methodologies to identify functionally related genes is cluster analysis which partitions genes into groups and clusters based on the similarity of expression patterns. By clustering, it is useful for elucidating the role of certain genes that appear in the same cluster and the relation of differentially expressed gene clusters in a particular phenotype\textsuperscript{221}.

Microarray technology has also been applied to transcription factor binding analysis and genotyping. The former is combined with chromatin immunoprecipitation to determine binding sites of transcription factors that regulate the activation or inhibition of gene expression\textsuperscript{219}. The latter usually refers to single-nucleotide polymorphism (SNP) genotyping, commonly used in discovering variation in a single nucleotide that occurs at a specific position in whole genome\textsuperscript{222}. Moreover, SNP genotyping is widely used in cancer research. Knowing that tumour formation involves simultaneous changes in cells and genes, SNP genotyping can identify single gene mutation, cancer biomarkers, target genes of tumour suppressors as well as the identification of genes associated with chemoresistance to provide information for drug discovery\textsuperscript{223}.

Microarray has provided scientists with a convenient and useful tool for genome-wide analysis; however, with recent advancements and radical decline costs in next generation sequencing technologies, it offers another attractive option for genome-wide studies and may supersede many applications of microarray in the future.

1.6 Hypothesis and aims

Given that the placental environment is affected by pregnant complications, it would be important to investigate whether the biological properties of MSCs derived from GDM placenta were altered. On the other hand, the high risk of developing diabetes of women
with a GDM history and their offspring, placental MSCs come to be a valuable source for their future cell therapy. Therefore, we aim to characterise AMSC-/CMSC- derived from GDM and healthy placenta and investigate their differentiation potential for insulin-producing cell generation. Furthermore, we used DNA microarray technology to comprehensively understand the biological properties between healthy- and GDM- MSCs.

The aims of this study can be divided into three main objectives:

- Characterise AMSCs and CMSCs from GDM and healthy women via biological (morphology and immunophenotypes), functional (growth and tri-lineage differentiation), and immunological (T-cell and macrophage modulation) characterisation.

- Develop a feasible approach to generating insulin-producing cells from Healthy-/GDM-CMSCs and AMSCs in an attempt to explore their therapeutic potential in diabetes therapy.

- Perform DNA microarray to identify gene profiles and investigate benefits and disadvantages of using CMSCs from healthy and GDM women in future regenerative medicine.
Chapter 2

Materials and methods
2.1 Materials

Table 2-1. List of materials

<table>
<thead>
<tr>
<th>Catalogue number</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>21985023</td>
<td>ThermoFisher Scientific</td>
</tr>
<tr>
<td>ab113851</td>
<td>Abcam</td>
</tr>
<tr>
<td>M6494</td>
<td>ThermoFisher Scientific</td>
</tr>
<tr>
<td>I7018</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>D9542</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>A3219</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>A6283</td>
<td>ThermoFisher Scientific</td>
</tr>
<tr>
<td>MAK082</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>A3157</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>A5553</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>A8960</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>G5422</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>23227</td>
<td>ThermoFisher Scientific</td>
</tr>
<tr>
<td>11433164</td>
<td>ThermoFisher Scientific</td>
</tr>
<tr>
<td>KAA002</td>
<td>Merck Millipore</td>
</tr>
<tr>
<td>C/4960/17</td>
<td>ThermoFisher Scientific</td>
</tr>
<tr>
<td>10780004</td>
<td>ThermoFisher Scientific</td>
</tr>
<tr>
<td>CLS3460-48EA</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>C6158</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>D2915</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>D2650</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Product Description</td>
<td>Code</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Dulbecco’s Modified Eagle Medium (DMEM)- 4.5 g/L glucose</td>
<td>BE12-709F</td>
</tr>
<tr>
<td>Dulbecco’s Modified Eagle Medium (DMEM)- 1g/L glucose</td>
<td>LZBE12-707F</td>
</tr>
<tr>
<td>DMEM, no glucose, no glutamine, no phenol red</td>
<td>A1443001</td>
</tr>
<tr>
<td>DMEM F12 1:1 mixture</td>
<td>BE04-687Q</td>
</tr>
<tr>
<td>Exendin-4</td>
<td>E7144</td>
</tr>
<tr>
<td>Ethanol (absolute)</td>
<td>E0650/17</td>
</tr>
<tr>
<td>Ethylene diamine tetra-acetic acid (EDTA)</td>
<td>BP2482-1</td>
</tr>
<tr>
<td>Foetal bovine serum (FBS)</td>
<td>FB-1001G/500</td>
</tr>
<tr>
<td>Glycerol</td>
<td>G6279</td>
</tr>
<tr>
<td>Glucose</td>
<td>G7021</td>
</tr>
<tr>
<td>Human Betacellulin</td>
<td>100-50</td>
</tr>
<tr>
<td>Human EGF</td>
<td>AF-100-15</td>
</tr>
<tr>
<td>Human GLP-1 (7-36a.a)</td>
<td>130-08</td>
</tr>
<tr>
<td>Human/Murine/Rat Activin A (E.coli)</td>
<td>120-14E</td>
</tr>
<tr>
<td>High-Capacity cDNA Reverse Transcription Kit</td>
<td>4368814</td>
</tr>
<tr>
<td>Human IL-2 Mini ABTS ELISA Development Kit</td>
<td>900-M12</td>
</tr>
<tr>
<td>Human IL-10 Mini ABTS ELISA Development Kit</td>
<td>900-M21</td>
</tr>
<tr>
<td>Human TNF-α Mini ABTS ELISA Development Kit</td>
<td>900-M25</td>
</tr>
<tr>
<td>Human Insulin ELISA Kit</td>
<td>ab200011</td>
</tr>
<tr>
<td>Human C-Peptide ELISA</td>
<td>80-CPTHU-E01.1-ALP</td>
</tr>
<tr>
<td>Human TGF-beta 3 (E.coli)</td>
<td>100-36E</td>
</tr>
<tr>
<td>Hydrogen peroxide solution (H₂O₂)</td>
<td>216763</td>
</tr>
<tr>
<td>Indomethacin</td>
<td>I7378</td>
</tr>
<tr>
<td>Insulin Antibody</td>
<td>sc-9168</td>
</tr>
<tr>
<td>Insulin, Transfferrin, Selenium (ITS)</td>
<td>I3146</td>
</tr>
<tr>
<td>Isopropanol</td>
<td>11398461</td>
</tr>
<tr>
<td>L-Glutamine</td>
<td>BE17-605E</td>
</tr>
<tr>
<td>LIVE/DEAD Viability/Cytotoxicity Kit</td>
<td>L3224</td>
</tr>
<tr>
<td>Item</td>
<td>Code</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>L-Proline</td>
<td>P5607</td>
</tr>
<tr>
<td>MEM Eagle NEAA (100X)</td>
<td>LZBE13-114E</td>
</tr>
<tr>
<td>Methanol</td>
<td>10141720</td>
</tr>
<tr>
<td>Mouse anti-rabbit IgG-Texas Red</td>
<td>sc-3917</td>
</tr>
<tr>
<td>Nicotinamide</td>
<td>N0636</td>
</tr>
<tr>
<td>Oil Red O</td>
<td>O0625</td>
</tr>
<tr>
<td>PDX-1 Antibody (B-11) Alexa Fluor 488</td>
<td>sc-390792</td>
</tr>
<tr>
<td>Penicillin-Streptomycin</td>
<td>DE17-603E</td>
</tr>
<tr>
<td>Phorbol 12-myristate 13-acetate (PMA)</td>
<td>P8139-5MG</td>
</tr>
<tr>
<td>Phycoerythrin conjugated antibodies CD105</td>
<td>130-098-845</td>
</tr>
<tr>
<td>Phycoerythrin conjugated antibody CD73</td>
<td>130-097-932</td>
</tr>
<tr>
<td>Phycoerythrin conjugated antibody CD90</td>
<td>130-098-906</td>
</tr>
<tr>
<td>Phycoerythrin conjugated antibody CD14</td>
<td>130-098-167</td>
</tr>
<tr>
<td>Phycoerythrin conjugated antibody CD19</td>
<td>130-098-168</td>
</tr>
<tr>
<td>Phycoerythrin conjugated antibody CD34</td>
<td>130-098-140</td>
</tr>
<tr>
<td>Phycoerythrin conjugated antibody CD45</td>
<td>130-098-141</td>
</tr>
<tr>
<td>Phycoerythrin conjugated antibody HLA-DR</td>
<td>130-098-177</td>
</tr>
<tr>
<td>Phycoerythrin conjugated antibodies IgG1 isotype</td>
<td>130-098-849</td>
</tr>
<tr>
<td>Phycoerythrin conjugated antibodies IgG2a isotype</td>
<td>130-098-849</td>
</tr>
<tr>
<td>Phytohaemaglutinin (PHA)</td>
<td>L166</td>
</tr>
<tr>
<td>Phosphate buffered saline (PBS)</td>
<td>BE17-516F</td>
</tr>
<tr>
<td>Radioimmunoprecipitation assay (RIPA) buffer</td>
<td>R0278-50ML</td>
</tr>
<tr>
<td>Retinoic acid</td>
<td>R2625</td>
</tr>
<tr>
<td>Rosewell Park Memorial Institute (RPMI1640)</td>
<td>12-918F</td>
</tr>
<tr>
<td>Product Name</td>
<td>Catalog Number</td>
</tr>
<tr>
<td>------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>RNAlater</td>
<td>R0901</td>
</tr>
<tr>
<td>Sodium butyrate</td>
<td>B5887</td>
</tr>
<tr>
<td>Sodium pyruvate</td>
<td>S8636</td>
</tr>
<tr>
<td>Taurine</td>
<td>T8691</td>
</tr>
<tr>
<td>TRIzol Reagent</td>
<td>15596026</td>
</tr>
<tr>
<td>Trypsin/Versene(EDTA)</td>
<td>BE02-007E</td>
</tr>
<tr>
<td>Trypan blue</td>
<td>T8154</td>
</tr>
<tr>
<td>Tween-20</td>
<td>P7949-100ML</td>
</tr>
<tr>
<td>QuantiFast SYBR Green PCR Kit</td>
<td>204054</td>
</tr>
<tr>
<td>UltraPure DNase/RNase-Free Distilled Water</td>
<td>10977049</td>
</tr>
</tbody>
</table>
2.2 Placental samples collection

All placentas in our research were collected from Royal Stoke University Hospital, UK, after obtaining Research Ethics Committee and Health Research Authority approvals (Reference 15/WM/0342). Women undergoing Caesarean sections were consented to donate their placenta. Term placentas were collected from healthy donors (n=10) and donors with GDM (n=11). Individuals were classified as GDM after clinical diagnosis using an OGTT between 24 and 28 weeks pregnant. The OGTT was carried out by the measurement of fasting plasma glucose (FPG) concentration, and 2 hours after a 75 g solution of glucose was consumed, plasma glucose was measured again. If the patients exceeded the NICE clinical guidelines for glucose concentration thresholds (section 1.1.1) were diagnosed with GDM. The cell isolation process was performed within an hour of collecting the placenta from Caesarean section. Maternal and fetal details of the samples used in this study were listed in Table 2-2.

For each placenta, both amniotic mesenchymal stem cell (AMSCs) and chorionic mesenchymal stem cells (CMSCs) were isolated from the same placental membrane. Independent samples were grouped into Healthy-CMSCs, Healthy-AMSCs, GDM-CMSCs, and GDM-AMSCs for all the comparisons and statistical analysis in this thesis.
### Table 2-2. Placenta sample details

<table>
<thead>
<tr>
<th>Samples</th>
<th>Ethnicity</th>
<th>Age</th>
<th>Weeks</th>
<th>BMI</th>
<th>Infant/Weight</th>
<th>Other Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy01</td>
<td>Nigerian</td>
<td>46</td>
<td>38</td>
<td>38</td>
<td>Girl / 3380</td>
<td>Hypertension / GDM in last pregnancy</td>
</tr>
<tr>
<td>Healthy02</td>
<td>Caucasian</td>
<td>26</td>
<td>39</td>
<td>22</td>
<td>Girl / 3400</td>
<td>Hepatitis B</td>
</tr>
<tr>
<td>Healthy03</td>
<td>Caucasian</td>
<td>33</td>
<td>37</td>
<td>24</td>
<td>Girl / 3280</td>
<td></td>
</tr>
<tr>
<td>Healthy04</td>
<td>Caucasian</td>
<td>33</td>
<td>39</td>
<td>30</td>
<td>Girl / 3440</td>
<td></td>
</tr>
<tr>
<td>Healthy05</td>
<td>Caucasian</td>
<td>29</td>
<td>39</td>
<td>37</td>
<td>Girl / 3280</td>
<td>Previous smoker</td>
</tr>
<tr>
<td>Healthy06</td>
<td>Caucasian</td>
<td>41</td>
<td>39</td>
<td>22</td>
<td>Girl / 3720</td>
<td></td>
</tr>
<tr>
<td>Healthy07</td>
<td>Caucasian</td>
<td>30</td>
<td>39</td>
<td>20</td>
<td>Girl / 3095</td>
<td>Current smoker</td>
</tr>
<tr>
<td>Healthy08</td>
<td>Caucasian</td>
<td>24</td>
<td>39</td>
<td>21</td>
<td>Girl / 3540</td>
<td>Previous smoker</td>
</tr>
<tr>
<td>Healthy09</td>
<td>Caucasian</td>
<td>30</td>
<td>39</td>
<td>27</td>
<td>Girl / 3780</td>
<td>GDM in last pregnancy</td>
</tr>
<tr>
<td>Healthy10</td>
<td>Caucasian</td>
<td>26</td>
<td>39</td>
<td>29</td>
<td>Girl / 3100</td>
<td></td>
</tr>
<tr>
<td>Healthy11</td>
<td>Caucasian</td>
<td>32</td>
<td>39</td>
<td>25</td>
<td>Girl / 3630</td>
<td></td>
</tr>
<tr>
<td>GDM01</td>
<td>Chinese</td>
<td>35</td>
<td>38</td>
<td>25</td>
<td>Boy / 3740</td>
<td></td>
</tr>
<tr>
<td>GDM02</td>
<td>Caucasian</td>
<td>31</td>
<td>39</td>
<td>22</td>
<td>Girl / 4660</td>
<td>Addison's disease / received hydrocortisone before delivery</td>
</tr>
<tr>
<td>GDM03</td>
<td>Caucasian</td>
<td>31</td>
<td>37</td>
<td>42</td>
<td>Boy / 3120 &amp; Boy / 3600</td>
<td>Non identical twins</td>
</tr>
<tr>
<td>GDM04</td>
<td>Caucasian</td>
<td>24</td>
<td>37</td>
<td>40</td>
<td>Boy / 3468</td>
<td></td>
</tr>
<tr>
<td>GDM05</td>
<td>Caucasian</td>
<td>23</td>
<td>37</td>
<td>34</td>
<td>Girl / 2920</td>
<td>Previous smoker</td>
</tr>
<tr>
<td>GDM06</td>
<td>Caucasian</td>
<td>43</td>
<td>39</td>
<td>44</td>
<td>Girl / 3860</td>
<td>GDM on metformin</td>
</tr>
<tr>
<td>GDM07</td>
<td>Caucasian</td>
<td>35</td>
<td>39</td>
<td>25</td>
<td>Boy / 3580</td>
<td>GDM on insulin</td>
</tr>
<tr>
<td>GDM08</td>
<td>Caucasian</td>
<td>32</td>
<td>36</td>
<td>29</td>
<td>Boy / 3581</td>
<td>GDM on insulin and metformin</td>
</tr>
<tr>
<td>GDM09</td>
<td>Caucasian</td>
<td>20</td>
<td>39</td>
<td>20</td>
<td>Boy / 3940</td>
<td>GDM on metformin</td>
</tr>
<tr>
<td>GDM10</td>
<td>Caucasian</td>
<td>32</td>
<td>39</td>
<td>36</td>
<td>Girl / 3380</td>
<td></td>
</tr>
</tbody>
</table>
2.3 Isolation and culture of AMSCs and CMSCs

The placenta dissection and cell isolation were conducted in a class II microbiological safety cabinet. All materials used in isolation process were sterile. The CMSCs/AMSCs isolation process was performed within an hour of collecting the placenta from Caesarean section, using the protocol described by Marongiu et al., (2010)\textsuperscript{224}. The placenta dissection process was demonstrated in Figure 2-1.

Umbilical cord was trimmed and cut an X-shaped incision onto the placental surface. Amniotic membrane was manually peeled from the underlying chorionic membrane and immediately washed with PBS for several times to remove blood clots. As chorionic membrane is attached to maternal tissues, a removal of decidual tissue was required. Decidual tissue and blood clots on chorionic membrane were carefully removed by forceps and washed with PBS. Following wash steps, membranes were placed in 20 ml prewarmed 0.05% trypsin/EDTA solution in 50 ml centrifuge tubes and incubated at 37°C for 1 hour. Membranes were then washed with PBS for 3-5 times to remove any residual trypsin solution. To release the cells, membranes were placed in freshly prepared digestion media containing 1 mg/ml collagenase type IV and 25 µg/ml DNase I in serum free Dulbecco’s Modified Eagle Medium (DMEM) in 50 ml centrifuge tubes. Digestion media was filtered through a 0.2 µm filter and prewarmed before use. Membranes were digested at 37°C incubator for 1-1.5 h and during the digestion process, the membranes were checked every 15 minutes. Incubating on a rotator or shaking the tubes every 15 minutes was sometimes required to enhance the digestion process. The incubation stopped once the membranes were completely dissolved. Equal volume of PBS was added to the centrifuge tubes containing digestion media and dissolved membranes. The mobilised cells were pelleted by centrifugation at 200g for 5 minutes and then supernatant was discarded, the pellet was
washed with PBS, and pelleted again at 200 g for 5 minutes. Cell pellet was then re-suspended in growth media consisting of 10% FBS, 1% L-glutamine, 1% Penicillin-Streptomycin, and 1% non-essential amino acids (NEAA) in DMEM and seeded at the density of $1 \times 10^5$ cells/cm$^2$.

Figure 2-1. MSC isolation from placental membranes.
AMSCs and CMSCs were isolated from amniotic and chorionic membrane, respectively. Following trimming the umbilical cord and cutting an X-shaped incision on placental surface, amnion was peeled from the underlying chorion and washed with PBS. Blood clots and decidual tissue attached to chorion were removed by forceps and chorion was washed with PBS. After the washing step, both amnion and chorion were digested with trypsin and digestion media containing 1 mg/ml collagenase type IV and 25 μg/ml DNase I in serum free DMEM to release the AMSCs and CMSCs from the membranes. Reproduced from Marongiu et al., 2010$^{224}$ and Koo et al., 2012$^{225}$
2.4 Cell culture techniques

All cell cultured procedures were performing using disposable sterile consumables in a class II microbiological safety cabinet. Cells were cultured in standard tissue culture T25, T75 flasks or multi-well culture plates and maintained in 5% CO₂ at 37 °C incubators.

2.4.1 Cell passage, cryopreservation, and recovery

For adherent cell lines, cells were sub-cultured when its growth reached 80-90% confluence. Media were aspirated, monolayer cells were rinsed with PBS, and sufficient amount of trypsin/EDT (0.05% trypsin/0.02% ethylenediaminetetraacetic acid (EDTA) diluted 1 in 10 in PBS) was added to cover cells. Cells were then incubated at 37 °C for about 10 minutes until detached. Cell maintenance media added to halt the trypsin activity in an equivalent volume of trypsin/EDTA solution and cell suspensions were transferred to a centrifuge tube for pelleting at 1,000 rpm for 5 minutes. Cell pellet was re-suspended in fresh maintenance media for seeding.

To cryopreserve the cells for future use, cells were detached using trypsin/EDTA and re-suspended in freezing media (10% FBS DMEM supplemented with 10% DMSO). 1 ml of freezing media containing approximately 2 x 10⁶ cells was transferred into a cryovial and placed in Mr. Frosty for slowly cooling to -80 °C before transferred to liquid nitrogen for further storage.

To recover frozen cells, cryovials taken out from liquid nitrogen were immediately placed into a 37 °C water bath. Thawed the cells by gently swirling the cryovials and transferred thawed cells to the desired amount of growth media in a centrifuge tube. Cells were pelleted at 1,000 rpm for 5 minutes, supernatant was aspirated, and pellets were re-
suspended in growth media for seeding.

2.4.2 Morphological observation and measurement

Changes in cell morphology were detected by a light microscope and images were processed with ImageJ software to analysis cell length and surface area. For analysis, 5 images were taken from each sample from passage 0-2. The images were open by ImageJ and to calibrate the images, scale was set based on a known distance. Images were adjusted by modifying the contrast and sharpening the images until the shapes of cells clearly appeared. To measure cell lengths, line tool in ImageJ was used to draw a line based on the longest axis from cell periphery and length of the line was measured to represent each cell length. At least 100 single cells were measured in each image. Cell surface area was measured by ImageJ through automatically circling the outline of cells and the edged cells were excluded (Figure 2-2).

Figure 2-2. Cell morphology analysis
(A) Original image (B) Contract and brightness adjustment (C) Cell length measurement (D) Cell surface area measurement. All images were analysed by ImageJ.
2.4.3 Cell counting and doubling time

Cells were suspended and diluted in culture media, if trypan blue was used, a small amount of cell suspension was mixed with the equal volume of trypan blue. 10 µl of the cell suspension was loaded into a haemocytometer adhered with a coverslip. Cells were counted from 4, 1 mm² corner squares under a microscope and each square represents a volume of 0.1 µl. To determine the number of cells/ml, the mean number of each square was multiplied by 10⁴ while if cell suspension was diluted 1:1 with trypan blue, the dilution factor was also taken into account by multiplying 2 in the calculation.

Cell numbers were counted every 2 days and the doubling time was calculated at passage 3. Equation for doubling time = \((T2-T1) \times \log 2/ (\log N2 – \log N1)\), where: T1, final time (hours); T2, initial time; N1, initial cell numbers; and N2, final cell numbers.

2.4.4 MTT assay

The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, ThermoFisher) assay has been widely used to determine cell viability and proliferation since its development by Mosmann in the 1980’s²²⁶. The measurement of MTT is based on mitochondrial function of cells by measuring activity of mitochondrial enzymes such as succinate dehydrogenase²²⁷. The increased measurement of MTT represents enhanced metabolic activity, which can be affected by cell proliferation, different conditions, chemical treatments, and cell death²²⁸. Therefore, MTT assay can only indirectly reflect the viable cell numbers and proliferation. Viable cells with active metabolism can convert soluble yellow-coloured MTT into an insoluble purple-coloured formazan product through NAD(P)H-dependent cellular oxidoreductase enzymatic activity, indicating mitochondrial activity²²⁹. The MTT compound was prepared in PBS at a concentration of 5 mg/mL, filtered through a
0.2 μm filter, and stored at -20 °C. Cells were seeded at 3,000 cells/well in a 96-well plate in triplicate and performed MTT assay every 2 days for a 12-day period. When performing MTT assay, media was aspirated and added 90 μl serum-free media plus 10 μl MTT solution into each well. Following incubating the plates at 37 °C for 4 hours, 100 μl DMSO was added and incubated at 37 °C for 30 minutes to dissolve purple formazan crystals. Plates were wrapped in foil and shaken on an orbital shaker for 5 minutes before reading the absorbance at wavelengths of 570 nm using a plate reader. As phenol red present in the media can generate background, wells without cells contained same proportion of serum free media, MTT solution, and DMSO was used as a blank. The results are presented as mean ± SD of triplicates, taking time as the horizontal axis and optical density (OD) as the longitudinal axis.

2.4.5 Production of conditioned media

Cells at passage 3 were seeded in T75 flasks and when reaching 80–90% confluence, cells were washed with PBS and then 15 ml of fresh media without FBS was added. After incubating for 48 hours, conditioned media was collected by transferring supernatant to a centrifuge tube and filtering through a 0.2 μm filter to remove cell debris. Supernatant was stored at −80 °C until further use.
2.5 Flow cytometry

Flow cytometry is a technique to investigate cell populations at the single-cell level through labelling cells with fluorescent antibodies and suspending cells in dynamic fluidics to pass through the flow cytometer. As the cells traverse the laser beam, fluorescent light emission from the cells is detected and converted to electronic signals, subsequently processed and visualised on a monitor for analysis (Figure 2-3).

Flow cytometry was used to investigate the cluster of differentiation (CD) surface antigens for MSC characterisation. Cells were obtained from a T75 flask at 90% confluence, trypsinised using trypsin/EDTA, and re-suspended in flow cytometry buffer (0.5% BSA and 2 mM EDTA in PBS). Suspension cells were equally divided into 10 Eppendorf tubes and centrifuged at 300 g for 10 minutes in preparation for antibody conjugation. Phycoerythrin conjugated antibodies (CD14, CD19, CD34, CD45, CD73, CD90, CD105, HLA-DR, and isotype controls IgG1 and IgG2a) were diluted in flow cytometry buffer. The diluted concentration of each antibody was based on manufacturer’s suggestion (Miltenyi Biotec). After centrifuging cell suspension, supernatant was discarded and cell pellets were re-suspended in 50 μl diluted antibody followed by incubation in the dark at 4 °C for 15 minutes. 1 ml of flow cytometry buffer was added to each tube and cells centrifuged at 300 g for 10 minutes, removed supernatant, re-suspended in 300 μl buffer for flow cytometry analysis. Flow cytometry was carried out using Beckton Dickinson FC500 and at least 50,000 events were acquired for each assessment. Data were analysed using Flowing Software to produce colour dot plots, histogram plots and set gates for analysing percentage of positive events. Isotype control IgG1 was used for CD19, CD73, CD90, CD105; IgG2a was for CD14, CD34, CD45, HLA-DR analysis.
Figure 2-3. Flow cytometry technique

The sheath fluid mobilises cell suspension and directs it through laser beam as a single event per time. Forward scatter, associated with the size of the particle, and side scatter, reflecting the granulosity of the cell can be detected without the requirement of specific labelling. The appropriate lasers should be assigned for the corresponding excitation and emission spectra which can identify the positive staining of fluorescent markers. Reproduced from Menon et al.\textsuperscript{230}
2.6 Tri-lineage differentiation and assessment

Cells at passage 3 were seeded in a 24-well plate in complete growth media (DMEM with 10% FBS, 1% L-glutamine, and 1% NEAA) overnight to allow attachment. Following cell adherence, the medium was replaced with a differentiation medium, which was changed every 3 days during the 21-day culture. All images of differentiation were monitored with an inverted optical microscope (Olympus).

2.6.1 Osteogenesis

To induce osteogenic differentiation, $2 \times 10^4$ cells/well were seeded in a 24-well plate and cultured in differentiation media consisting of 50 µM ascorbic acid, 10 mM β-glycerol phosphate, and 0.1 µM dexamethasone in complete growth media$^{231}$.

Osteogenesis was evaluated by the stain of mineral deposition in differentiated osteoblasts with alizarin red S. Following removing the differentiated media, cells were fixed by 500 µl/well of 10% formalin for 20 minutes, washed with PBS, and incubated in 2% alizarin red S solution for 10 minutes. Alizarin red S was prepared in distilled water (dH$_2$O) and paper filtered. Stained wells were then washed gently using tap water and allowed to dry for imaging.

2.6.2 Adipogenesis

For adipogenesis, $2 \times 10^4$ cells/well were seeded and cultured in complete growth media supplemented with 0.5 µM dexamethasone, 0.5 mM 3-Isobutyl-1-methylxanthine (IBMX), 10 µg/ml insulin, and 100 µM indomethacin$^{232, 233}$.

Adipogenesis was assessed by Oil Red O stain for intracellular lipid droplets. Oil Red O stock
solution was prepared by dissolving 350 mg of Oil Red O in 100 mL isopropanol and shaking overnight on a rotator. Oil Red O working solution was prepared freshly prior to staining by mixing 6 parts of Oil Red O stock solution with 4 parts of dH2O and filtered through a 0.2 μm filter. For staining, cells were washed, fixed with 10% formalin as described in osteogenesis assessment, and rapidly washed with 60% isopropanol. Filtered Oil Red O working solution was added and incubated for 10 min, which was then washed 3 times with dH2O and imaged immediately.

For quantitative analysis of positive staining, 500 μl of 100% isopropanol was added to each well and incubated for 10 minutes with gently shaking to ensure all the Oil Red O staining was eluted. 100 μl of the solution was transferred to each well in a 96-well plate and measured the absorbance at 500 nm. 100% isopropanol was used as blank.

2.6.3 Chondrogenesis

To induce chondrogenic differentiation, 1 x 10^5 cells were re-suspended in 8 μl of medium and dropped in the centre of the well as a micromass. After 1-hour incubation in the standard culture condition to allow cells to attach to the culture surface, micromass was then replenished with chondrogenic differentiation media, supplemented with 1% ITS, 0.1 μM dexamethasone, 50 μM ascorbic acid, 40 μg/mL L-proline, 1% sodium pyruvate, and 10 ng/mL TGF-β3 in complete growth media with reduced FBS to 1%.

After 21-day differentiation period, cells were fixed and proteoglycan-rich matrix accumulation was detected by Alcian blue for chondrogenesis evaluation. 1% Alcian blue solution was prepared by dissolving 0.5 g Alcian Blue 8GX in 50ml of 3% acetic acid (pH 1.5) and paper filtered. Fixed cells were incubated with 1% Alcian blue solution overnight, washed gently with tap water, and images were captured immediately.
2.7 RNA extraction and reverse transcription

Total RNA was extracted by TRizol reagent, a monophasic solution of phenol, guanidine isothiocyanate, and proprietary components for suppressing RNase activity and isolating RNA from large or small numbers of cells and tissue samples.

RNA isolation process was conducted in a biosafety cabinet. Cell monolayer was rinsed with PBS and 1 ml of TRizol reagent (ThermoFisher) per well in a 6-well plate was added to lyse the cells. Cell lysate was transferred to a 1.5 ml Eppendorf tube, vortexed thoroughly and incubated for 10 minutes to permit complete dissociation of the nucleoproteins complex. 0.2 ml of chloroform was added and samples were vortexed for 15 seconds repeating for 2-3 times. Following centrifuging at 12,000 g for 15 minutes at 4 °C, the mixture separated into a lower red phenol-chloroform, an interphase, and an upper aqueous phase where RNA remained exclusively. The upper aqueous phase was then transferred to a new Eppendorf tube containing 0.5 ml of isopropanol, mixed and incubated for 10 minutes before centrifuging at 12,000 g for 10 minutes at 4 °C to allow RNA precipitation. A white small pellet at the bottom of the tube was washed with 1 ml 75% ethanol twice by briefly vortexing and pelleting at 7,500 g for 5 minutes at 4 °C. Supernatant was discarded and air dried the RNA pellet for 10 minutes, followed by re-suspending the pellet in 20 µl of RNase-free water. To solubilise the pellet, Eppendorf tubes were incubated in a 55 °C water bath for 10–15 minutes. RNA was stored at -80 °C for further applications.

RNA concentration and purity was determined by Nanodrop spectrophotometer (ND-2000). 1 µl of RNA was used for measurement and the ratio of A_{260}/A_{280} was around 1.8-2.2 which is generally accepted as good RNA quality. For microarray experiments, in order to obtain high purity of RNA, 1 x 10^7 cells were pelleted at 1,000 rpm for 5 minutes and stored in 1 ml of RNAlater solution (Sigma) at 4 °C. Samples were sent to Welgene Biotech Company for
Complementary DNA (cDNA) was prepared from 1 μg of total RNA using High-Capacity cDNA Reverse Transcription Kit (ThermoFisher). RNA was diluted to a desired concentration in RNase-free water with a total volume of 10 μl. Equal volume of reverse transcription master mix was prepared based on manufacturer’s instruction and mixed with diluted RNA samples. Samples were briefly centrifuged and loaded to a thermal cycler (MJ Research PTC-200). The program for reverse transcription: 25 °C for 10 minutes, 37 °C for 2 hours, 85 °C for 5 minutes, and cooling down to 4 °C before removing the samples from thermal cycler. The cDNA samples were stored in -20 °C for further applications.
2.8 Real-time polymerase chain reaction (qPCR)

Gene expression analysis was evaluated by real-time PCR using QuantiFast SYBR Green PCR Kit (Qiagen). All cDNA was diluted 1:4 in RNase-free water and used to perform real-time PCR. 2 μl of diluted cDNA was mixed with an appropriate amount of SYBR Green master mix based on manufacturer’s instruction alongside 250 nM of respective forward and reverse primers. Primers were designed to be fully complementary to template DNA sequences using NCBI Primer-BLAST online tool. Primers were 18 - 25 nucleotides in length, containing 40 - 60% GC content, and lacking significant secondary structures, and primer pairs were approximately the same length. Regions of complementarity at the 3’ end of primers were minimised to reduce the potential for the formation of primer dimer236.

SYBR Green generates a fluorescent signal when bound to double stranded DNA during the course of amplification. The fluorescent signal represents the relative abundance of product determined by the comparison of the cycle number that each sample has accumulated sufficient fluorescence to cross an arbitrary threshold value. The threshold level is set in the exponential phase of product amplification and above background levels for all samples (Figure 2-4A). A melting curve (dissociation curve) analysis shows the change in fluorescence observed when double-stranded DNA with incorporated dye molecules (SYBR Green) dissociates into single-stranded DNA as the temperature of the reaction is raised237. Primer-dimers, non-specific or mismatched sequences generally have a lower melting temperature than the specific PCR product of the reaction (Figure 2-4B). Therefore, melting curves analysis was used to check real-time PCR reactions for primer-dimers and to ensure reaction specificity during assay optimisation. Real-time PCR used in this study depended on relative quantification and was unaffected by the lack of quantitative DNA standards, as the ratio of two targets was assessed within the same assay and many of the sources of
measurement uncertainty similarly affected both determinations, and thus did not influence the final result.238

Figure 2-4. Real-time PCR amplification and dissociation curve
(A) The three phases of fluorescence accumulation across cycles during a real-time PCR amplification – initiation phase (early exponential), exponential phase (log-linear), and plateau phase. A threshold is set on the log-linear phase of amplification curve. (B) The post-amplification melting curve (dissociation curve) analysis to differentiate specific PCR products from primer dimers.

The cycle at which the threshold is passed (CT) was normalised for all samples using the CT
value for the housekeeping reference gene GAPDH (glyceraldehyde 3-phosphosphate dehydrogenase). The choice of GAPDH as the reference gene was validated for every sample and confirmed that it remained constant in all samples being compared at all points of the experiment. All runs included a no-template control (NTC) which contained all reaction components except the cDNA sample. If an amplification curve appears in NTC, it indicates the existence of primer-dimers or contamination with completed PCR reaction product, which can lead to inaccurate expression levels. Every pair of primers used in this study was optimised for its ideal melting temperature (Tm, Table 2-3), which results in the lowest variation in replicates, a negative NTC, a melting curve analysis revealing detection of a specific product and high reproducibility between replicate reactions (Figure 2-4B). All primers were optimised via a test run, including three experimental samples in triplicates and a NTC control.

The total volume of each reaction mixture was 15 μl and real-time PCR was carried out in real-time PCR system (Agilent Stratagene Mx3000P). Primer sequences for each gene are shown in Table 2-3. All samples were amplified at 95 °C for 10 minutes followed by 40 cycles of a denaturation step at 95°C for 10 seconds, and a 30-second annealing step at the optimised temperature for the primers (Table 2-3). The expression levels of genes were normalised to the reference gene, GAPDH ($\Delta Ct = Ct_{(target)} - Ct_{(reference)}$), and compared with controls to generate the $2^{-\Delta \Delta Ct} (\Delta \Delta Ct = \Delta Ct_{(experimental)} - \Delta Ct_{(control)})$ for calculating relatively fold changes.
<table>
<thead>
<tr>
<th>Gene ID</th>
<th>Forward sequence</th>
<th>Reverse sequence</th>
<th>Tm</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADIPOQ</td>
<td>AGGCCGTGATGGCAGAGATG</td>
<td>CTTCTCCAGGTTCTCTTCTGC</td>
<td>60</td>
</tr>
<tr>
<td>ALDH1A1</td>
<td>TCAAAACCAGCAGAGCAAAC</td>
<td>TAGGCCCATACACAGGAGAACCA</td>
<td>60</td>
</tr>
<tr>
<td>ALDH2</td>
<td>CTGCTGACCGTGGTAGTAC</td>
<td>CTCTGACGGTGGCTCTTCT</td>
<td>60</td>
</tr>
<tr>
<td>ALDH3B1</td>
<td>GCTGAGGAGCAGCGAGATTAC</td>
<td>GCTGGGACTACCTGGGACCTC</td>
<td>60</td>
</tr>
<tr>
<td>AQP1</td>
<td>CTGAGCTGAGGCCTCTTCTTA</td>
<td>TCAAGGAGACGGGTGGAATTG</td>
<td>60</td>
</tr>
<tr>
<td>CCL17</td>
<td>CGGGACTACCTGGGACCTC</td>
<td>CCTCACTGCTGCTTCTTCTTA</td>
<td>60</td>
</tr>
<tr>
<td>CD24</td>
<td>CGGGACTACCTGGGACCTC</td>
<td>AGAGGTGACGCGCAAGGGAC</td>
<td>60</td>
</tr>
<tr>
<td>CELSR1</td>
<td>TACTCTGCGGTGCTTGTTT</td>
<td>GCAAAAAACGGTTGCTCCTTCC</td>
<td>58</td>
</tr>
<tr>
<td>CTCF</td>
<td>GCCTGTTCCAAGACCGCTG</td>
<td>GGGCTACTGGTCTATGCTTA</td>
<td>60</td>
</tr>
<tr>
<td>CXCL8</td>
<td>CGGGACTACCTGGGACCTC</td>
<td>CTTTGGCAGCAAGACAGGTCTT</td>
<td>60</td>
</tr>
<tr>
<td>CXCL12</td>
<td>CGGGACTACCTGGGACCTC</td>
<td>GGGCTAAACGGTTGCTCCTTCC</td>
<td>58</td>
</tr>
<tr>
<td>EDN1</td>
<td>CCATGAGGAAACACGGCAGT</td>
<td>CGAAAGGTCTGTCACCAATGT</td>
<td>60</td>
</tr>
<tr>
<td>FLNB</td>
<td>TGATCTTATGCTGCTCTTCCGT</td>
<td>GACAGTTTAGCCGAGCTGC</td>
<td>60</td>
</tr>
<tr>
<td>GAPDH</td>
<td>GCACAGGCTGACACCTC</td>
<td>GCACAGGCTGACACCTC</td>
<td>58</td>
</tr>
<tr>
<td>GLUT2</td>
<td>GCACAGGCTGACACCTC</td>
<td>GCACAGGCTGACACCTC</td>
<td>58</td>
</tr>
<tr>
<td>HBEFG</td>
<td>ACTCTGCTGACTGCACCACC</td>
<td>GCACTGTGCAAGCAAGAG</td>
<td>60</td>
</tr>
<tr>
<td>HMOX1</td>
<td>TCCCTGACTGCACTGCTTACC</td>
<td>GAGATGTGACTGCTTGGGGG</td>
<td>60</td>
</tr>
<tr>
<td>IL-1B</td>
<td>ATCTCTGACTGAAAGGCTTCA</td>
<td>TATCCGACTGCTGAGAAG</td>
<td>60</td>
</tr>
<tr>
<td>IL-10</td>
<td>TCAGGCGGACTGAAAGCCTTAC</td>
<td>CCTTGCTCTTCCATGACAG</td>
<td>60</td>
</tr>
<tr>
<td>IL-12</td>
<td>AAAGGAGACATCTGCGAGAGAGT</td>
<td>CAAAGGATCCGAGCGTGCCTATC</td>
<td>60</td>
</tr>
<tr>
<td>INS</td>
<td>TGCCAACAATCTCATACTCAA</td>
<td>TACAGACAGGAGGACCAGAGCAT</td>
<td>58</td>
</tr>
<tr>
<td>ISL1</td>
<td>GCAGCTCTTGTGAACCAAACA</td>
<td>TTCCCACCACTAGTGTAGAGA</td>
<td>58</td>
</tr>
<tr>
<td>MET</td>
<td>TGTCAGAGAGAGAATGG</td>
<td>TATCTGGATGGGAGTATCCG</td>
<td>58</td>
</tr>
<tr>
<td>MRC1</td>
<td>ACCTCACAAGCCAACACCAC</td>
<td>CTTTTCATGGACTGCAAGGA</td>
<td>58</td>
</tr>
<tr>
<td>NANOG</td>
<td>CAACTGGTCAATTTCAGGAGGA</td>
<td>TTGAGGAAGGATTTGACAT</td>
<td>55</td>
</tr>
<tr>
<td>NEUROG3</td>
<td>CCCAGGCTTACTCTTCTACCAC</td>
<td>ATCTGCTGACTGAGAAGGA</td>
<td>60</td>
</tr>
<tr>
<td>NMX2.5</td>
<td>CACAGGCTTACTCTTCTACCAC</td>
<td>ATCTGCTGACTGAGAAGGA</td>
<td>60</td>
</tr>
<tr>
<td>NOG</td>
<td>CATGCCGAGGACGATCAA</td>
<td>CAGCCGATCGTAACTCCCTTCT</td>
<td>60</td>
</tr>
<tr>
<td>NPPB</td>
<td>TGAAGAAGTCCGGTTTACAG</td>
<td>GACTTTCAAGCAACCTGTTGGG</td>
<td>60</td>
</tr>
<tr>
<td>NQO1</td>
<td>GGAGATGACACCACTGATT</td>
<td>AGTGGGATCAGGAGAA</td>
<td>60</td>
</tr>
<tr>
<td>OCT4</td>
<td>CTATTCTTCTGCGCCGGTTAGA</td>
<td>CTCAGGGGTCACTGGGACAGT</td>
<td>55</td>
</tr>
<tr>
<td>PAX6</td>
<td>GTCCAGGTGCTGCTTCTTGA</td>
<td>CTCAGTTGTAAGCATGGGGA</td>
<td>58</td>
</tr>
<tr>
<td>PDGFA</td>
<td>GGAAAGCGAGGAGGAGAAGA</td>
<td>GGCCAGGAGGAGGAGGAACAG</td>
<td>58</td>
</tr>
<tr>
<td>PDX1</td>
<td>TGTCAACAGGATGGTTAGTA</td>
<td>TCCCGCTTTACTGCGGGTATTTT</td>
<td>60</td>
</tr>
<tr>
<td>PPARG</td>
<td>GGAGAGATCTCAAGGACTT</td>
<td>CTTGCAAGATGTTGCAACTTG</td>
<td>58</td>
</tr>
<tr>
<td>Gene</td>
<td>Exon 1</td>
<td>Exon 2</td>
<td>Length</td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------</td>
</tr>
<tr>
<td>RASIP1</td>
<td>CGTCTCCTTGAGAACCACC</td>
<td>CATCCACGCGGGATAAGA</td>
<td>60</td>
</tr>
<tr>
<td>RSPO3</td>
<td>CACCCTTATCTGACAATTGA</td>
<td>ATGCAGGAGGATCTGACATA</td>
<td>60</td>
</tr>
<tr>
<td>SOD2</td>
<td>GGACAAACCTCAGCCTAACC</td>
<td>GCCGTCAGCTTCTCTTAAA</td>
<td>60</td>
</tr>
<tr>
<td>SOX2</td>
<td>TTCCGGAAGAAAAGAGCCA</td>
<td>AAACAGGTCCCAAGGATGAAT</td>
<td>57</td>
</tr>
<tr>
<td>TGFBR2</td>
<td>ATCGCGCATTGCTTTAGA</td>
<td>ACCCTTTGGTTCGTTATC</td>
<td>60</td>
</tr>
</tbody>
</table>
2.9 Immunology characterisation

2.9.1 Culture and stimulation of Jurkat cells

Jurkat T cells were originally cultured in 10% FBS RPMI 1640 and gradually adapted to 10% FBS DMEM through culturing in a mixture of RMPI and DMEM at the ratio of 4:1, 2:1, 1:1, 0.5:1, and 0:1 with each subculture. For subculture, suspension Jurkat T cells were transferred to a centrifuge tube, pelleted at 1,000 rpm for 5 min, removed supernatant, and re-suspended in fresh growth media. Cells were seeded at a density of $1 \times 10^5$ cells/ml in 25 ml growth media in a T75 flask.

To induce activation of Jurkat T cells, $5 \times 10^5$ cells/ml were stimulated with 5 μg/ml phytohaemagglutinin (PHA, stock solution 0.5 mg/ml in PBS) and 50 ng/ml phorbol 12-myristate 13-acetate (PMA, stock solution 100 μg/ml in DMSO) and control samples (without PHA and PMA) were received same amount of DMSO treatment. PHA is a lectin that binds to the T cell receptor and leads the stimulation of signal transduction for IL-2 secretion. Likewise, PMA is a small organic compound, which can diffuse through cell membrane into cytoplasm and directly activate protein kinase C leading to IL-2 production. The combination of PHA and PMA strongly enhanced Jurkat cells IL-2 production\textsuperscript{339}.

2.9.2 Supernatant collection

The secretion of cytokine interleukin 2 (IL-2) is considered as an active state of Jurkat cells. Activated Jurkat cells were cultured in conditioned media from CMSCs or AMSCs for 24, 48, and 72 hours. Supernatant was collected at each time point for IL-2 ELISA assays, centrifuged at 1,500 rpm for 5 minutes to remove cell debris and transferred to a new Eppendorf tube for storage in a -80 °C freezer. CMSC and AMSC conditioned media
incubated in an empty well without Jurkat cells was used as a blank control.

2.9.3 Culture and stimulation of THP-1 cells

Human monocytes THP-1 cells were maintained in DEME containing 10% FBS, 1% L-glutamine, 1% Penicillin-Streptomycin. As both Jurkat cells and THP-1 monocytes are suspension cell lines, the same sub-cultured method described in section 2.9.1 was applied to THP-1.

To simulate THP-1 cells for microphage polarisation, THP-1 cells were treated with 50 ng/ml PMA for 24 hours. Roughly 80% of suspension THP-1 attached to flask after 24 hours, indicating a differentiated state (M0 macrophage) and the suspension cells were removed by media change. M0 macrophages were polarised to M1 macrophages by incubation with 20 ng/ml of interferon-γ (IFN-γ) and 10 pg/ml of lipopolysaccharide (LPS). Macrophage M2 polarisation was induced by incubation with 20 ng/ml of interleukin 4 (IL-4).

2.9.4 Co-culture system

In co-culture experiments, 5 × 10^5 THP-1 cells were placed to a well in 12-well plates and treated with PMA for 24 hours. Media was gently aspirated and changed to 1.5 ml fresh media. The Transwell inserts (membrane pore size of 0.4 μm, Corning) were then placed into each well and 5 × 10^5 CMSCs or AMSCs in 0.5 ml media were added to the Transwell insert. Following incubation for 24 hours, supernatant was collected, centrifuged at 1,500 rpm for 5 minutes, and transferred to a new Eppendorf tube for storage at -80 °C. The adherent THP-1 cells at the bottom of the wells were lysed with TRlzol reagent (ThermoFisher) for RNA extraction.
2.10 ELISA assay

ELISA (enzyme-linked immunosorbent assay) is designed for detecting and quantifying peptides, proteins, and hormones. ELISA assays performed in this study were sandwich ELISA, which involved an attachment of a capture antibody to a microplate, binding of target protein to the capture antibody, and then the detection of signals via a conjugated antibody and an enzymatic substrate. ELISA was performed in a 96-well plate and all samples were performed in duplicate.

2.10.1 IL-2, IL-10, TNF-α

The human IL-2, IL-10, and TNF-α development kits were purchased from PeproTech containing a recombinant protein, standards, capture antibody, detection antibody (biotinylated antibody). For ELISA assay, every wash step mentioned in this protocol was performed by adding 300 μl wash buffer (0.05% Tween-20 in PBS) per well, flicking the plate for aspiration, patting the plate on a paper towel and the entire procedure was done in 3-4 repeats.

To coat the plate with capture antibody for targeting the specific antigen in the samples, monoclonal capture antibody (IL-10, IL-2, TNF-α) was diluted in PBS to a concentration of 1 μg/ml and added 100 μl to each well. The plate was sealed and incubated overnight at room temperature. Following the wash step, 300 μl blocking buffer (1% BSA in PBS) was added to each well and incubated for 1 hour. The plate was then washed and ready for protein (antigen) detection from supernatant collected in section 2.9. The standard was serially diluted from 0.01 μg/ml to zero in diluent (0.05% Tween-20, 0.1% BSA in PBS). 100 μl of standard or samples was added to each well and incubated at room temperature for 2 hours. For signal detection, the plate was washed and incubated with 100 μl diluted detection
antibody (IL-10, IL-2, TNF-α; 0.5 μg/ml in diluent) recognising a different epitope on the target protein for 2 hours, followed by Avidin-HRP conjugate through incubation with diluted Avidin-HRP secondary antibody (1:2000 in diluent) for 30 minute. To read the signal by plate reader, the plate was washed and 100 μl of ABTS-substrate (2,2’-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid)) was added to each well, which changed the colour from yellow to green/blue-ish during reaction, indicating the presence of the protein-of-interest in the samples. The plate was read every 5 minute intervals until desired OD readings were obtained for a maximum 40-minute period. The signal was read at 405 nm with wavelength correction set at 650 nm by a plate reader. The standard curves used to determine the concentration of the samples were shown in Figure 2-5. The best fitting trendline and equation was calculated by Excel using a second- or third-degree polynomial equation based on the R² value. R² evaluates the scatter of the data points around the fitted regression line. The R² value >0.99 was used for standard curve equation.

**Figure 2-5. ELISA standard curves for IL-10, TNF-α, and IL-2**
The mean O.D. values of the standards (X-axis) obtain from duplicate absorbance were plotted against the known concentration of the standard (Y-axis). The best fitting standard curves and equations were calculated based on the $R^2$ value greater than 0.99.

### 2.10.2 Insulin and C-peptide

The secreted insulin, C-peptide, and intracellular insulin content was measured by commercialised specific insulin or C-peptide ELISA with pre-coated plate and highly specific capture antibody. To induce insulin/C-peptide release, undifferentiated CMSCs/AMSCs (controls) or CMSC/AMSC-derived insulin producing cells were washed with PBS and pre-incubated for 1 hour in phenol red-free DMEM without glucose and then media was switched to phenol red-free DMEM with glucose at different concentration for glucose challenge. The media volume for glucose challenge was 1 ml/well in a six well plate. Cells were first incubated in 5.5 mM glucose (low glucose) phenol red-free DMEM for 1 hour and supernatant was collected by centrifuging at 1,500 rpm for 5 minute to remove cell debris and stored in -80 °C for measurement of released insulin/C-peptide with ELISA assays. Cells were then incubated in 25 mM glucose (high glucose) phenol red-free DMEM for 2 hours and supernatant was collected for ELISA analysis. The phosphodiesterase inhibitor, IBMX (0.5 mM) known to stimulate insulin secretion was added together with 5.5 mM or 25 mM glucose in phenol red-free DMEM. After subsequently incubating with low and high glucose media, cells were trypsinised and lysed in 200 µl RIPA buffer (radioimmunoprecipitation assay buffer) for measuring the intracellular insulin content by ELISA. The protein concentration was measured using Thermo BCA (bicinchoninic acid) protein assays and absorbance was detected by a plate reader against a BSA standard. All samples (supernatant and protein) were stored at -80 °C until use.

The insulin ELISA was performed following the manufacturer’s instructions (Abcam). All the solutions were provided with the kit. Briefly, 50 µl of all samples and serially diluted
standards was added to each well and incubated with 50 µl antibody cocktail for 2 hours on a plate shaker at 400 rpm. Antibody cocktail was prepared by diluting the capture and detector antibody in diluent. The plate was washed 3 times and 100 µl of 3,3′,5,5′-Tetramethylbenzidine substrate (TMB) was added for a 30-minute incubation in the dark on a plate shaker. Following the addition of 100 µl stop solution to each well, an endpoint reading was recorded at 450 nm using a plate reader.

The C-peptide ELISA was performed by ALPCO C-peptide ELISA kit, using the test procedure for 25 µl sample volume as per the manufacturer’s instructions. 50 µl of assay buffer was added to each well and the plate was incubated on a shaker at 800 rpm for 2 hours. Following incubation, each well was washed and samples were incubated with 100 µl enzyme conjugate solution. For signal detection, the plate was washed, 100 µl TMB was added to the well, and incubated for 30 minutes on a plate shaker. 100 µl of stop solution was then added to each well and absorbance measured at 450nm by a plate reader. The insulin and C-peptide ELISA standard curves were shown in Figure 2-6 and the calculation methods were described in section 2.10.1.
Figure 2-6. ELISA standard curves for insulin and C-peptide
The mean O.D. values of the standards (X-axis) obtain from duplicate absorbance were plotted against the known concentration of the standard (Y-axis). The best fitting standard curves and equations were calculated based on the R2 value greater than 0.99.
2.11 Live/dead viability assay

Cell viability assay was assessed using two-colour fluorescence LIVE/DEAD viability/cytotoxicity assay kit (ThermoFisher) and fluorescent images were captured by confocal microscope. The calcein-acetoxy methyl (calcein-AM, ThermoFisher) indicates intracellular esterase activity while ethidium homodimer-1 (EthD-1, ThermoFisher) indicates the loss of membrane integrity. Adherent cells were washed with PBS and incubated with calcein-AM (1 µM) and EthD-1 (4 µM) in PBS at 37 °C in the dark for 20 minutes. Cells were then gently rinsed with PBS to remove residual fluorescent dyes and viewed under a confocal microscope. Images were taken immediately and fluorescence emission was detected at 530 nm for calcein-AM (live cells) and at 645 nm for EthD-1 (dead cells).

2.12 Beta-galactosidase senescence assay

Senescence was characterised by the induction of senescence-associated β-galactosidase (SA-β-gal) activity, which is present only in senescent cells, not in quiescent or proliferating cells. Senescence was confirmed by the catalytic activity of SA-β-gal which catalyses the hydrolysis of Xgal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside, Merck) and results in the accumulation of blue precipitate.

To detect SA-β-gal activity, cells were washed with PBS before being fixed using fixation solution supplied with the cellular senescence kit (Merck) for 15 minutes at room temperature. The SA-β-gal detection solution was prepared following the manufacturer’s instruction by diluting the Xgal in staining solution and PBS. After fixation, cells were washed with PBS and incubated with the detection solution at 37 °C in the dark for at least 4 hours or overnight. The detection solution was then removed and cells were washed with
PBS. However, sometimes salt crystals were observed when incubating overnight while excess amount of salt crystals could be removed by briefly incubating the stained samples with DMSO for 10 seconds. Images were obtained under bright-field microscope and blue stained cells were counted from several random fields of each samples.

### 2.13 Immunofluorescence staining

The staining was performed on insulin producing cells (IPCs) to confirm the differentiated state of CMSCs/AMSCs. Cells were cultured in an 8-well chamber slide for IPC differentiation and fixed with 4% paraformaldehyde in PBS for 20 minutes at the end of differentiation period to inhibit degradative process of proteins. Fixed cells were either covered in PBS and stored in 4 °C up to a week or performed immunostaining straight away.

Before any antibodies were introduced, cells were permeabilised with 0.3% TritonX-100 in PBS for 15 minutes and blocked potential nonspecific binding sites by incubation with blocking buffer (1% BSA, 0.1% TritonX-100 in PBS) for 1 hour at room temperature. The primary antibody was diluted in 1% BSA in PBS. The appropriate amount of diluted primary was added into the samples and incubated overnight at 4 °C. After washing with PBS, the samples were then incubated with secondary antibodies diluted in 1% BSA in PBS and incubated at room temperature for 2 hours following by counterstained with 4,6-diamidino-2-phenylindole (DAPI) for 10 minutes. The samples were washed with PBS before taking images by confocal microscope.

The following antibodies and dilutions were used – anti-insulin (1:100, Santa Cruz Biotechnology, sc-9168), anti-PDX-1 conjugated to Alexa Fluor 488 (1:100, Santa Cruz Biotechnology, sc-390792 AF488), and Alexa Fluor 594 secondary antibody (1:200, Invitrogen).
2.14 Migration assay

2.14.1 Transwell assay

Transwell assay was performed at passage 3. Cells were trypsinised and re-suspended in serum free DMEM. Transwell filters with 8 μm pores were placed in a 24-well plate and 2 x 10^5 cells in 200 μl serum free media were added to a Transwell chamber. The plate was incubated in 37 °C incubator for 10 minutes and then 550 μl of complete growth media containing 10% FBS was added to the lower chamber. Cells were allowed to migrate for 8 or 24 hours at 37 °C.

To assess the migration, at the end of incubation period, Transwell inserts were carefully transferred to a new empty well and cells that did not migrate through the pores remaining on the upper side of the filter were removed with a cotton swab. This process was repeated 3-4 times to completely remove cell debris and every time a clean cotton swab was moisturised with dH₂O to avoid breaking Transwell membrane when wiping off the cells. Cells that migrated through the membrane were fixed by placing Transwell inserts in 100% methanol for 15 minute and rinsed with PBS. Cell staining was performed by placing Transwell inserts in 0.1% crystal violet dissolved in 20% ethanol/PBS solution for 15 minutes. The excess crystal violet was removed by briefly washing with dH₂O for few seconds and the upper side of the membrane was gently wiped with a cotton swap. The membrane was allowed to dry for one hour and images were captured by light microscope. Cell migration was quantified by counting migrated cells in five randomly selected fields in each sample.

2.14.2 Wound healing assay

A number of 5 x 10^5 cells was seeded into each well in a 6-well plate and cultured for 2 days
until reaching confluence as a monolayer. Wound was created by scratching with a 200-μl pipette tip across the surface of the well. After scratching, wells were washed twice with media to remove suspension cells and cell debris. In order to obtain the same field during image acquisition at different time points, the reference point was made by marking the plate with a fine tip marker on the outer bottom of the plate. The plate was then incubated at 37 °C for 6 or 12 hours and cell migration towards the gap area was recorded using a light microscope. Relative cell migration was calculated by measuring final wound area compared to initial area using ImageJ.

### 2.15 ALDH activity assay

Aldehyde dehydrogenase (ALDH) enzymatic activity was quantified by Sigma’s ALDH Activity Assay Kit. In ALDH activity measurement, acetaldehyde was oxidised by ALDH generating nicotinamide adenine dinucleotide (NADH), which reacted with a probe and generated a colorimetric (450 nm) coloured product proportional to the ALDH activity present. According to manufacturer’s instruction, one unit of ALDH is the amount of enzyme that will generate 1.0 μmole of NADH per minute at pH 8.0 at room temperature.

1 x10⁶ cells were homogenised in 200 μl of ice-cold ALDH assay buffer and centrifuged at 13,000 g for 10 minutes to remove insoluble cell debris. The supernatant was transferred to Eppendorf tubes and kept on ice. Reaction mix was prepared by adding an appropriate proportion of ALDH assay buffer, ALDH substrate mix, and acetaldehyde supplied with the kit based on manufacturer’s instruction. For background signal correction, a blank was set up for each sample by omitting the acetaldehyde from reaction mix. 50 μl of supernatant from each sample or serially diluted standard was added into a 96-well plate and then the equivalent volume of reaction mix was added to each well. The plate was protected from light and incubated on a plate shaker for 5 minutes. Changes in absorbance for ALDH activity
were measured at 450 nm every 5 minutes over a 30-minute period. The plate was protected from light during the entire incubation period. All samples were performed in duplicate.

The absorbance was corrected to the blank and the activity of ALDH was calculated by the following equation:

\[
\text{ALDH activity} = \frac{(T_{\text{final}} - T_{\text{initial}})}{(\text{Reaction time (minutes)})} \times V
\]

The absorbance at 450 nm at the initial \(T_{\text{initial}}\) or final \(T_{\text{final}}\); the amount (nmole) of NADH generated between initial and final \(T_{\text{final}} - T_{\text{initial}}\); duration time between initial and final (Reaction time); sample volume added to the well \(V\). ALDH activity is described as nmole/min/mL = milliunit/mL

### 2.16 Detection of ROS

Reactive oxygen species (ROS) was indicated by 2',7' - dichlorofluorescin diacetate (DCFDA, also known as H2DCFDA, Sigma). After diffusion into cells, DCFDA is deacetylated by intracellular esterases and oxidised by ROS converting into 2', 7' - dichlorofluorescein (DCF). DCF is a highly fluorescent compound which can be detected by fluorescence spectroscopy with an excitation and emission spectra of 485 nm and 535 nm, respectively.

Cells were seeded at 10,000 cells/well in a 96-well plate and allowed attachment for overnight incubation at 37 °C. The DCFDA working solution was prepared by diluting 20 mM DCFDA/DMSO in assay buffer to a concentration of 25 μM. After attachment, cells were washed with PBS and incubated with 25 μM DCFDA solution for 45 min at 37 °C in the dark. DCFDA solution was then removed and cells were treated with glucose to induce metabolic activity for the desired time period. Tert-Butyl Hydrogen Peroxide (TBHP) solution supplied
with the kit was used as positive control.

For fluorescent images, ROS detection was observed by confocal microscope. Images were taken from randomly selected fields in each sample. The intensity of fluorescence was measured by a fluorescence plate reader (SpectraMax i3x) and signal was read at excitation/emission: 485/535 nm. A blank well containing no cells (media only) was used as background signal.
Chapter 3

Characterisation of AMSCs/CMSCs from GDM and healthy pregnancies
3.1 Introduction

Cell therapy and tissue engineering using mesenchymal stem cells (MSCs) have emerged as an attractive option in disease treatments seeking to maintain, restore, or enhance tissue regenerate and function. Safe, effective, and reliable cell sources remain a major issue for use in regenerative medicine clinical applications. Bone marrow MSCs have now been widely and successfully used in clinical applications for a number of decades, however some limitations have caused concerns, such as their limited expansion capacities, scarcity within bone marrow, and the invasive and labour intensive isolation process which can associate with an increased risk of infection for the donor. Thus far, MSC derivation has been reported from a wide range of adult tissues including; fat, dental, lung tissue and peripheral blood.

The human placenta, generally discarded post-partum, is now becoming recognised as a plentiful and alternative source of stem cells. Placental MSCs are phenotypically similar to BM-MSCs, in terms of plastic adhesion, immunophenotype, and lineage differentiation potential. It has also been suggested that the placental MSC provides a substantial expansion potential and delayed senescence. Moreover, the ease of access, reduced ethical conflicts, and reduced age-acquired DNA damage makes them a promising source for stem cell therapy.

The placenta plays a vital role in fetal development and maternal health by regulating the metabolic interaction between the mother and fetus. As the intrauterine environment is closely related to placental state, pregnant complications have been associated with abnormal placentation. Gestational diabetes mellitus (GDM), the common pregnancy complication, affects both the mother and fetus during pregnancy, where maternal hyperglycaemia influences fetal programming and leaves mother and child with high a risk
of developing type 2 diabetes later in life\textsuperscript{33, 34}. The GDM environment is also known to have an impact on placental pathology, as discussed in section 1.2.3, implying that the characteristics of stem cells and progenitor cells in GDM placenta are likely to be affected. For example, Hadarits \textit{et al.} (2003) reported the increased proportion of haematopoietic stem cells in cord blood of new-born from GDM pregnancies\textsuperscript{248}; another study showed that perivascular stem cells from umbilical cord of GDM pregnancies had lower cell yield and proliferative rate when compared to healthy pregnancy\textsuperscript{249}. Environmental factors can cause significant effects on cell populations and behaviours; therefore, understanding the biological properties of stem cells is important before applying these cells in clinical applications.

In this study, MSCs were isolated from different sides of the placental membrane – amnion and chorion in healthy and GDM placenta. Due to the higher risk of developing diabetes in women who have had GDM and children from GDM pregnancies, autologous amniotic and chorionic MSCs (AMSCs/CMSCs) free of ethical conflicts and immune rejection hold great therapeutic potential for diabetes therapy. Recent examples include the transplantation of MSC-derived islet cells\textsuperscript{250} and the use of MSC secretome cytokines to promote the regeneration of pancreatic cells\textsuperscript{251, 252} (section 1.4.4). However, the application of MSC therapy to the treatment of human disease requires extensive studies. Establishing biological properties is an essential first step to evaluate the therapeutic potential of each type of MSCs.
3.2 Aim

Considering that the placental environment is affected by pregnant complications and having an impact on placental cells, it would be important to investigate whether the CMSCs and AMSCs derived from GDM placenta are an ideal candidate for cell therapy. Therefore, we aimed to investigate biological differences between AMSCs and CMSCs obtained from GDM and healthy pregnancies for exploring the fundamental differences and environmental impacts on AMSCs and CMSCs.

The main objectives of the chapter:

- Isolate and expand AMSCs/CMSCs from healthy and GDM placental membrane.
- Characterise MSCs via morphological analysis and surface marker expression.
- Examine cell proliferation and tri-lineage differentiation ability (osteogenesis, adipogenesis, chondrogenesis).
- Investigate immunomodulatory capacity of MSCs secretome via conditioned media and co-culture system.
3.3 Methods

Following informed consent placenta was collected from 10 healthy and 10 GDM women undergoing elective caesarean sections, as described in section 2.2. MSCs were isolated from amniotic and chorionic membranes processed in sterile conditions (section 2.3) and cultured in DMEM supplemented with 10%FBS, 1% L-glutamine, 1% NEAA and 1% Penicillin-Streptomycin. Morphologically changes were examined at every passage (section 2.4.2) and all characterisation was performed at passage 3.

Experiments performed in this chapter are summarised in Figure 3-1. Cell morphology was analysed from passage 0-3 and proliferation capacity was examined via cell count, doubling time calculation, and MTT assay during a 12-day period (section 2.4). Surface marker characterisation for MSCs was performed via flow cytometry as described in section 2.5. Tri-lineage differentiation was performed by inducing osteogenesis, adipogenesis, and chondrogenesis in specific differentiation media for 21 days and followed by histological staining with alizarin red, Oil Red O, and alcian blue, respectively (section 2.6). Adipogenic potential was further assessed through destaining of Oil Red O and marker examination by real-time PCR (section 2.6 - 2.8). Immunosuppression of AMSCs/CMSCs was characterised by MSC conditioned media via modulation of Jurkat T cell proliferation and cytokine secretion. Conditioned media was collected from CMSCs/AMSCs and stored at -80°C until further ELISA analysis (section 2.9.2). Co-culture system was used to investigate the immunomodulation of MSCs on THP1 monocyte polarisation and cytokine secretion, as described in section 2.9.
Figure 3-1. Summary of the methodology in chapter 3

Statistical analysis

One-way ANOVA and Tukey post-hoc tests or two-way ANOVA where appropriate were used to determine the statistical significance of observed differences in the mean values among different groups by GraphPad Prism (GraphPad Software). The comparison within two groups was analysed by the simple t-test. The data was presented as mean ± SEM. Each data point represents the average of at least three independent experiments with three repeats in each experiment. A p-value below 0.05 was indicated as statistically significant (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001).
3.4 Results

3.4.1 Morphological analysis

*AMSCs and CMSCs have distinct morphologies independent of disease state*

AMSCs and CMSCs lines derived from healthy (n=10) and GDM (n=10) placenta were used in this study. The details of each pregnancy are shown in Table 3-1. Statistical analysis demonstrated that there were no significant differences between healthy and GDM groups.

<table>
<thead>
<tr>
<th>Table 3-1 Maternal and fetal characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>BMI (kg/m2)</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
</tr>
<tr>
<td>Infant weight (g)</td>
</tr>
<tr>
<td>Gender (female/male)</td>
</tr>
</tbody>
</table>

*Included one non-identical twins placenta.

Data are presented as mean (± standard deviation)

Morphological observation was performed from passage 0-3 indicating that CMSCs from healthy (H-MSCs) and GDM (G-CMSCs) pregnancies exhibited similar fibroblast-like morphologies from passage 0 and maintained stable morphological features during subsequent culture (Figure 3-2A). Conversely, AMSCs morphology differed between healthy (H-AMSCs) and GDM (G-AMSCs) groups where the H-AMSCs displayed a triangular or spindle shape post-seeding for 24 hours while the G-AMSCs, which attached more slowly, displayed reduced adherence and a more cuboidal shape. Typical MSC morphology of H-
G- AMSCs was observed at later passages (Figure 3-2B).
Figure 3-2. Observation of cell morphologies

The morphology of human H-/G- (A) CMSCs and (B) AMSCs from primary culture to passage 2. Images of passage 0 were taken after seeding for 7 days; images of passage 1 and 2 were taken 5 days after subculture. Scale bar = 200 μm.
Although human MSCs, derived from many different tissues, are characterised by a fibroblast-like morphology, cell length could be various depending on different origins\textsuperscript{253}. The CMSC length (the longest axis from the cell periphery) gradually increased and was longer than AMSCs between passage 0 to 2. The morphology of AMSCs became elongated in the subsequent passages, where more fibroblast-shaped cells were detected. Comparison between GDM and healthy pregnancies demonstrated that G-CMSC displayed comparable length to H-CMSCs (Figure 3-3A), while G-AMSCs were shorter than H-AMSCs (Figure 3-3B). Surface area measurement indicated that AMSCs displayed a larger and broader surface area than CMSCs. There was no significant difference in surface area between CMSCs or AMSCs taken from healthy and GDM pregnancies (Figure 3-3C).
Figure 3-3. Cell length and surface area analysis
Cell length of H-/G- (A) CMSCs and (B) AMSCs was measured from passage 0-2. Data are expressed as the mean ± SEM. One-way ANOVA and post-hoc test were conducted to determine the significant differences. (C) Box and whiskers plot of cell surface area measured at passage 2 of each group. Whiskers indicate minimum and maximum, box area the interquartile range with the median indicated by the mid-point line. Data of cell length and area was based on 150 cells per population from 5 independent experiment and analysed by Image J. ***p < 0.001, ****p < 0.0001
3.4.2 Cell proliferation and doubling time

*CMSCs display a faster proliferative rate than AMSCs while GDM has an opposite impact on CMSCs and AMSCs doubling rates*

The proliferation capacity was evaluated every 2 days during a 12-day culture window via cell counting and both H-/G- CMSCs and AMSCs were seeded at 10,000 cells/well in a 24-well plate. H-CMSCs and G-CMSCs both evidenced a short lag-phase at day 0-4, followed by an exponential growth curve from days 4-12. The exponential growth kinetics showed a more significant increase in H-CMSCs than G-CMSCs (Figure 3-4A). On the other hand, the cell numbers of H-AMSCs and G-AMSCs slowly increased for the initial 8 days and gradually reached plateau from day 8-12 with more cell numbers in G-AMSCs than H-AMSCs (Figure 3-4B). Cell doubling time was calculated when H-/G- CMSCs and AMSCs reached exponential growth phase at passage 3. A lower proliferation capacity was exhibited in H-/G- AMSCs with a doubling time of 91.4 hours for H-AMSCs and 81.6 hours for G-AMSCs compared to CMSCs from healthy and GDM placenta with doubling times of 37.9 hours and 44.0 hours, respectively (Figure 3-4C). The data indicated that CMSCs proliferate more rapidly than AMSCs and when comparing the healthy and GDM group, G-CMSCs showed a lower growth ability than H-CMSCs while AMSCs displayed the converse.
10,000 cells at passage 3 were plated in 24-well plates and cell numbers were counted every 2 days. Growth curves of H-/G- (A) CMSCs and (B) AMSCs were shown for a 12-day period. Results are presented as mean from three replicates. (C) Cell doubling time for CMSCs/AMSCs from healthy and GDM placenta was calculated based on cell counts at passage 3. Results represent mean ± SEM. One-way ANOVA was conducted to determine the significant differences, **p < 0.01, ***p < 0.001.
MTT assay was used to indirectly reflect viable cell numbers based on the measurement of mitochondrial metabolic rate\textsuperscript{228}. A reduced metabolic activity in G-CMSCs was observed from day 4 when compared to H-CMSC through the detection of cleaved MTT by metabolically active cells (Figure 3-5A). This may reflect the reduced cell counts observed in the G-CMSCs population (Figure 3-4A). Between H-AMSCs and G-AMSCs the converse was noted where G-AMSCs showed a relatively higher metabolic level than H-AMSCs which was consistent with both previous cell number and doubling time observations (Figure 3-5B and 3-4B). However, no obvious increase in the numbers H-/G- AMSCs at day 8-12 was observed, but the OD value of MTT results continued to increase with time, which may infer that H-/G- AMSCs were still slowing metabolising but not in active cell division phase.

Figure 3-5. Cell proliferation assessed by MTT assay
Metabolic activity was assessed by measuring the MTT dye absorbance in a 12-day period. H-/G- CMSCs and AMSCs were seed at a number of 1,000 cells per well in a 96-well plate and performed MTT assay every 2 days. All assays were conducted in triplicate. OD was read at wavelength of 570 nm. Results represent mean ± SEM, n=6. One-way ANOVA was conducted to determine the significant differences, *p < 0.05, **p < 0.01, ***p < 0.001.
3.4.3 Cell immunophenotype

*Healthy- and GDM- CMSCs/AMSCs immunophenotypes are broadly comparable*

Immunophenotypes of AMSCs and CMSCs were characterised by surface marker expression according to the International Society for Cellular Therapy minimal definition criteria\textsuperscript{109}. H-\textsuperscript{}/G- CMSCs and AMSCs were incubated with antibodies to CD19, CD73, CD90, CD105, CD14, CD34, CD45, HLA-DR and the recommended non-specific isotype control, either IgG\textsubscript{1} or IgG\textsubscript{2a}. Representative histograms of fluorescence intensity for all markers by flow cytometry are shown in Figure 3-6A. The immunophenotype of H-\textsuperscript{}/G- CMSCs and AMSCs were comparable and displayed high levels of expression of typical MSC markers; CD73, CD90, CD105, and low levels of CD14, CD19, CD34, CD45 and HLA-DR. There was no significant difference between CMSCs and AMSCs in either GDM or healthy groups. However, CD45 expression was slightly higher in G-CMSCs/AMSCs when compared to their healthy counterparts; 17.5% ± 2.06% in G-CMSCs, 7% ± 2.6% in H-CMSCs (Figure 3-6B) and 19% ± 1.02% in G-AMSCs, 6.33% ± 1.45% in H-AMSCs (Figure 3-6C).
Figure 3-6. Immunophenotype of H-/G- AMSCs and CMSCs

Immunophenotypic characterisation of H-/G- CMSCs and AMSCs at passage 3 was assessed by FACS to examine the expression of typically negative (CD14, CD19, CD34, CD45, HLA-DR) and typically positive (CD73, CD90, CD105) MSC markers. (A) Representative histograms of MSC markers. Filled histogram, isotype control IgG1 or IgG2a; coloured-line histogram, G-/H-CMSCs or AMSCs samples. (B and C) The graph compared the positive percentage of MSCs marker expressions between H-CMSCs and G-CMSCs or H-AMSCs and G-AMSCs. Similar levels of CD marker expressions were observed in GDM and healthy MSC except for the marginally higher CD45 expression. Results represent mean ± SEM, n=6. Two-sample t-test was conducted to determine the significant differences, *p < 0.05.
3.4.4 Tri-lineage differentiation

GDM environment promotes MSC lineage commitment toward adipogenesis

To investigate differentiation potential, H-/G- CMSCs and AMSCs were exposed to specific differentiation media to induce tri-lineage differentiation as identified by histological staining (Figure 3-7). Following culture in osteogenesis differentiation media, evidence of mineralisation in H-/G- CMSCs and AMSCs was evidenced by alizarin red S stained bone nodules. CMSCs and AMSCs from both GDM and healthy samples had similar level of stained mineralised regions, indicating comparable osteogenic potential.

For chondrogenesis, Alcian blue was used to stain glycosaminoglycans produced during differentiation. H-/G- CMSCs and AMSCs had partly detached from culture plate, formed condensations, showing positive Alcian blue staining, although H-/G- CMSCs formed condensations to a greater extent than H-/G- AMSCs.

Adipogenic potential was assessed by Oil-Red-O stain of lipid droplets produced by cells undergoing adipogenesis. Following culture in adipogenesis differentiation media, H-CMSCs and G-CMSCs stained strongly with Oil-Red-O, especially in G-CMSCs with more stained lipid vesicles. In contrast, H-AMSCs and G-AMSCs appeared to have reduced staining of lipid droplets.

Overall, CMSCs from healthy and GDM samples both exhibited a tri-lineage differentiation capacity while H-AMSCs and G-AMSCs displayed bi-lineage differentiation ability and very limited capacity toward adipogenesis.
Figure 3-7. Tri-lineage differentiation – osteogenesis, adipogenesis, chondrogenesis
Representative images of tri-lineage differentiation of H-/G- CMSCs and AMSCs following culture in monolayer for 21 days in differentiation media. H-/G- CMSCs/AMSCs were induced to differentiate towards osteogenic lineage and stained with Alizarin Red S to identify calcified matrix, adipogenic lineage verified by Oil-Red-O for lipid accumulation, and chondrogenic lineage detected by Alcian blue for glycosaminoglycans. Scale bar = 200 µm.
The enhanced adipogenic capacity in G-CMSCs was confirmed with other GDM samples undergoing 21-day culture in differentiation media and the results of Oil-Red-O stain were displayed in Figure 3-8. Abundant Oil-Red-O positive lipid vacuoles were exhibited in both H-CMSCs and G-CMSCs while more lipid droplets accumulation could be observed in GDM groups (Figure 3-8A). In contrast, only a few or small Oil-Red-O-stained granules were detected in H-AMSCs and G-AMSCs (Figure 3-8B).

To quantify the lipid droplets produced during adipogenesis, positive stain of Oil-Red-O was eluted with 100% isopropanol and the absorbance of the elutes was measured at 500 nm using a plate reader. H-/G- CMSCs and AMSCs cultured in growth media were used as control and adipogenic differentiation was examined on day 14 and day 21 after inducing differentiation. Quantitative analysis in Figure 3-8C indicated no significantly increased amount of lipid droplet formation in H-/G- CMSCs or AMSCs in the initial 14 days of induction. Lipid content significantly increased in H-CMSCs and G-CMSCs on day 21 while in H-AMSCs and G-AMSCs, no significant changes was detected by Oil-Red-O elution. However, smaller and reduced numbers of stained lipid droplets were observed from histological staining (Figure 3-8B). Quantification of Oil-Red-O confirmed the histological observations with significantly more intense staining in G-CMSCs after differentiation for 21 days (Figure 3-8C).
Figure 3-8. Oil-Red-O stain and elution

(A and B) Adipogenic potential in H-/G- CMSCs and AMSCs was examined by Oil-Red-O stain after 21 day of differentiation. Scale bar = 100 μm. (C) Quantification of lipid accumulation by detecting the absorbance of Oil-Red-O extracts with isopropanol. The mean OD values were obtained from 5 independent experiments and expressed as mean ± SEM. One-way ANOVA was used to determine statistical significance. ***p < 0.001 indicates G-CMSCs vs. H-CMSCs; #p < 0.001 indicates H-/G- CMSCs vs. control.
To further investigate enhanced adipogenic potential in MSCs from GDM placenta, the basal RNA levels of two major factors involved in adipogenesis, peroxisome proliferator-activated receptor (PPAR)-γ and adiponectin (ADIPOQ), were examined. PPARγ is a nuclear receptor that functions as a transcription factor regulating adipocyte-specific genes and triggering adipogenesis. ADIPOQ is usually expressed late in adipogenesis and also functions as an autocrine factor promoting differentiation and lipid accumulation. The expression of PPARγ and ADIPOQ was examined in H-/G- CMSCs and AMSCs before the induction of adipogenesis. G-CMSCs and G-AMSCs both showed a 2 to 3-fold increase in ADIPOQ basal expression levels vs. Healthy- CMSCs/AMSCs (Figure 3-9A). Likewise, higher PPARγ expression was exhibited in G-CMSCs than H-CMSCs but not in G-AMSCs (Figure 3-9B).

Figure 3-9. Basal activity of adipogenesis-regulating genes
Basal expression levels of (A) ADIPOQ and (B) PPARγ were examined before inducing differentiation. The data were normalised to GAPDH and expressed as mean ± SEM of 8 independent experiments. The fold changes were calculated by comparing the relative expression levels in GDM vs. Healthy groups. One-way ANOVA was used to determine statistical significance. **p < 0.01, ***p < 0.001.
PPARγ and ADIPOQ closely reflect adipogenic progression; therefore, the expression of PPARγ and ADIPOQ during adipogenesis at passage 3 were examined at five different time points (days 7, 10, 14, 17, 21). The data was normalised to GAPDH and compared with undifferentiated H-/G- CMSCs/AMSCs on day 0. PPARγ and ADIPOQ expression in H-/G- CMSCs displayed elevation across the differentiation time course, peaking at around day 10-14 and PPARγ decreasing thereafter while ADIPOQ remaining elevated (Figure 3-10). During adipogenic differentiation G-CMSCs expressed significantly higher levels of both PPARγ and ADIPOQ than H-CMCS at almost all time points. PPARγ displayed some upregulation in H-/G- AMSCs but not to levels seen with H-/G- CMSCs. The gradual increase of PPARγ was observed in H-AMSCs and G-AMSCs from day 0-10 and day 0-14, respectively (Figure 3-10A). Notably, ADIPOQ was initially higher in G-AMSCs than H-AMSCs but no significant induction during the differentiation period was seen (Figure 3-10B).

The PPARγ and ADIPOQ RNA levels were determined in adipogenically differentiated H-/G- CMSCs/AMSCs and then correlated to lipid accumulation within the cells shown in Figure 3-8. It suggested that increased expression of PPARγ and ADIPOQ during early stage induced adipogenesis initiation and the lipid formation happened at later stage of adipogenesis which may be associated with elevated level of ADIPOQ expression. Overall, the results once again confirmed that G-CMSCs have enhanced adipogenic capacity whereas H-/G- AMSCs have a limited adipogenic capacity in spite of G-AMSCs displaying increased basal expression levels of adipogenesis-regulating genes.
Figure 3-10. Examination of adipogenic progression through marker expression

Time course of adipogenic marker expressions – (A) PPARγ and (B) ADIPOQ during differentiation process were analysed by real-time PCR. The above graph shows the comparison between GDM and Healthy groups; the below graph shows the comparison of gene expression changes within the same group over 21 days. Relative levels of gene expression were normalised to GAPDH and displayed as fold changes over day 0. Each data represents mean ± SEM of 5 independent experiments. Two-way ANOVA was used to determine statistical significance, continuous variable - days, *p < 0.05, **p < 0.01, ***p < 0.001, +p < 0.001 differentiated H-/G- CMSCs (day 7, 10 ,14, 17, 21) vs Day 0 (undifferentiated H-/G- CMSCs), #p < 0.05 differentiated H-/G- AMSCs (day 7, 10,14, 17, 21) vs Day 0 (undifferentiated H-/G- AMSCs)
3.4.5 Effect of conditioned media on Jurkat T cells

*Conditioned media from H-/G- CMSCs and AMSCs has a significant antiproliferative effect on T-cells*

MSCs are known to mediate immune cell activity through cell-cell contact and the production of paracrine factors. To evaluate the immunoregulatory properties of secreted factors from Healthy- and GDM- CMSCs/AMSCs, conditioned media (CM) were collected at passage 3 after culturing in serum free media for 48 hours. 10% of FBS were later on added to CM when exposure Jurkat T cells to H-/G- CMSCs/AMSCs CM while 10%FBS DMEM without H-/G- CMSC/AMSCs CM was used as controls. The proliferation and inflammatory cytokines secretion of Jurkat T cells were investigated to compare the immunomodulatory effect of H-/G- CMSCs/AMSCs.

Jurkat T cells cultured in complete growth media (10%FBS) showed a steady increase in proliferation and stable growth rate. A significant reduction in Jurkat T cells was noted following on from exposure to either H-/G- CMSC or AMSCs CM. In comparison to the inhibitory effect of H-/G- AMSCs CM, both Healthy- and GDM- CMSCs CM showed more significant reduction in Jurkat T cell proliferation which maintained a consistent inhibitory effect for 3 days. The growth of Jurkat T cells cultured in H-/G- CMSCs/AMSCs CM resumed on day 4 and day 5 (Figure 3-11A).

Jurkat T cells were stimulated with phytohemagglutinin (PHA) and phorbol 12-myristate 13-acetate (PMA) to induce T cell activation and immune responses. The PHA/PMA activated Jurkat T cells had a slow growth rate even when culturing under complete growth media which exhibited more than 50% reduction in proliferation upon activation. However, PHA/PMA activated Jurkat T cells still displayed a sensitivity to H-/G- CMSCs and AMSCs CM and similarly displayed a reduced proliferation rate following on from exposure. Likewise,
CM from both H-/G- CMSCs and AMSCs suppressed Jurkat T cells proliferation to a significantly greater extent with CM from H-/G- CMSCs. No differences in proliferative suppression by CMSCs/AMSCs CM were noted between healthy and GDM groups (Figure 3-11B).

Interleukin-2 (IL-2), produced upon PHA/PMA stimulation, regulates proliferation of activated T-cells and leads to immune response. As the significant inhibitory effect of H-/G-CMSCs/AMSCs CM on Jurkat T cells proliferation was observed from day 0-3 and cell growth resumed, the secretion of IL-2 was measured for a 3-day period. Jurkat T cells released sustainable levels of IL-2 and showed increased secretion over 3 days. In the first 24 hours after stimulating Jurkat T cells with PHA/PMA, IL-2 secretion did not show significant suppression by H-/G- CMSCs or AMSCs CM. However, the supernatant from activated Jurkat T cells cultured in H-/G- CMSCs CM contained significantly reduced levels of secreted IL-2 on day 2 and 3. H-/G-AMSCs CM also suppressed IL-2 secretion but the suppressive effect was lower than that of H-/G-CMSCs CM (Figure 3-11C).

The immunosuppressive capacity in H-CMSCs vs. G-CMSCs and H-AMSCs vs. G-AMSCs were rather comparable where no significant difference in inhibitory effect on Jurkat T cell proliferation and IL-2 secretion was observed. Healthy- and GDM- CMSCs showed a more pronounced effect on suppressing Jurkat T cell proliferation and diminishing the secretion of IL-2 than H-/G- AMSCs.
Figure 3-11. Suppression of T-cells proliferation and IL-2 secretion
Jurkat T cells were cultured in the presence of Healthy- and GDM- CMSCs/AMSCs CM (A) without activating with PMA/PHA or (B) with 50 ng/ml PMA and 5 μg/ml PHA. Cell proliferative ability was measured by MTT assay in a 5-day period. #p < 0.001 H-/G-CMSCs vs. 10%FBS, ^p < 0.001 H-/G-AMSCs vs. 10%FBS (C) IL-2 secretion after PHA/PMA stimulation was measured by ELISA from day 0-3. Results were normalised to IL-2 secretion without PHA/PMA stimulation and presented as mean ± SE of 5 independent experiments. Two-way ANOVA was conducted to determine the significant differences, continuous variable – days, **p < 0.01, ***p < 0.001, ****p < 0.0001.
3.4.6 Co-culture system of CMSCs/AMSCs and macrophage

Distinct immunoregulatory properties of H-/G- CMSCs and AMSCs evaluated by macrophage modulation

MSCs modulate immune cell function through a variety of mechanisms. In addition to T cell regulation, MSCs are also known to modulate macrophage-mediated inflammatory responses. Macrophages are key regulators of initiation and control of inflammation, and are typically divided into two types: classically activated type 1 macrophages (M1), characterised by the production of pro-inflammatory cytokines with an acute inflammatory phenotype, and alternatively activated type 2 macrophages (M2), secreting anti-inflammatory cytokines and promoting wound healing\textsuperscript{256}. THP-1 is a human immortalised monocyte-like cell line derived from an acute monocytic leukemia patient\textsuperscript{257}.

The secretome of MSCs has known to mediate immune responses and modulate macrophage population. Bone marrow MSC-derived soluble factors showed the ability to promote the conversion on monocytes or inflammatory M1 macrophage into anti-inflammatory M2 macrophage\textsuperscript{258, 259}. To investigate the immunomodulatory function of H-/G- CMSCs’ and AMSCs’ secretome on macrophage polarisation, H-/G- CMSCs/AMSC were cultured in a co-culture Transwell with THP-1 monocytes without direct contact. Suspension-cultured THP-1 monocytes were differentiated into macrophages (M0) in the presence of PMA (PMA-THP1) where they adhere to the culture plate and can be further polarised into M1 or M2 macrophages. For M1 and M2 polarisation control\textsuperscript{260}, PMA-THP1 (M0) was activated by interferon-γ (IFN-γ) and lipopolysaccharide (LPS) in order to obtain inflammatory M1 macrophages while interleukin 4 (IL-4) was used to induce anti-inflammatory M2 macrophages. To investigate H-/G- CMSCs/AMSCs paracrine effects on M0 macrophage polarisation, PMA-THP1 (M0) without any stimulation was seeded in the
lower chamber and co-cultured with H-/G- CMSCs or AMSCs in the upper Transwell inserted chamber (Figure 3-12).

**Figure 3-12. Schematic representation of macrophage polarisation**

A co-culture system of the macrophage polarisation procedure. THP-1 cells were pre-treated with 50 ng/ml PMA for 24 hours to obtain M0 macrophage. For M1 and M2 macrophage phenotype controls, M0 macrophages were stimulated with 20 ng/ml IFN-γ and 10 pg/ml LPS to obtain M1 polarisation while stimulated with 20 ng/ml IL-4 for M2 polarisation. To examine the effect of H-/G- CMSCs’/AMSCs’ secretome on M0 polarisation, $5 \times 10^5$ H-/G- CMSCs/AMSCs were seeded in an upper Transwell chamber and $5 \times 10^5$ M0 macrophages were seeded in the lower chamber. After co-culture for 24 h, supernatant was collected from all samples for ELISA analysis, and RNA was extracted from H-/G- CMSCs/AMSCs-co-cultured M0 macrophages and M1/M2 controls for further characterisation of macrophage phenotypes.

Following co-culture of H-/G- CMSCs or AMSCs with PMA-THP1, PMA-THP1 were collected to examine the macrophage polarisation through gene expressions. M1 macrophages are characterised by the expression of inflammation-related genes and the production of inflammatory cytokines. High level of inflammatory marker expression, including $IL-1β$, $IL-12$, and $CXCL8$ were detected in IFN-γ/LPS-treated PMA-THP1, suggesting the induction of M1 polarisation (Figure 3-13A). When PMA-THP1 co-cultured with H-/G- CMSCs or AMSCs,
there was no significant increase in inflammatory marker - *IL-1β, IL-12*, and *CXCL8* expression, compared to PMA-THP1 (M0) and M1 macrophages (Figure 3-13A). Notably, *CXCL8* was significantly induced in PMA-treated THP1 (M0) while the expression was significantly suppressed after co-culturing with H-/G- CMSCs/AMSCs. Although the expression of *CXCL8* was higher in H-/G- AMSCs-co-cultured than H-/G- CMSCs-co-cultured PMA-THP1, the expression levels were significantly lower than M1 macrophages controls. Thus, the data suggested that the secretome of H-/G- CMSCs and AMSCs did not promote M1 macrophage polarisation of THP1 cells.

On the other hand, anti-inflammatory M2 macrophages are characterised by increased expression of *IL-10, MRC1*, and *CCL-17* which were detected in IL-4 stimulated PMA-THP1, suggesting the induction of M2 polarisation (Figure 3-13B). High levels of M2 macrophage markers were also observed PMA-THP1 when co-cultured with H-/G- CMSCs or AMSCs, indicating that PMA-THP1 were polarising towards M2 phenotypes through the regulation of H-/G- CMSCs’/AMSCs’ secretome. PMA-THP1 co-cultured with H-/G- CMSCs expressed significantly higher levels of *MRC1* and *CCL-17* than co-cultured with H-/G- AMSCs, which suggested that H-/G- CMSCs had a more profound effect on promoting M2 marker expression in PMA-THP1 than H-/G- AMSCs. Moreover, no significant difference was detected in the ability to induce M2 macrophage polarisation in H-/G- AMSCs but in CMSCs higher *MRC1* and *CCL-17* expression could be observed when PMA-THP1 co-cultured with H-CMSCs than with G-CMSCs (Figure 3-13B).
Figure 3-13. Examination of M1/M2 marker expression in THP1
THP1 monocytes polarisation was examined by M1/M2 marker gene expression. Apart of negative control (THP1), all groups were treated with PMA for 24 hours to induce M0 macrophages. M1 phenotypes were further induced with IFN-γ and LPS while M2 phenotypes were induced with IL-4. To examine the effect of H-/G- CMSCs/AMSCs on THP1 polarisation, PMA-treated THP1 were co-cultured with H-/G- CMSCs/AMSCs for 24 hours and RNA from THP1 cell were extracted for gene expression analysis. All cells were cultured in the same basal media, 10% FBS DMEM. (A) M1 macrophage markers - IL-1β, IL-12, CXCL8 and (B) M2 macrophage marker - IL-10, MRC1, CCL-17 expressions were examined by real-time PCR. The values were normalised to GAPDH and fold changes were calculated by comparing to THP1 control. Each data shown represents mean ± SEM of 6 independent experiments. One-way ANOVA was conducted to determine the statistical significance, *p < 0.05, **p < 0.01, ***p < 0.001 relative to PMA-treated control.

Macrophages exert their functions by releasing a series of cytokines to activate and recruit other immune cells during immune responses. Cytokines secretion bias the macrophage’s phenotypes towards M1 or M2 macrophage. M1 macrophages secrete pro-inflammatory cytokines TNF-α, IL-1β, IL-6, IL-12, IL-23 while M2 macrophages secrete high levels of
immunosuppressive cytokine IL-10 and also a little amount of pro-inflammatory cytokines. Supernatant from co-culture of PMA-THP1 and H-/G- CMSCs/AMSCs was collected to examine TNF-α and IL-10 release for identifying M1 or M2 phenotypes. No significant increase in TNF-α secretion (Figure 3-14A) was seen but an upregulation in IL-10 (Figure 3-14B) was detected when co-culturing PMA-THP1 with H-/G- CMSCs or AMSCs. Comparing with M2 markers gene expression (Figure 3-13B), though H-/G- AMSCs co-cultured PMA-THP1 expressed lower levels of M2 markers, the IL-10 secretion was comparable to H-/G- CMSCs co-cultured PMA-THP1. Overall, CMSCs and AMSCs derived from healthy or GDM placenta were equally capable of promoting PMA-THP1 towards M2 polarisation. The GDM environment did not significantly alter macrophage regulation ability in G-CMSCs and G-AMSCs, compared to their healthy counterparts.

![Figure 3-14. Cytokines release by M1/M2 macrophages](image)

Cytokines secretion from PMA-THP1 in H-/G- CMSCs or AMSCs co-culture was examined by ELISA. Supernatant was collected after 24 h co-culture and measured the levels of TNF-α and IL-10 secretion. Each data shown represents mean ± SEM of 6 independent experiments. One-way ANOVA was conducted to determine the statistical significance, ***p < 0.001.
3.5 Discussion

The placenta, usually discarded after delivery, is a valuable source of plentiful perinatal MSCs for regenerative medicine without ethical concerns. Cell therapies using placental-derived MSCs have already been applied to various disorders treatment in animal models and some clinical trials, such as ischaemic stroke, Crohn’s disease, and idiopathic pulmonary fibrosis. However, few studies have investigated differences in therapeutic potential of placenta-derived MSCs from women with pregnancy complications. In this study, we provided a thorough comparison of CMSCs vs. AMSCs and reported the effects of GDM environment on CMSCs and AMSCs biological properties.

Biological characterisation of H-/G- CMSCs/AMSCs

Derived from different layers of the same placental membrane, CMSCs and AMSCs show diverse cell biological characteristics. AMSCs have been widely studied as the clinical applications of amniotic membrane began several years ago. The isolation process of AMSCs has also been well-established; however, the role of CMSCs remained unclear until recent years. The observation of the reduced proliferation rate of AMSCs compared with CMSCs in our study is consistent with some recent reports. A study demonstrated the limited ex vivo expansion potential of AMSCs, where CMSCs were found to have higher proliferation ability than AMSCs and BM-MSCs. Likewise, Araujo et al. compared the growth kinetics of amniotic (AMSCs), chorionic (CMSCs), placental decidua (DMSCs) and umbilical cord MSCs. They found the superior proliferation ability in CMSCs and DMSCs which were able to maintain a steady growth rate until passage 10 while AMSCs had a short lifespan, low doubling time, and were unable to expand after passage 5. Indeed, we also noticed the difficulty in AMSCs expansion at late passages.
We further investigated differences in growth ability between GDM and healthy CMSCs/AMSCs via direct counting of viable cells and measurement of metabolic activity. It has been suggested previously that umbilical cord derived-MSCs from GDM women displayed decreased cell growth with early cellular senescence accompanied by the expression of p16 and p53\textsuperscript{266}. Alternatively, Pierdomenico et al. described MSCs obtained from umbilical cord of both healthy and diabetic mothers where the later demonstrated an increased proliferative ability along with an upregulation of CD44, CD29, CD73, CD166, SSEA4 and TERT\textsuperscript{267}. We found that GDM had distinct effect on CMSCs and AMSCs proliferation, where G-CMSCs displayed reduced rates when compared to H-CMSCs while G-AMSCs, by contrast, showed higher proliferation rates than H-AMSCs. As AMSCs are derived from the amniotic membrane adjacent to the fetus, the higher proliferation rate of diabetic AMSCs may reflect features of GDM including heavier fetal weights on resultant cell phenotype.

Immunophenotypic analysis characterised H-/G- CMSCs/AMSCs surface marker expression (positive for CD90, CD73, CD105; negative for CD14, CD19, CD34, CD45 and HLA-DR). Overall, H-/G- CMSCs and AMSCs express similar levels of surface markers and all meet the minimal criteria for MSC definition. However, the surface protein expression profile may vary depending on different MSC sources. The level of CD45 expression was higher in both G-CMSCs and G-AMSCs compared to healthy counterparts. CD45 is a transmembrane protein tyrosine phosphatase that regulates signal transduction in immune cells and mainly expressed on hematopoietic stem/progenitor cells (HSCs)\textsuperscript{268}. CD45 also plays a role in regulating the motility of bone marrow progenitor cells and their retention. CD45 knockout bone marrow progenitors showed increased cell adhesion and defective motility, mediated by reduced matrix metalloproteinase 9 secretion and imbalanced Src kinase activity\textsuperscript{269}. Our study showed that approximately 17% of G-CMSCs and 19% of G-AMSCs were positive for
CD45 expression. Although we were unclear whether higher CD45 expression in G-CMSCs/AMSCs was associated with cell motility, the enhanced migration in ability in G-CMSCs was demonstrated in chapter 5 via microarray analysis and \textit{in vitro} migration assays. In fact, CD45 is a typical HSC marker but BM-MSCs can still express some degree of CD45 under certain condition. The CD45 expression was found around 15% in BM-MSC derived from older donor at passage 1 while the expression decreased at later passage\textsuperscript{270}. Approximately 15% of decidual MSCs\textsuperscript{271} and 17% of AMSCs\textsuperscript{272} shown positive for CD45 expression were also reported in some studies. However, we performed immunophentyping at passage 3 and did not examine the possible expression change at later passage.

\textbf{GDM pregnancy and adipogenesis tendency in MSCs}

Emerging research has highlighted the importance of the intrauterine environment as a risk factor in the likelihood of offspring developing obesity and metabolic diseases\textsuperscript{273, 274}. The underlying biological mechanism for the link between GDM and the increased risk of future diabetes is poorly understood, although the GDM environment has potential to modify the epigenetic state of fetal genes. Increased methylation of \textit{PYGO1} and \textit{CLN8} genes in offspring exposed to a GDM environment is proposed as being associated with long-term adverse effects on fetal health\textsuperscript{275, 276}. GDM is associated with newborn hyperinsulinemia with effects on offspring fat mass seen until 6 weeks. Elevated preperitoneal adipose tissue in newborns is linked with increased risk of obesity in later life\textsuperscript{277}. We found that the CMSCs and AMSCs differentiation potential are influenced by maternal environment during gestation. Under the same culture condition, elevated adipogenic differentiation was found in GDM-MSCs than with MSCs from healthy pregnancies. Moreover, higher basal expression levels of adipogenic transcription factors in G-CMSCs and subsequent lipid content associated with
increased transcription factor expression during differentiation indicated an enhanced adipogenic potential when compared to H-CMSCs and H-/G- AMSCs. This suggests that the GDM environment itself may have less of a role in affecting fetal cell properties than that of the membrane itself.

In addition, although H-/G-CMSCs demonstrated adipogenic potential verified by substantial lipid droplet accumulation and increased adipogenesis-associated gene expression, the reduced expression in PPARγ and ADIPOQ was noticed on day 21. The adipogenic transcription factor, PPARγ plays a critical role in initiating adipogenesis and ADIPOQ is involved in adiponectin formation. The reduced expression may reflect the loss of adipocyte phenotype. For instance, the deletion of PPARγ in adipose tissues contributed to impaired adipocyte function and maturation, adipocyte death, and reduced fat weights or lipodystrophy. On day 14 and 17, PPARγ and ADIPOQ showed high expression levels in differentiated H-/G- CMSCs, which may suggest the optimal induction period. Some studies demonstrated adipocyte maturation during 14-day adipogenesis protocols from bone marrow MSCs, umbilical cord MSCs, and placental MSCs. As adipogenesis protocols for different cell types may vary from 14-21 days, our data might suggest that a 17-day culture period with adipogenesis media might be ideal for H-/G-CMSCs differentiation. However, it is still unclear whether H-/G- CMSCs differentiated into fully mature adipocytes or remained in immature state. To optimise the ideal differentiation protocol, it may benefit from the comparison between human adipocytes and MSC-differentiated adipocytes at different time points during adipogenesis process.

**Immunosuppression of H-/G- CMSCs/AMSCs**

For successful clinical application of MSC therapy, the immunoregulatory potential of H-/G-CMSCs and AMSCs is an important area of consideration. The immune responses mediated
by T-cells may lead to cell transplant rejection or Graft-versus-Host disease\textsuperscript{284}. MSCs have been reported to modulate the proliferation and function of immune cells by both cell-to-cell contact and the secretion of growth factors, cytokines, and chemokines\textsuperscript{285}. Immunosuppressive capacity of MSCs is a therapeutic option for the treatment of various immunological disorders. Given that the placenta plays a critical role in fetal-maternal tolerance and contains cells that display immunomodulatory properties, MSCs derived from placenta not only have superior immunomodulatory potential but also have therapeutic potential for the mothers and offspring\textsuperscript{286}. In our study, H-/G- CMSCs and AMSCs displayed differential levels of immunosuppressive capacities in T-cell regulation. Both H-/G- CMSCs and AMSCs suppressed T cell proliferation while H-/G- CMSCs showed superior inhibitory effect than H-/G- ASMCs. The mechanism of MSCs suppressing T-cell proliferation has been widely investigated. BM-MSCs are able to inhibit T-cell proliferation through the induction of cell division arrest\textsuperscript{287}, apoptosis via Fas ligand-dependent apoptotic pathway\textsuperscript{288}, and blocking T cell effector function via contact-dependent interaction\textsuperscript{289}.

Moreover, T-cell mitogenic cytokine IL-2 is released upon T-cell activation. The suppressive effect of IL-2 production was more profound in H-/G- CMSCs CM than H-/G- ACMSC CM while GDM environment did not show significant alteration in CMSCs/AMSCs ability to suppress T cell activation. IL-2 is associated with various immune responses, including T cell proliferation, survival, differentiation, supporting the activation of natural killer cells, and promoting activation-induced cell death\textsuperscript{290}. The reduction of IL-2 secretion by MSCs suppresses immune reactions triggered by T cells and improves engraftment in cell transplant\textsuperscript{291}.

Apart from well-studied mechanisms of MSC-mediated T-cell activity, there is an increasing interest in MSCs immunomodulation on macrophages over the past few years. MSCs
involve in regulating innate immune response by modulating macrophage polarisation and inhibiting the secretion of inflammatory cytokines. M1 macrophage induced by intracellular pathogens, tissue damage and infection, is associated with inflammation, along with the secretion of inflammatory cytokines. M2 macrophages have high phagocytosis capacity, tissue remodelling ability, and involve in producing extracellular matrix (ECM) components and anti-inflammatory factor, IL-10. Transferring M2 macrophages into autoimmune type 1 diabetes mouse models showed protection against inflammation and the transferred M2 macrophages homed to the inflamed pancreas, promoting β-cell survival. The transplantation of MSCs into an in vivo model showed increased recruitments of M2 macrophages to the wound site and enhanced damaged tissue repair. More and more evidences indicate the interaction between MSCs and macrophages recently, for instance, increased expression of M2 macrophage makers was observed following the injection of MSCs to rat infarct myocardium which was initially infiltrated with M1 macrophage.

In our finding, H-/G- CMSCs and AMSCs were evidenced to divert the differentiation of naïve macrophages (M0) into M2 phenotypes through a co-culture system, which also implied that CMSCs/AMSCs were able to regulate macrophage differentiation through their secretome functions without the need of direct cell-cell contact. Several soluble factors secreted by MSCs have been considered as mediators to regulate immune cells, such as IL-6, prostaglandin E2 (PGE₂), indoleamine 2,3-dioxygenase (IDO), and lactate. Moreover, some studies have demonstrated the possibility of MSCs-mediated macrophage activation shift from M1 to M2 phenotypes. BM-MSCs attenuated M1 macrophage function with a concomitant shift towards M2 state through the alteration in AMPK and mTOR pathway activities. These findings could be beneficial for the treatments of inflammatory diseases such as rheumatoid arthritis, asthma, or fibrosis where M1 macrophages play a vital role in...
disease progression.

Although H-/G- CMSCs and AMSCs were capable of promoting M2 polarisation, the higher expression of \textit{MRC1} and \textit{CCL17} were found in H-/G- CMSCs than H-/G- AMSCs co-cultured macrophages, particularly the highest expression in H-CMSCs. MRC1 (C-type mannose receptor 1), also known as CD206, is a typical M2 macrophage marker which binds to glycoproteins and collagen ligands. A recent study showed that CD206$^+$ M2-like macrophages in adipose tissues created a microenvironment that inhibited growth and differentiation of adipocyte progenitors. In the \textit{in vivo} mouse model, the reduction in the numbers of CD206$^+$ M2-like macrophages resulted in a down-regulation of TGFβ signalling, together with upregulated adipocyte progenitors differentiation\textsuperscript{300}. M0 macrophages under H-CMSCs co-culture displayed significantly upregulated levels of CD206 expression than G-CMSCs co-cultured macrophages. The increased adiposity in GDM pregnancy may somehow reflect the significantly lower CD206 expression in G-CMSC-induced than H-CMSC-induced M2 macrophages. However, immune functions of CD206 has not yet fully understood while CD206 is also involved in migration, pro-inflammatory cytokine secretion, and fetal-maternal immunological tolerance\textsuperscript{301}. Besides, CCL-17 and IL-10 released by M2 macrophage are known to have a critical role in inhibiting M1 macrophage polarisation\textsuperscript{302}. Although CCL-17 was lower in M2 macrophage under H-/G- AMSCs than H-/G- CMSCs co-culture, the secretion of IL-10 was comparable in all groups.

Notably, the GDM environment had no significant effects on the immunosuppressive ability of MSCs in all aspects. Despite an increase in M2 marker expressions after co-culturing PMA-THP1 with H-CMSCs, which might suggest a better macrophage modulation potential in H-CMSCs than G-CMSCs, G-CMSCs showed a comparable ability in regulating Jurkat T cells activity and modulating cytokine secretion. Likewise, the responses from Jurkat cells
treated with G-AMSCs conditioned media or macrophages co-cultured with G-AMSCs were similar to the results from H-AMSCs.
3.6 Summary

In summary, human placenta is comprised of several stem cells niches that mostly originate from extraembryonic tissue, and connect to maternal tissues, which may be a promising autologous source for cell therapy in both the mother and her offspring. Bone marrow MSCs isolated from elder donors have been reported to have reduced biological activity, thus leading to poor therapeutic potential\textsuperscript{303}. Insufficient numbers of MSCs or impaired MSCs function from patients with rheumatoid arthritis and diabetes, respectively, have also been reported\textsuperscript{304, 305}. Therefore, an understanding of MSC behaviours under different growth environment is essential. In this study, we provide a comparison between CMSCs and AMSCs from healthy and GDM placenta, and evaluate the biological characteristics of both. CMSCs and AMSCs have distinct biological properties. The superior proliferation, differentiation and immunomodulatory properties in CMSCs than AMSCs make them a promising alternative source for autologous cell transplantation. In addition, we demonstrated the importance of the maternal GDM intrauterine environment and its differential effects on CMSCs and AMSCs
Chapter 4

Generation of insulin producing cells from Healthy- and GDM- AMSCs/CMSCs
4.1 Introduction

Women with a history of GDM have an increased risk of developing type 2 diabetes postnatally compared with women without previous GDM. Roughly 5-10 years following on from a GDM-affected pregnancy approximately half of these women are diagnosed with type 2 diabetes\textsuperscript{34, 37}. GDM is associated with gestational programming in the fetus and may predispose offspring to an increased incidence of childhood obesity and impaired glucose tolerance, leading to type 2 diabetes later in life\textsuperscript{306, 307}. Evidence has demonstrated a positive correlation between GDM and the risk of developing type 2 diabetes in women with a history of GDM, as well as children from GDM pregnancies\textsuperscript{308, 309}.

Patients with type 2 diabetes require lifelong anti-diabetic drug or insulin treatment. However, neither of these either reverse the disease or correct the beta cell dysfunction\textsuperscript{310, 311}. Transplantation of cadaveric islet cells has therefore become a promising therapeutic strategy for diabetes, and though first conducted in 1999\textsuperscript{312} a shortage of donors and immune rejection have limited its clinical usage. Nowadays, mesenchymal stem cells (MSCs) which possess a multi-lineage differentiation potential coupled to immunomodulatory properties offer an alternative to β-cell replacement therapy\textsuperscript{313}.

**IPC generation protocols**

Several studies have reported the generation of insulin-producing cells (IPC) from adult tissue-derived MSCs, such as bone marrow\textsuperscript{314, 315}, adipose tissue\textsuperscript{210}, and liver\textsuperscript{316}. However, these existing approaches lack a consistent protocol applicable to all source of MSCs\textsuperscript{317}. The IPC differentiation method was originally developed from mouse embryonic stem cells (mESCs)\textsuperscript{318} and then modified for generating IPC from human ESCs (hESCs)\textsuperscript{319}. The successive exposure of hESCs to different growth factors and small molecules in order to
mimic the environment during pancreagenesis *in vivo* has successfully generated endocrine-like tissue from hESCs. Figure 4-1 lists a variety of multistep procedures to induce differentiation of hESCs into IPCs.

Due to the limited availability and ethical concerns of using hESCs, some studies have modified and applied IPC generation method to bone-marrow MSCs (BM-MSCs). However, a major limitation of MSCs derived from adult tissues is that they are considered more likely to differentiate toward mesenchymal lineages due to their mesodermal origin, while β-cells are of endodermal origin\(^3\). Inducing definitive endoderm is an essential step for IPCs generation. To do this, activin A is commonly used for definitive endoderm formation\(^3\) although administration concentrations may vary depending on different conditions. Other challenges include the low generation rate of IPCs from BM-MSCs or the immature state of the IPCs where they fail to release insulin\(^3\), \(^3\).

MSCs from fetal origins, such as placenta and amniotic fluid, on the other hand have been demonstrated to express endoderm lineage and embryonic markers\(^3, 3\). This is suggestive of a less restricted potency of fetal-related tissue derived MSCs and a potentially broader differentiation potential.
Figure 4.1. Time lines of multistep procedures for IPC differentiation.

Various protocols to induce IPC differentiation from hESCs. ActA, Activin A; bFGF, basic fibroblast growth factor; BMP4, bone morphogenetic protein 4; CM, conditioned media; DAPT, γ-secretase inhibitor; EGF, epidermal growth factor; HGF, hepatocyte growth factor; IGF1/2, insulin-like growth factor 1/2; KGF, keratinocyte growth factor; MEFs, mouse embryonic fibroblast feeders; Nic, nicotinamide; RA, retinoic acid. Reprinted from Van Hoof et al., 2009319
A common feature of the various strategies described for the differentiation of MSCs into IPCs is a high glucose culture environment\textsuperscript{326, 327}. During pancreatic islet development multiple stimuli are required including hormones, growth factors, and nutrients\textsuperscript{328}. Within all these stimulators, glucose is suggested to play an important regulatory role in β-cell growth, survival, and proliferation\textsuperscript{329}. In the human body, elevated blood glucose level is a primary activator of β-cell expansion in situations where β-cell compensation is required due to increased metabolic demand\textsuperscript{330}. A glucose concentration of 20-30-mM was sufficient to significantly enhanced β-cell replication in both \textit{in vitro} and \textit{in vivo} models\textsuperscript{331}. With human bone marrow MSCs a culture environment containing 23.3 mM glucose for 15 days was shown to stimulate expression of pancreatic-related genes; \textit{PDX1}, \textit{PAX4}, \textit{GLUT2}, and \textit{INS} and induce the formation of β-cell precursors\textsuperscript{332}. Collectively, glucose seems to be an essential factor for IPC generation. GDM-CMSCs/AMSCs are under prolonged exposure due to hyperglycaemia during pregnancy, the suitability of the high glucose concentration, applied in many IPC differentiation protocols, used to mimic the β-cell development environment, for GDM-CMSCs/AMSCS remains to be determined.

**Markers for beta-cell maturity**

A human islet cluster contains not only insulin-secreting β-cells but also several endocrine cell types which secrete different hormones, including α-cells, δ-cells, PP-cells, and ε-cells that express glucagon, somatostatin, pancreatic polypeptide, and ghrelin, respectively\textsuperscript{333}. Given the common origin and the similar environment for these pancreatic cells development, the examination of marker expressions is hence useful for identifying different pancreatic cell types and staging the differentiation of MSCs to β-cells whether \textit{in vivo} or \textit{in vitro}. The expression of pancreas-associated transcription factors at intermediate developmental stages are shown in Figure 4-2. Some of the markers used in this chapter
are described in detail below.

The expression of transcription factor neurogenin 3 (NGN3 or NEUROG3) induces endocrine lineage development and functions as an activator of several endocrine gene transcriptions in progenitor cells. The NGN3 expression peaks at endocrine stage and reduces in mature β-cells. Insulin gene enhancer binding protein-1 (ISL1) is one of the endocrine lineage markers that controls the proliferation and survival of endocrine cells during islet developmental stage. ISL1 also involves in cell fate specification regulating the endocrine cells lineage commitment into different pancreatic cell subtypes.

With regard to pancreatic development, insulin promoter factor 1 (PDX1) is the most studied marker, expressed during early development of endocrine cells and sustained presence in mature islets. PDX1 is involved in several regulations of β-cell function and survival. The deficiency of PDX1 is associated with pancreatic agenesis, β-cell dysfunction, and increases cell death and diabetes both in rodent and human. The transcription factor paired box protein PAX6 is generally expressed in terminally differentiated endocrine cells in the process of developing into pancreatic hormone-producing cells. Both PAX6 and PDX1 are crucial for insulin synthesis in β-cells through the transcriptional regulation of insulin gene.

The insulin (INS) and major glucose transporter GLUT2 are expressed in mature β-cells and essential for glucose stimulated insulin secretion (GSIS). The genetic inactivation of GLUT2 significantly suppressed glucose uptake and GSIS pathways, suggesting an important role of GLUT2 in glucose sensing and homeostasis.
Figure 4-2. Defined transcription factors for pancreatic development

Different cell types in pancreatic islets are derived from a common precursor. The developmental stages are marked by expression of a number of pancreas-associated transcription factors. Reproduced from Van Hoof et al., 2009.
4.2 Aim

Given that both the woman and child from a pregnancy affected by GDM have an increased risk of developing diabetes, autologous AMSCs and CMSCs provide a potentially valuable source as a cell therapy. In an attempt to establish a therapeutic use potential of autologous placental membrane-derived MSCs for diabetes treatment, we aimed to establish a feasible approach for the generation of IPCs from CMSCs/AMSCs and determine the role, if any, of GDM in this capacity.

The main objectives of the chapter:

- Investigate high glucose culture effect on H-/G- CMSCs and AMSCs
- Establish a step-wise approach for IPC generation from H-/G- CMSCs/AMSCs
- Characterise H-/G- CMSC/AMSC derived IPCs via morphological changes, marker expression, and insulin release.
4.3 Methods

All maternal and fetal details of placentas used in this chapter were described in chapter 2 section 2.2. Pluripotent marker expression of CMSCs and AMSCs were analysed by real-time PCR for pluripotent gene expressions (section 2.8) and performed with all placenta samples. For high glucose effect investigation, healthy samples used for analysis were from Healthy03, 06, 07, 08 and GDM samples were from GDM05, 06, 07, 08 (Table 2-1). Prior to high glucose exposure, Healthy- and GDM- CMSCs/AMSCs were cultured in 5.5 mM glucose DMEM supplemented with 10% FBS, 1% L-glutamine, 1% NEAA and 1% Penicillin-Streptomycin from passage 0-3. At passage 3, media were switched to 25 mM glucose DMEM. Cells were cultured for indicated periods (10, 20, 30 days) and then examined for cell death/survival by cell viability assay (section 2.11) and cellular senescence by β-galactosidase activity assay (section 2.12).

For three-stage IPC differentiation protocol development, 6 healthy samples (Healthy03, 06, 07, 08, 10, 11) and 7 GDM samples (GDM03, 04, 05, 06, 07, 08, 10) were used. Molecules and growth factors used in differentiation protocols are described in detail in section 4.4.4. Briefly, cells at passage 3 were pre-cultured in 25 mM glucose DMEM for 10 days and then trypsinised, re-suspended in stage 1 differentiation media, and seeded at a density of 1 x 10^6 cells/well in a six-well plate. For stage 1, cells were cultured in serum-free 17.5 mM glucose DMEM/F12 that contained 1% BSA, 50 μM 2-mercaptoethanol, 1mM sodium butyrate, and 50 ng/ml activin A for 3 days before adding 2 μM retinoic acid to the media and culturing for an additional 3 days. At stage 2, cell media was switched to DMEM/F12 containing 1% BSA, 20 ng/ml EGF and 0.3mM taurine for 3 days. At stage 3, 10 mM nicotinamide and 50 nM glucagon-like peptide (GLP)-1 were added to stage 2 media to induce IPC maturation and insulin formation, and 1% NEAA were added to support cell
growth. Cell were cultured in stage 3 media for another 7 days. To further induce AMSC-IPC maturation, exendin-4 and betacellulin known to induce insulin secretion were used at stage 3 to replace GLP-1. The purpose of exendin-4 or betacellulin supplementation is described in result section 4.4.5.

IPC characteristics were assessed by cell morphological observation (section 2.4.2), pancreatic marker examination through real-time PCR (section 2.8), immunofluorescence staining (section 2.13), and ELISA (section 2.10.2). The experimental flow and methodology adopted in this chapter are summarised in Figure 4-3.
Figure 4-3. Summary of the methodology in chapter 4

Statistical analysis

The percentage of SA-β-gal-positive cells, cell viability, real-time PCR results of IPCs marker expression, and ELISA for protein secretion were compared using one-way ANOVA and Tukey post-hoc tests. 30-day high glucose treatment on pancreatic gene expression changes were analysed by two-way ANOVA to determine the statistical significance among different groups, p-value below 0.05 was considered significant. Analysis was performed using GraphPad Prism (GraphPad Software). The data was presented as mean ± SEM.
4.4 Results

4.4.1 Pluripotent markers expression

Transcription factors which help to maintain the pluripotent state in stem cells include \textit{NANOG}, \textit{SOX2}, and \textit{OCT4}. These are highly expressed in undifferentiated embryonic stem cells (ESCs) and provide an indication of the capacity of self-renewal, proliferation, survival, and multi-lineage differentiation potential. The expression of pluripotent markers is usually low in adult tissue-derived MSCs and gradually decreases further as the passage number increases\textsuperscript{344}. The gene expressions of \textit{NANOG}, \textit{SOX2}, and \textit{OCT4} in H-/G- CMSCs/AMSCs were examined and compared to ESCs and BM-MSCs.

ESCs expressed significantly higher levels of \textit{NANOG} and \textit{OCT4} than BM-MSCs. Similarly, placental MSCs (H-/G- CMSCs/AMSCs), \textit{NANOG} and \textit{OCT4} expression were also significantly lower than ESCs. The \textit{NANOG} expression in H-/G- CMSCs and AMSCs was comparable and significantly higher compared to BM-MSCs (Figure 4-4A). Likewise, the placental MSCs expressed significantly higher levels of \textit{OCT4} than BM-MSCs; in addition, G-AMSCs showed an increased \textit{OCT4} expression than H-AMSCs (Figure 4-4B).

Placental MSCs expressed high levels of \textit{SOX2}, particularly in H-/G- CMSCs which showed significantly increased \textit{SOX2} expression than in H-/G- AMSCs, ESCs, and BM-MSCs (Figure 4-4C). Overall, H-/G- CMSCs and AMSCs showed higher level of \textit{NANOG}, \textit{SOX2}, and \textit{OCT4} than BM-MSCs which may indicate a broader differentiation capacity.
Figure 4-4. Pluripotent marker expression

Gene expression levels of pluripotent markers – *NANOG*, *OCT4*, and *SOX2* in H-/G- CMSCs and AMSCs compared with embryonic stem cell line (SHEF2) and BM-MSCs. Results represent mean ± SEM. One-way ANOVA was conducted to determine the significant differences, *p* < 0.05, **p** < 0.01, ***p** < 0.001. ESCs, embryonic stem cells; BM-MSCs, bone marrow MSCs; *NANOG*, nanog Homeobox; *OCT4*, octamer-binding transcription factor 4; *SOX2*, SRY (sex determining region Y)-box 2.
4.4.2 High glucose effect on H-/G- AMSCs/CMSCs

Prolonged exposure of CMSCs/AMSCs to high glucose culture induces morphological changes, premature senescence, and decreased cell viability

As glucose concentration is crucial for β-cell growth, replication, and widely used in the IPC generation process, we investigated the effect of high glucose on H-/G- CMSCs/AMSCs as a first step in determining a suitable environment for IPC differentiation from placental MSCs. CMSCs and AMSCs were cultured in high glucose (HG) DMEM (25 mM) and low glucose (LG) DMEM (5.5 mM) media containing 10% FBS for a 30-day period. H-CMSCs cultured under HG conditions began to form condensations after day 20 where the number and dimension of cell condensations continued to increase until day 30. Similar, though less pronounced, changes were also observed in G-CMSCs under the same conditions whereas no apparently morphological change was observed after 10-day HG culture in either H-CMSCs or G-CMSCs (Figure 4-5).

H-/G- AMSCs demonstrated less obvious morphological changes in HG culture. Some small cell condensations were detected in H-AMSCs whereas no distinguishable difference in morphology of G-AMSCs was observed during the 30-day culture period in either HG or LG conditions (Figure 4-5).
H-/G- CMSCs/AMSCs were cultured in 5.5 mM glucose DMEM until passage 2 and then exposed to 25 mM glucose (HG) DMEM to investigate the effect of glucose on morphological changes. Controls were maintained in 5.5 mM glucose (LG) DMEM. Phase contrast images of H-/G- CMSCs/AMSCs in HG culture over 10, 20, 30 days. H-/G- CMSCs/AMSCs in LG condition showed steady growth in the same time period and remained adherent fibroblast-like morphology. Representative image was from one of four independent experiments. Scale bar, 200 μm; HG, high glucose; LG, low glucose.

<table>
<thead>
<tr>
<th></th>
<th>HG – day10</th>
<th>HG – day20</th>
<th>HG – day30</th>
<th>LG – day30</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-CMSCs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G-CMSCs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-AMSCs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G-AMSCs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
In addition, live/dead fluorescence staining indicated that long-term HG exposure contributed to significantly reduced cell viability. Intracellular esterase activity discriminates live from dead cells by staining with calcein-AM (green) while ethidium homodimer-1 (red) indicates dead cells with loss of plasma membrane integrity. The reduced cell viability was observed in H-CMSCs and G-CMSCs under HG culture for 20 and 30 days. (Figure 4-6A). Viable H-CMSCs percentage declined from 97.7 ± 2.1% on day 20 to 90.6 ± 3% on 30 while viable G-CMSCs were also reduced with the percentage of 93.5 ± 3.6% and 87.8 ± 2.5% on day 20 and 30, respectively. There was no significant difference in decreasing rate of cell viability between H-CMSCs and G-CMSCs.

Likewise, H-AMSCs and G-AMSCs exposed to HG concentration resulted in lower viable cell numbers when compared with LG control (Figure 4-6B). Significant reductions in H-/G-AMSC viability was observed from day 20-30 with the percentage decreasing from 93.2-80.6% in H-AMSCs and 92.5-77.8% in G-AMSCs. The reduction was more marked in H-/G-AMSCs than CMSCs. Although HG culture contributed to significantly reduced cell viability, H-/G- CMSC and AMSC viability was maintained around 99-100% in 10-day HG culture.
Figure 4-6. Decreased cell viability in HG culture

Left panel: Fluorescent images of the viable or dead H-/G-CMSCs/AMSCs using calcein-AM (green, alive cells) and ethidium homodimer-1 (red, dead cells) Scale bar, 400 μm. Right panel: the mean percentage of live and dead cells calculated from 3 independent experiments.
Cellular senescence is considered as an irreversible cellular state of growth arrest. HG was noted to induce senescence in H-/G- CMSCs and AMSCs with increased incubation time. The staining of senescence-associated-beta-galactosidase (SA-β-Gal) activity is used to identify the occurrence of senescence. Significantly elevated SA-β-Gal was first detected after 20 days of HG culture in G-CMSCs rising to approximately 30% of cells by day 30. On the other hand, significant elevation of SA-β-Gal was only seen at day 30 in H-CMSCs with around 15% of the population staining positively (Figure 4-7A and C). G-CMSCs showed an earlier and more profound HG-induced senescence response than H-CMSCs on both day-20 and day-30 HG culture.

H-AMSCs and G-AMSCs both displayed elevated SA-β-Gal from day 10 onwards with markedly elevated and significant increases seen thereafter (Figure 4-7B). A greater number of senescent cells were detected in G-AMSCs than in H-AMSCs from day 20 onwards reaching 75% by day 30 vs. 55% with H-AMSCs (Figure 4-7C).

Prolonged HG culture contributed to higher levels of SA-β-Gal staining in GDM- than Healthy- CMSCs/AMSCs. However, this did not occur in LG culture with SA-β-Gal activity in H-/G- CMSCs remaining unchanged during the culture period while an increase in SA-β-Gal activity was observed in H-/G- AMSCs on day 30 (Figure 4-7C).
Figure 4-7. Cellular senescence in HG culture

(A and B) Representative images of cellular senescence was examined on day 10, 20, 30 in both HG and LG culture. Senescent cells showed positive staining of SA-β-Gal. Scale bar, 200μm. (C) Quantification of SA-β-Gal-positive cells. The SA-β-Gal-positive cells of 100 random cells was counted from at least three images of each sample (n=3) using phase-contrast microscopy. Data are expressed as mean ± SEM. Statistical significance were calculated by one-way ANOVA, ***p<0.001
4.4.3 High glucose induces pancreatic lineage markers

MSCs exposed to HG condition has been suggested to induce endocrine lineage markers expression and promote β-cell differentiation\(^{346}\). Thus, the expression of pancreatic lineage genes (\textit{NEUROG3, PDX1, INS}) under HG culture were examined by real-time PCR. The fold changes of genes were calculated by comparing with the expression level on day 0 and the significant upregulation was compared to LG-Day30.

When exposing H-/G- CMSC to HG condition for 10 days, there was an induction in \textit{PDX1} (Figure 4-8A) and \textit{NEUROG3} (Figure 4-8B) expression. \textit{PDX1} expression in H-CMSCs was significantly elevated at day 10 and gradually increased until day 30. \textit{NEUROG3} expression in H-CMSCs was also significantly elevated at day 10 and thereafter. G-CMSCs similarly displayed upregulated \textit{PDX1} and \textit{NEUROG3} expression at day 10 but which both then declined with continued culture. HG-cultured H-AMSCs and G-AMSCs had similar expression patterns of \textit{NEUROG3} and \textit{PDX1}. \textit{PDX1} and \textit{NEUROG3} in H-/G- AMSCs were both significantly increased after initial HG culture with both undergoing reductions across the remaining time course (Figure 4-8A and B). Moreover, mature β-cell marker, insulin (\textit{INS}) expression was examined (Figure 4-8C). The expression of \textit{INS} showed no increase in G-CMSCs and H-/G-AMSCs over the 30-day HG culture period; however, H-CMSCs had an approximately 5-fold increase in \textit{INS} expression. Taken together this is suggestive that while HG culture was inductive for pancreatic lineage differentiation conversion of H-/G- CMSC and AMSCs into mature insulin producing cells (IPCs) required additional factors.
Figure 4-8. Pancreatic markers expression in HG culture
Gene expression (NEUROG3, PDX1, INS) was analysed by real-time PCR at day 10, 20, and 30 of HG culture. The expression was normalised to GAPDH and the fold change was calculated by comparing to the expression level on day 0. There was no change in PDX1, NEUROG3, and INS expression under LG culture in each group. Data are expressed as mean ± SEM of 4 independent experiments. One-way ANOVA was used to determine statistical significance, *p<0.05, **p<0.01, ***p<0.001
4.4.4 Stepwise differentiation and IPC morphology

A three-stage differentiation protocol for reprogramming H-/G- CMSCs and AMSCs into IPCs after high glucose pre-culture

HG culture promoted formation of H-/G- CMSC condensations and while H-CMSCs displayed elevated pancreatic β-cell marker, G-CMSCs did not. Further, neither H-AMSCs nor G-AMSCs formed condensations or displayed upregulated β-cell markers. Long-term HG culture resulted in cell death and accelerated cellular senescence; however, the critical transcription factors for β-cell development were induced after 10-day HG culture. Therefore, we primed H-/G- CMSCs and AMSCs in 25mM glucose media for 10 days and sequentially stimulated cells with small molecules and growth factors to induce IPC maturation.

To induce definitive endoderm cell populations were then switched into a 17mM glucose DMEM/F12 containing bovine serum albumin (BSA), sodium butyrate, 2-mercaptoethanol base media for 3 days with Activin A\textsuperscript{347} followed by 3 days with Retinoic Acid\textsuperscript{348}. The base media was used to protect against cellular stress induced by serum free media and promote chromatin rearrangements\textsuperscript{349, 350}. Next, cells were cultured for a further three days in DMEM/F12 supplemented with BSA, EGF and Taurine. EGF was used to enhance the growth of endocrine progenitor cells and Taurine, a beta-sulfonic acid, was known to induce insulin production and release at different concentrations in pancreatic beta cells \textit{in vitro} culture\textsuperscript{351} as well as type 1 diabetic and obese-induced diabetic mouse models\textsuperscript{352}. It has been suggested that using Taurine at low concentration promoted pancreatic specialisation in endocrine lineage cells\textsuperscript{317, 353, 354}. Thus, Taurine was used at 0.3 Mm at stage II media and increased to 3 mM at stage III with the additional supplementation of GLP-1, nicotinamide, and NEAA to induce the maturation and proliferation of IPCs\textsuperscript{355, 356} (Figure 4-9A). GLP-1,
with many important physiological functions in fetal beta-cell development, insulin synthesis, and secretion has been widely used in IPC differentiation protocols, including embryonic stem cells and bone-marrow MSCs while the supplement of 10 mM nicotinamide was showed to increase the function of GLP1 in insulin production.

H-CMSCs and G-CMSCs were seeded and grown in adherent monolayers for HG pretreatment before stimulating with IPC differentiation media. After the exposure to stage 1 differentiation media, H-/G- CMSCs formed small condensations which seemed to loosen but yet to detach from the substrate. The subsequent incubation with stage 2 differentiation media promoted suspension cell clusters formation in both H-CMSCs and G-CMSCs. In stage 3 increased dimension and mass of spheroid clusters was accompanied by detachment from the substrate and continued culture as organoids. H-CMSCs and G-CMSCs had similar morphological changes at each stage of the differentiation process (Figure 4-9B).

In contrast, H-/G- AMSCs cultured under the same differentiation condition displayed evidence of condensation formation during stage 1 and 2 whereas the adherent condensations showed no sign of detaching. The increasing size of condensations was observed at subsequent differentiation stages, along with some single cells suspending in the media. Suspension cells were collected during media change and transferred to a new culture plate; however, these cells did not grow, form clusters, or re-attach to culture plate. The suspension H-/G- AMSCs observed during IPC differentiation from were removed with differentiation media change. At the end of 3-stage differentiation process, H-/G- AMSCs still remained adherent without any detached spheroid formation (Figure 4-9B).
Figure 4-9. Optimised IPC differentiation approach and IPC morphology

(A) Differentiation scheme for IPC generation illustrates the growth factors, small molecules, and incubation time at each stage. BSA, bovine serum albumin; 2-ME, 2-mercaptoethanol; EGF, epidermal growth factor; GLP-1, glucagon-like peptide-1; NEAA, non-essential amino acids; IPC, insulin-producing cell. (B) Morphological changes during IPC differentiation. Control images were undifferentiated H-/G- CMSCs/AMSCs cultured in complete growth media (5.5 mM glucose DMEM containing 10% FBS) which remained fibroblast-like morphology. The image was a representative image of six independent experiments (scale bar, 200 μm).
4.4.5 Expression of pancreatic markers expression

**H-/G- CMSC-IPCs exhibited high level of pancreatic lineage markers whilst the lack of mature beta-cell markers in H-/G-AMSC-IPCs was improved by betacellulin**

To determine whether H-/G- CMSCs/AMSCs were programmed into endocrine hormone-producing cells, pancreatic lineage marker expression was examined by real-time PCR. The differentiated H-/G- CMSCs and AMSCs showed evidence of IPC differentiation by the expression of endocrine progenitor markers (*NEUROG3, ILS1*) and pancreatic lineage transcription factors (*PDX1, PAX6*). Gene expression was examined at the end of 3-stage differentiation process and the increased fold changes of each gene were calculated by comparing to undifferentiated H-/G- CMSCs/AMSCs.

*NEUROG3* and *ILS1*, promoting endocrine lineage differentiation, expression was noted in H-/G-CMSC-IPCs and showed comparably upregulated levels in both healthy and GDM group with approximately 13-fold increase in *NEUROG3* and 10-fold in *ILS1*. The upregulation of *NEUROG3* and *ILS1* displayed significantly enhanced levels in H-/G-AMSC-IPCs vs. H-/G-CMSC-IPCs. H-AMSC-IPCs and G-AMSC-IPCs both showed an 18-20-fold increase in *NEUROG3* and *ILS1* expression (Figure 4-10A).

Pancreatic lineage differentiation and β-cell development transcriptional markers, *PAX6* and *PDX1*, were also significantly induced in differentiated groups. H-CMSC-IPCs expressed higher level of *PAX6* induction than G-CMSC-IPCs while the expression of *PAX6* in H-AMSC-IPCs and G-AMSC-IPCs were comparable. Notably, there was a significantly increased expression of *PDX1* in H-/G-AMSC-IPCs compared with H-/G-CMSC-IPCs (Figure 4-10B).

The induction of endocrine progenitor and pancreatic lineage markers was previously
shown to be enhanced in 10-day HG culture without further stimulation by any compounds. The 3-stage differentiation protocol did not enhance the induction of these markers in H-/G- CMSCs but had a significant effect on promoting H-/G- AMSCs pancreatic markers expression. However, the 3-stage differentiation protocol was intended to promote the maturation of IPCs that failed to achieve in HG culture.

Mature β-cell markers, INS and GLUT2 were examined by real-time PCR. Significantly elevated expression of INS and GLUT2 were observed in H-/G- CMSC-IPCs (vs. H-/G- AMSC-IPCs) with approximately 30-fold and 10-15-fold induction, respectively. On the other hand, H-/G-AMSC-IPCs expressed significantly lower levels of mature β-cell marker expression. The expression of both INS and GLUT2 displayed no significant changes vs. undifferentiated H-/G- AMSCs (Figure 4-10C).

Direct comparison of IPCs generated from GDM- and Healthy- CMSCs established that, with the exception of PAX6 which was lower in G-CMSC-IPCs, both expressed comparable level of progenitor and, pancreatic transcription factors, and mature β-cell genes. Given the level of endocrine progenitor markers expression (NEUROG3, ISL1, and PDX1) and β-cell markers (INS and GLUT2) in H-/G- AMSC-IPCs vs. CMSC-IPCs it remains possible that the IPCs derived from H-/G- AMSCs may reflect an immature β-cell state.
Gene expression was analysed by real-time PCR. The relative expression level of (A) endocrine progenitor markers, *NEUROG3* and *ILS1* (B) pancreatic lineage transcription factors, *PDX1* and *PAX6* (E) mature β-cell makers – *INS* and *GLUT2*, were normalised to *GAPDH* and compared with undifferentiated CMSCs/AMSCs. Data are expressed as mean ± SEM of 6 independent experiments. One-way ANOVA was used to determine statistical significance, *p*< 0.05, **p*< 0.01, ***p*< 0.001.

Figure 4-10. Induction of pancreatic markers by IPC differentiation protocol
The basal induction of mature β-cell marker expression in H-/G- AMSC-IPCs was inconsistent with endocrine and pancreatic lineage gene expression. To explore induction further we explored additional supplementation with three molecules to improve their maturation; GLP-1, Exendin-4, and Betacellulin. GLP-1 was incorporated at Stage III of our original protocol (at the concentration of 50 nM) to promote IPC maturation. Both exendin-4, a synthetic stable GLP-1 analogue, and betacellulin, a member of the epidermal growth factor family, have been demonstrated to improve β-cell maturation, proliferation and increase insulin content\textsuperscript{360,361}. Dosage used in the screening was based on literature finding.

Figure 4-11 showed the result of INS and GLUT2 expression in H-/G- AMSC-IPCs when replacing GLP-1 with exendin-4 or betacellulin at stage 3. GLP-1 induced INS expression with an approximately 5-fold increase in H-/G- AMSC-IPCs compared to undifferentiated AMSCs while the induction showed no dose-dependent effect on INS expression levels. There was no significant induction of GLUT2 expression under either 50 nM or 100 nM GLP-1 supplementation.

Exendin-4 at the concentration of 10 nM was reported to induce insulin expression in umbilical cold MSCs\textsuperscript{362}. We showed that the induction of INS expression showed a 5-fold increase in H-/G- AMSC-IPCs vs. undifferentiated AMSCs at 10 nM exendin-4 supplementation while there was no dose-dependent effect with higher exendin-4 concentration. Exendin-4 at 10 nM induced GLUT2 expression in H-AMSC-IPCs but no effect on GLUT2 expression in G-AMSC-IPCs.

Betacellulin was used in many IPCs differentiation protocols, including bone-marrow MSCs, embryonic stem cells, and umbilical cord MSCs at various concentrations\textsuperscript{363-367}. Whilst 1 nM betacellulin was the most common concentration used in literature, we investigated the effect of betacellulin at the concentration of 1 and 2 nM on H-/G-AMSC-IPCs maturation.
The expression of *INS* and *GLUT2* was significantly improved by 1 nM betacellulin and with higher concentration of betacellulin (2 nM), further enhanced expression of *INS* was observed in H-/G-AMSC-IPCs. H-/G-AMSCs were found to be more responsive to betacellulin stimulation for β-cell maturation than GLP-1 or exendine-4.

**Figure 4-11. Improving AMSC-IPC maturation by betacellulin**
The improvement of *INS* and *GLUT2* expression in H-/G-AMSC-IPCs by GLP1, exendin-4, or betacellulin supplementation. The gene expression was normalised to *GAPDH* and γ-axis shows the fold increase by comparing with undifferentiated H-/G-CMSCs/AMSCs. Data represent mean ± SEM. One-way ANOVA was used for statistical significance, #p<0.001 indicates significantly increased gene expression under betacellulin compared with GLP-1 or Exendin-4 supplementation.
4.4.6 Immunofluorescence staining and ELISA

**Comparable insulin protein expression in H-/G- CMSC-IPCs and AMSC-IPCs but insufficient insulin secretion function in AMSC-IPCs**

Immunofluorescence staining was used to verify protein expression of β-cell markers but is not a precise measurement of protein expression levels due to variations from staining and imaging procedures depending on morphological differences. H-/G- CMSCs were differentiated to IPCs using original protocols with the stimulation of GLP-1 at stage 3 while H-/G- AMSCs was induced to IPCs via optimised protocol where GLP-1 was replaced with betacellulin at the last differentiation stage. Cells were fixed on the last day of differentiation and stained for insulin (red) and transcription factor PDX1 (green) expression (Figure 4-12).

Immunofluorescence labelling indicated that Insulin was co-expressed with transcription factor PDX1 in both Healthy- and GDM- CMSC-IPC spheroids. On the other hand, suspension spheroid cultures were not observed with H-/G- AMSC-IPCs with little progression beyond cell condensations at the end of differentiation process. However, irrespective of above co-expression of insulin and PDX1 was noted in H-/G- AMSC-IPCs (Figure 4-12).

The result confirmed the mature IPC differentiation and suggested that the upregulated pancreatic lineage genes were also expressed on protein levels in differentiated groups (H-/G- CMSC-/AMSC- IPCs) compared to undifferentiated H-/G- CMSCs/AMSCs.
<table>
<thead>
<tr>
<th></th>
<th>IgG control</th>
<th>IgG control/DAPI</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-CMSC-IPC</td>
<td><img src="155" alt="Image" /></td>
<td><img src="155" alt="Image" /></td>
</tr>
<tr>
<td>G-CMSC-IPC</td>
<td><img src="155" alt="Image" /></td>
<td><img src="155" alt="Image" /></td>
</tr>
<tr>
<td>H-AMSC-IPC</td>
<td><img src="155" alt="Image" /></td>
<td><img src="155" alt="Image" /></td>
</tr>
<tr>
<td>G-AMSC-IPC</td>
<td><img src="155" alt="Image" /></td>
<td><img src="155" alt="Image" /></td>
</tr>
</tbody>
</table>

**Legend:**
- **PDX1/Insulin**
- **H-CMSC-IPC**
- **H-AMSC-IPC**
- **G-CMSC-IPC**
- **G-AMSC-IPC**

Scale bar: 100 μm
Functional β-cells are characterised by the ability to secrete adequate amounts of insulin in response to a glucose challenge. To establish functionality of IPC, we performed ELISA assays to investigate the secretion of insulin and C-peptide following glucose challenge (Figure 4-13). C-peptide is a by-product from the maturation process of insulin which is stored and released in equimolar quantities with insulin granules. H-/G- CMSC-IPCs and AMSC-IPCs were incubated in glucose free media for 2 hours prior to sequentially challenging with low glucose (5.5mM) for 1 hour and high glucose (25mM) for 2 hours, followed by measurement of insulin release into supernatants. The phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine (IBMX) known to induce insulin secretion was supplemented at the concentration of 0.5 mM to 5.5 mM and 25 mM glucose media.

Undifferentiated H-/G- CMSCs and AMSCs released low or undetectable basal level of insulin and C-peptide into the media. H-CMSC-IPCs and G-CMSC-IPCs secreted insulin to low glucose challenge and released an increased amount of insulin in response to glucose content changes (Figure 4-13A). Likewise, a similar result was demonstrated in C-peptide release, where the increased C-peptide production was observed from low to high glucose challenge (Figure 4-13B). The insulin and C-peptide release levels showed no statistical
differences between H-CMSC-IPCs and G-CMSC-IPCs.

In contrast, IPCs derived from H-/G- AMSCs released insulin and C-peptide in response to low glucose challenge but failed to produce increased amount of insulin at high glucose stimulation. Similar levels of insulin release in H-/G- CMSC-IPCs and AMSC-IPCs were noted when challenging with 5.5 mM glucose concentration. However, when increasing the glucose to 25 mM, around 50% of H-AMSC donor samples displayed evidence of glucose sensitivity while G-AMSC-IPCs failed to consistently produce insulin responsive to glucose concentration changes (Figure 4-13A). The C-peptide expression was consistent with insulin release in H-/G-AMSC-IPCs (Figure 4-13B).
Figure 4-13. Insulin and C-peptide ELISA
Functional IPCs were accessed by insulin releasing capacity upon glucose challenge. IPCs were subsequently incubated with 5.5 mM glucose DMEM containing 0.5 mM IBMX for 1 hour and switched to 25 mM glucose DMEM containing 0.5 mM IBMX for 2 hours. The supernatant was collected and measured for (A) insulin and (B) C-peptide release by ELISA. Left panels show the secretion level measured by ELISA and right panels show the percentage of increased insulin/C-peptide secretion in 25 mM glucose vs. 5.5 mM glucose. Data were normalised to undifferentiated H-/G- CMSCs/AMSCs and expressed as mean ± SEM. Each data point was conducted in duplicates. One-way ANOVA was used for statistical significance, ***p < 0.001.
Finally, we examined the intracellular insulin protein content to further understand whether the poor response to glucose stimulation in H-/G- AMSC-IPCs was caused by low insulin synthesis during differentiation. H-/G- CMSC-IPCs and AMSC-IPCs were lysed and insulin content was measured by ELISA normalising to total protein content within the cells. Significantly increased insulin content was observed in IPC groups compared to undifferentiated H-/G- CMSCs/MASCs. Surprisingly, no significant difference in intracellular insulin level was observed across all IPCs suggesting a broad comparability in insulin synthesis ability (Figure 4-14). The insufficient insulin secretion from H-/G- AMSC-IPCs might due to impaired glucose uptake or inadequate insulin exocytosis rather than insulin synthesis.

![Insulin content](image)

**Figure 4-14. ELISA of intracellular insulin**

Insulin content in H-/G- CMSC-/AMSCs- IPCs were measured by ELISA after incubating with 25 mM glucose challenge. The expression levels were normalised to total protein content. Each data point was conducted in duplicates. One-way ANOVA was used for statistical significance, ***p< 0.001 indicates significant difference compared to undifferentiated MSCs; ns, no significant difference between each group.
4.5 Discussion

Embryonic stem cells normally express high levels of *NANOG*, *SOX2*, and *OCT4*. We demonstrated that H-/G- CMSCs and AMSCs showed either higher or comparable levels of *SOX2* expression than embryonic stem cells although the high expression levels were not found in *NANOG* and *OCT4*. Notably, H-/G- CMSCs/AMSCs showed significantly increased expression of *NANOG*, *SOX2*, and *OCT4* than bone marrow MSCs. Neonatal tissue-derived MSCs have been reported to express higher levels of stemness markers than bone marrow MSCs in some studies. For instance, amniotic epithelial cells and mesenchymal cells showed more *OCT3/4*, *NANOG*, and *KLF4* expression than bone marrow MSCs\(^2\)\(^7\). Chorion stem cells were highly positive for *OCT-4*, *NANOG*, *SSEA-3*, and *TRA-1–60* expression\(^3\)\(^6\).\(^9\). Our results show that AMSCs and CMSCs from both healthy and GDM women have higher levels of stemness markers than bone-marrow MSCs.

**Glucose effect on pancreatic development**

Adult β-cells are mostly quiescent with only a small proportion having the ability to proliferate in respond to hyperglycaemia\(^3\)\(^7\).\(^0\). Owing to the limited regenerative capacity of endogenous β-cells, researchers have been looking for alternative approaches to restore or promote β-cell function for diabetes patients. Generation of functionally mature β-cell from MSCs is one of the attractive alternative for β-cell replacement therapies. Various extrinsic factors have been used to mimic the environment in order to facilitate β-cell differentiation.

Glucose is a critical factor for pancreatic islet development *in vitro* and *in vivo*\(^3\)\(^7\).\(^1\). During pregnancy, maternal glucose levels raise to allow fetus to have sufficient nutrients for development in the late second to third trimester, which is also the crucial period for pancreatic islet development while the remodelling and maturation of fetal pancreas
continues until early childhood\textsuperscript{372}. In \textit{in vivo} animal studies, elevated maternal glucose levels contributed to increased fetal pancreatic insulin content, promoted β-cell proliferation, and enhanced insulin secretion in response to glucose\textsuperscript{373, 374}. The influential role of glucose in β-cell development, survival and insulin biosynthesis and secretion has also been evidenced in many studies\textsuperscript{375, 376}. Therefore, glucose is considered as an inducer for β-cell differentiation and commonly used in IPC generation protocols\textsuperscript{377}.

Although glucose availability regulates fetal islet development, it is known that abnormal maternal hyperglycaemia may lead to adverse effects and cause β-cell exhaustion\textsuperscript{378}. Given that GDM-MSCs were under prolonged exposure to hyperglycaemia during pregnancy, to know whether glucose is a suitable factor for IPC generation from GDM-MSCs, we exposed H-/G- CMSC/AMSCs to HG culture for a 30-day period. Reports have indicated that with a glucose concentration at 20-30, β-cell replication was significant enhanced\textsuperscript{379}. The starvation of bone-marrow MCSs in serum-free LG media prior to 7 days 25 mM glucose (high glucose) culture resulted in the formation of small spheroid clusters and upregulated expression of GLUT2, glucagon, and insulin\textsuperscript{380}. We did not observe 7-day HG culture-induced spheroid cluster formation with either H-/G- CMSCs or AMSCs. The obvious cell condensations formed around 20-day of HG culture in H-/G- CMSCs while the morphological changes were not profound in H-/G- AMSCs. However, we did note upregulated pancreatic transcription factor expression following on from short-term HG exposure. The increased expression of \textit{PDX1} and \textit{NEUROG3} in HG-cultured H-/G- CMSCs/AMSCs indicated the formation of endocrine progenitor cells while the lack of \textit{INS} expression suggested that those progenitor cells failed to differentiate into mature endocrine cells. \textit{PDX1} and \textit{NEUROG3} were reported to be essential factors for beta-cell development, where the expression of \textit{PDX1} remained high over the entire pancreatic islets development period and also in mature beta-cells\textsuperscript{381} whereas \textit{NEUROG3} was induced
during endocrine progenitor cells formation and the expression slightly reduced in mature beta-cells\textsuperscript{382}. Although we detected the increase in \textit{PDX1} and \textit{NEUROG3}, little or no increase in \textit{INS} expression was observed across all populations under HG culture indicating failure to mature under HG culture alone even though HG concentration induced \textit{INS} expression was shown in some studies\textsuperscript{380, 383, 384}.

In addition, long-term HG culture led to cell death in both Healthy- and GDM-CMSCs/AMSCs. HG is associated with reactive oxygen species production and induced cell apoptosis\textsuperscript{385}. In BM-MSCs, HG was found to affect cell proliferation, mitochondrial function, and result in apoptosis\textsuperscript{386}. Direct comparison of our findings to other studies is not possible though noteworthy comparisons are provided via elevated caspase-3 and caspase-8 pro-apoptotic activity in adipose-derived MSCs from type 2 diabetes patients\textsuperscript{387}.

Cellular senescence is a state of growth arrest and an inability to proliferate which is generally present in primary MSCs culture, especially at late passage\textsuperscript{388}. We found that prolonged HG exposure accelerated cellular senescence in both H-/G- CMSCs and AMSCs, but showed its greater effect on GDM samples than Healthy counterparts. Glucose at the concentration of 25 mM promoted BM-MSCs premature senescence through the expression of p16 and p21 over 28 days culture\textsuperscript{389}. In many IPC differentiation studies, MSCs were under a long period of HG culture from a couple of weeks to four months\textsuperscript{346, 390, 391}. Although some research showed positive results of IPC generation through HG culture, we pointed out the adverse effect of long-term HG culture, including increased cell death and cellular senescence which might affect the differentiation capacity for IPC generation. High glucose environment leading to cell senescence and impaired beta-cell survival was reported in many \textit{in vivo} studies. In high-fat diet-induced diabetic mice, hyperglycaemia resulted in beta-cell senescence with recued beta-cell mass and insufficient insulin
release\textsuperscript{392}. The glycaemic level changes in obesity mice were associated with beta-cell death and dedifferentiation, leading to loss of functional beta-cell population\textsuperscript{393}. Glucose is an important factor for pancreatic beta-cell development but long-term exposure may cause adverse effects.

**Optimised IPC generation approach**

Short-term HG culture provided a balance point with low levels of cell death, senescence, and elevated $\beta$ cell-linked transcripts for priming of placental membrane MSCs followed by incubation and induction of mature IPC differentiation following our three-stage differentiation process.

Our three-stage protocol was modified from previously published protocol by Chandra \textit{et al.}\textsuperscript{353} who generated IPCs from adipose derived-MSCs. The protocol has also been applied to umbilical cord-derived MSCs by Wang \textit{et al.}\textsuperscript{394}. However, several steps were modified in our study. Firstly, the ITS (insulin-transferrin-selenium) used in Chandra’s differentiation media was withdrawn in our protocol. ITS is commonly used in serum free media to maintain cell growth whereas BSA and 2-mercaptoethanol were sufficient to support most of CMSC/AMSCs survival in serum free media. The insulin contained in ITS may enhance the chance of taking up insulin from differentiation media instead of insulin synthesis in IPCs. Secondly, after stimulating with activin A, an inducer for definitive endoderm formation\textsuperscript{321} at the stage 1, the additional 2-day retinoic acid (RA) stimulation combined with activin A improved morphological changes towards condensations and spheroid cluster formation at later stages (Figure 4-9B). RA signalling is essential for pancreatic development that induces the generation of endocrine progenitors and functions as an effective inducer for pancreatic transcription factor $PDX1$ expression while the disruption of RA signalling leads to pancreatic agenesis\textsuperscript{361, 395, 396}. Thirdly, Chandra’s protocol established a 10-day maturation
protocol for IPC generation; however, it was not reproducible with H-/G- CMSCs or AMSCs. A longer incubation time was required especially for the last maturation stage, as well as the additional supplementation with EGF and nicotinamide to enhance the growth and maturation of IPCs\textsuperscript{397, 398}.

In the present three-stage IPC differentiation approach, among all various factors GLP-1 plays a crucial role in promoting the maturation of IPC. GLP-1 has important physiological functions in fetal β-cell development, insulin synthesis, and secretion\textsuperscript{399, 400}; therefore GLP-1 has been widely used at the last differentiation stage in many IPC differentiation protocols. H-/G-CMSCs displayed good responsiveness to our IPC induction protocol with enhanced mature beta-cell marker expression and the ability to secrete insulin. However, in immunostaining, we found that some cell populations showed PDX-1 positive but not insulin. These cell populations may be at immature differentiation stage or other endocrine cell types. PDX1-expressing progenitor cells give rise to β-cell and also α-cells and δ-cells that secrete glucagon and somatostatin, respectively\textsuperscript{401}. It is likely that the cell clusters formed in H-/G-CMSC-IPCs may contained different endocrine cell types.

Given the low expression of mature beta-cell markers in H-/G-AMSCs, we further optimised our protocol for promoting AMSC-IPCs maturation. We explored the supplementation with either exendin-4 or betacellulin as a substitute for GLP-1 in the last IPC maturation stage. Exendin-4 is a GLP-1 agonist which improves glucose tolerance in diabetes patients via enhanced insulin secretion\textsuperscript{402, 403}. A previous report has indicated that exendin-4 supplementation promoted β-cell gene transcription in mouse embryonic stem cell-derived IPCs\textsuperscript{404}. In this instance we saw no significant, or dose-dependent, induction of either INS or GLUT2 transcription in H/G-AMSC-IPCs following exendin-4 supplementation.

In contrast, we noted significant increases in both INS and GLUT2 in H-/G- AMSCs following
betacellulin supplementation. Betacellulin is an epidermal growth factor (EGF) family member with demonstrable regulation of pancreatic regeneration through activation of EGF receptors (EGFR), ErbB1 and ErbB2. Further, in β-cell development from human embryonic stem cells the addition of betacellulin sustained PDX1 expression and improved the differentiation process. In present study, H-/G-AMSCs were more responsive to betacellulin than GLP-1 or exendin-4. GLP-1 and exendin-4 interact with the high affinity receptor, GLP-1R, while GLP-1R lacks kinase activity and depends on EGFR to activate its downstream pathways. In turn, signal transduction of GLP-1R via EGFR require the proteolytic processing of membrane-anchored betacellulin or other EGF-like ligands. Therefore, the direct treatment of betacellulin likely had a more direct effect on EGFR regulation of insulin expression.

Irrespective of above, successful induction of insulin gene and protein expression was not reflected in significant increases in insulin secretion from H-/G-AMSC-IPCs upon glucose challenge, regardless of their comparable pancreatic gene and intracellular insulin expression levels with H-/G-CMSC-IPCs. Notably, three H-AMSC-IPCs samples (Healthy 03, 06, 10) were able to release insulin in response to high glucose environment but AMSC-IPCs derived from Healthy 07, 08, and 11 failed to secrete increased insulin. Although Healthy 07 and 08 had a history of smoking which might affect cell biological properties, such as DNA methylation, we were unable to identify whether smoking has a direct effect on poor insulin secretion. However, cigarette and nicotine were found to have impacts on impaired insulin secretion and insulin resistance. Moreover, we noticed that AMSC-IPCs derived from Healthy 08 and 11 had lower expression of GLUT2 gene. The glucose transporter, GLUT2 plays an important role in glucose sensing and homeostasis. The low expression of GLUT2 may reflect the less responsiveness to high glucose environment in H-AMSC-IPCs.
A notable difference between H-/G-AMSC-IPCs and H-/G-CMSC-IPCs during differentiation was that the former displayed a morphology of attached cell condensations which did not progress into suspension spheroids. Current perspectives have suggested β-cell glucose stimulation requires the formation of small spheroid clusters either in suspension or loosely adhered to extracellular matrix and that single cells are not responsive\textsuperscript{413, 414}. This reflects our observations where spontaneously detached, spheroid cultures, supported IPC differentiation and maturation in H-/G-CMSCs
4.6 Summary

Coupled to the growing interest in autologous, and allogeneic, cell therapy, an understanding of how disease state impairs the regenerative capacity of endogenous MSCs is crucial. In this study we have provided three key observations; the first being the description of a comprehensive protocol for the generation of IPCs from placental chorionic membrane-derived MSCs, the second being that amniotic membrane-derived MSC are refractory to IPC differentiation, and the third being that the above primary characteristics are GDM-independent. GDM-derived CMSCs were capable of transdifferentiation into IPCs, expressing β-cell markers and functionally indistinguishable from healthy CMSC-IPCs but G-AMSCs failed to differentiate into mature IPCs. This suggests that the pathophysiological state of GDM may cause irreversible impairment in the differentiation capacity of AMSCs. Notably, G-CMSCs possessed comparable IPC differentiation potential to H-CMSCs.
Chapter 5

Microarray study of Healthy- and GDM- CMSCs transcriptional profile
5.1 Introduction

Mesenchymal stem cells (MSCs) are present in many adult tissues and responsible for tissue regeneration and maintenance. Their regenerative potential provides numerous benefits for disease treatment. In terms of differentiation potential toward multiple lineages and immunomodulatory capacity MSC may share certain levels of common transcriptional signature\(^\text{415}\). However, transcriptional profile can also be unique to MSCs derived from different tissues. Stem cell therapies are somehow hampered by our incomplete knowledge of their fundamental differences\(^\text{416}\). Unlike embryonic stem cells, MSCs niche in adult tissues may affect and determine the gene expression in specific tissue-derived MSCs. It is likely that many genes critical to regenerative functions of MSCs or altered gene signature in different MSC sources are not yet fully understood. A better knowledge of MSCs gene profile provides more effective strategies for using MSCs in regeneration medicine.

DNA microarray is a powerful tool to study genomic-scale transcriptome profiling and through various bioinformatic methods, image data can be processed and converted to gene expression values. Even when the microarray data is processed to gene expression value, thousands of genes expressed within the cells make the analysis of these complex datasets challenging. There are a number of commercially or open source bioinformatic software available to assist microarray studies and analyse biological significance\(^\text{417}\). In this chapter, analysis methods, including identification of differentially expressed genes, clustering of data, relevant biological function analysis, and interaction networks were used via different bioinformatics tools. Other bioinformatics analysis techniques such as biomarker identification has been widely used in cancer research and toxicogenomics is commonly used in drug screening.

However, when microarray data is obtained from different platforms, the procedures can
vary greatly with gene expression. Reliability and reproducibility of microarray data has raised concerns. For example, two studies attempted to investigate survival after chemotherapy for diffuse large B-cell lymphoma by gene expression profiling using different microarray platforms. The results showed different gene classifiers with a low number of overlapping genes\(^4\). Likewise, inconsistent results were found in some stem cell studies on exploring gene signature of embryonic and adult stem cells\(^4\). Since the inconsistency issue has been addressed, the MicroArray Quality Control project initiated by the US Food and Drug Administration attempted to enhance intra-platform and cross-platform consistency\(^4\) which has improved nowadays microarray technology.

In addition, verification of microarray results through laboratory experiments is considered as a reliable method to validate the accuracy of microarray data. As DNA microarray analyses transcriptome activity, using semi-quantitative reverse transcription PCR or real-time PCR to examine gene expression is a common first step to verify microarray data\(^4\). However, with the increasing availability of microarray chips and affordable prices, some studies are able to enhance the accuracy of microarray data and reduce sample-to-sample variance by improving sample size. These studies can thereby provide more powerful evidence and forgo performing validations through laboratory gene analysis assay\(^4\). Given that biological functions mainly depend on protein activities, validating array results at the protein level corresponding to gene expression is equally important\(^4\). Validation of protein expression and its relevant biological functions revealed by microarray analysis can be carried out through immunoblotting, immunostaining, function assays, or \textit{in vivo} experiments.

Owing to the fact that umbilical cord blood-derived MSCs/HSCs (U-SCs) have been studied and applied in clinical therapies for many years, there are many U-SCs microarrays or gene
sequencing data available on GEO database (GEO, gene expression omnibus, https://www.ncbi.nlm.nih.gov/geo/). However, very few studies have investigated whether the genomic profile of these perinatal tissue-derived stem cells are altered by pregnancy complications. A microarray study on umbilical vein endothelial cells (HUVEC) derived from GDM pregnancies indicated altered gene expression in insulin sensing and extracellular matrix reorganisation\textsuperscript{428}. Another study performed microarrays on umbilical cord tissue from diabetic pregnancies and found alterations in genes associated with vascular development and function\textsuperscript{429}. However, the gene profiling research on regenerative ability of MSCs from GDM women is limited. Moreover, microarray data of CMSCs is yet to be found on GEO database.

In chapter 3, we showed that CMSCs can be isolated in high numbers, with steady growth and proliferation rate under a standard culture environment. In addition, CMSCs derived from GDM and healthy women demonstrated comparable regenerative potential towards tri-lineage differentiation. These findings leading to conclude that the GDM environment did not significantly hamper the differentiation ability of CMSCs. GDM-CMSCs were able to behave similarly to healthy CMSCs and successfully reprogrammed into insulin producing cells as demonstrated in chapter 4. GDM-CMSCs seem to have promising potential to be used in regenerative medicine. Therefore, to further evaluate the therapeutic potential of CMSCs, we performed DNA microarray to comprehensively understand their gene profiles and investigate the potential clinical application based on their transcriptional signature.
5.2 Aim

With increasing interest in the utilisation of placental MSCs and their banking for clinical purposes, understanding the characteristics and regenerative potential of placental MSCs has become an important subject. Thus, we sought to explore gene expression profiles between CMSCs from healthy and GDM placenta by DNA microarray analysis. Moreover, we aimed to investigate the biological differences or similarities based on gene expression and validate these changes in functionality through experimental assays to provide a comprehensive understanding of healthy and GDM CMSCs.

The main objectives of the chapter:

- Perform DNA microarray with 3 healthy and 3 GDM CMSC samples
- Analyse microarray data using bioinformatic software
- Validate gene expressions with 10 healthy and 11 GDM samples
- Investigate biological differences through *in vitro* functional assays
5.3 Methods

DNA microarray

Samples used for microarray analysis were 3 H-CMCS (Healthy03, 07, 08) of similar ages and BMI, and 3 GDM-CMCS (GDM06, 07, 08) treated with either metformin (06), insulin (07), or both (08), representing the different severity of GDM. Cells were collected at passage 2 for microarray analysis. Apart from RNA extraction and microarray raw data collection conducted by Welgene Biotech Company, all analysis and validation experiments in this chapter were carried out by the author for this thesis.

Microarray experimental flow is showed in Figure 5-1 conducted by Welgene Biotech Company. The 0.2 μg of total RNA was amplified and labelled with Cy3 (CyDye, Agilent Technologies) for in vitro transcription process. 0.6 μg of Cy3-labeled cRNA was fragmented to an average size of about 50-100 nucleotides and then pooled and hybridized to Agilent SurePrint Microarray (Agilent Technologies) at 65 °C for 17 hours. After washing process by nitrogen gun blowing, microarrays were scanned with an Agilent microarray scanner and images were analysed by Feature extraction10.7.3.1 software (Agilent Technologies).

![Microarray experimental flow diagram](image)

Figure 5-1. Microarray experimental flow

A common external RNA control, poly A+ RNA with Spike-IN, is a set of unlabelled, poly-adenylated transcripts of known sequence and quantity used to calibrate measurements in RNA hybridization assays\(^\text{430}\). Microarray experiments were performed using Agilent
SurePrint technology by Welgene Biotech Company.

**Microarray analysis using bioinformatics software**

Venn diagram and hierarchical clustering heat maps were created by AltAnalyze software (Gladstone Institution, UCSF) used to identify commonly up-regulated or down-regulated genes and illustrate the differentially expressed gene lists of interest.

Ingenuity Pathway Analysis (IPA, Qiagen; www.qiagen.com/ingenuity) was used to analyse the genes with fold changes greater than 1.5 in GDM samples vs. healthy samples (differentially expressed genes, DEGs). Overrepresented and underrepresented biological functions and canonical pathways were identified based on the DEGs involved in Ingenuity Knowledge Database (Qiagen). The chi-squared test and Fisher's exact test are used to compare statistical significance between two variables when the comparing groups are independent and not correlated. The chi-squared test applies when the sample size is large, while the Fisher's exact test runs an exact procedure as the chi-squared test but for a small sample size\(^431\). In this study, the two variables in the microarray analysis are the total DEGs (up-/down- regulated genes) and associated biological functions/pathways, when the independent comparing groups are Healthy and GDM. Due to the small-sized samples in our study, the Fisher's exact test was used for analysing significance via IPA software. The p-value is calculated by considering the number of DEGs that participate in a specific biological function vs. the total number of genes that are known to be associated with that biological function in the IPA database (Ingenuity Knowledge Base, Qiagen). The p value < 0.05 indicates statistical significance.

The downstream function analysis was used to identify biological functions that are expected to be increased or decreased based on the activation Z-score. The activation Z-
scores were calculated by IPA, which assess the potential activation state of a biological function by using information about (1) the up- or down- regulatory state of each gene involved (2) the statistical significance of these genes in the biological function. The positive activation Z-score indicates increased activation and the negative activation Z-score indicates decreased activation.

Pathway network visualisation was created by Cytoscape v.3.6.1. Enriched gene sets identified by IPA pathway analysis were selected and used as input nodes. The interaction network was generated according to literature findings and public database. The network was manually curated and distributed with circles for easier visualisation.

The experimental workflow of microarray analysis and validation was demonstrated in Figure 5-2.
10 Healthy and 11 GDM CMSC samples were used for validating microarray data through gene expression and functional assays. The selected upregulated/downregulated genes in microarray data were validated by real-time PCR (Section 2.8). Functional assays were used to validate enriched biological function in GDM-CMSCs, including Transwell migration assay (Section 2.14.1), wound healing assay (Section 2.14.2), ALDH activity analysis (section 2.15) and ROS detection (Section 2.16). Real-time PCR and migration results were compared using Student’s t-test to determine the statistically significance between two groups. ALDH activity and ROS detection was analysed using one-way ANOVA to compare the significance between two groups at different time points. Analysis was performed using GraphPad Prism (GraphPad Software).
5.4 Results

5.4.1 Identification of differentially expressed genes

Gene expression profiling of CMSCs derived from 3 healthy (H-CMSCs) and 3 GDM women (GDM-CMSCs) were assessed by DNA microarray analysis at passage 2. The details of samples used for microarray analysis (Healthy03, 07, 08 and GDM06, 07, 08) are listed in Table 2-2. The 3 H-CMSCs (Healthy03, 07, 08) were chosen based on similar ages and BMI. GDM samples were selected from GDM patients that had received glycaemic control treatments during pregnancy, as this cohort showed excessive physiological glucose levels vs. healthy women or untreated GDM patients, and could be more representative cohort to explore hyperglycaemic effects on GDM-CMSCs. Two GDM samples (GDM 06 and 07) were treated with metformin and insulin, respectively while a sever GDM sample (GDM08) received a combined treatment with both metformin and insulin.

Within the thousands of genes analysed in microarray, a small number of informative genes which display altered expression patterns and are mostly responsible for the differences between two biological conditions under investigation, are defined as differentially expressed genes (DEGs). DEGs can be identify by specific selection criteria. In this study, a cut-off of $P < 0.05$ and 1.5-fold change in gene expression were used to identify the DEGs between H-CMSCs and GDM-CMSCs. Compared to H-CMSCs, there is a total of 431 DEGs, including 162 up-regulated and 269 downregulated genes in all 3 GDM samples (Figure 5-3). The sample from the women received both metformin and insulin treatment (GDM08) exhibited the highest number of total DEGs.

The top 10 differentially upregulated or downregulated genes are listed in Table 5-1 with the expression log₂ fold change. Functional interpretation of top ranked genes was defined
by Gene Ontology Consortium (http://www.geneontology.org/). In the down-regulated
genes, PRKCB, FAM20A, ALDH1A1, and ATP8B4 were associated with catalytic activity; GJA8
and ATP8B4 were involved in transport activity; and CXCL12, CXCL3, CXCL, and RSPO3 in
chemokine activity. The majority of the top 10 up-regulated genes were related to protein
or ion binding and RPS4Y1, COL17A1, SPRR3, KRT5, HAPLN1 were also involved in structural
molecule activity.

Figure 5-3. Venn diagrams of DEGs
Venn diagrams show the numbers of genes that are up- or down- regulated 1.5-fold more
in GDM-CMSCs vs. H-CMSCs. The overlapping areas of 3 circles were co-regulated genes in
GDM-CMSCs, defined as differentially expressed genes (DEGs).
### Table 5-1. Top ranked up- and down-regulated genes in GDM-CMSCs vs. Healthy-CMSCs

<table>
<thead>
<tr>
<th>Top 10 Down-regulated genes</th>
<th>Average log₂ ratio</th>
<th>Top 10 Up-regulated genes</th>
<th>Average log₂ ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PRKCB</strong></td>
<td>-5.566</td>
<td><strong>RPS4Y1</strong></td>
<td>9.873</td>
</tr>
<tr>
<td><strong>GJA8</strong></td>
<td>-4.166</td>
<td><strong>COL17A1</strong></td>
<td>9.344</td>
</tr>
<tr>
<td><strong>CXCL12</strong></td>
<td>-3.436</td>
<td><strong>DDX3Y</strong></td>
<td>8.528</td>
</tr>
<tr>
<td><strong>FAM20A</strong></td>
<td>-3.379</td>
<td><strong>CDH1</strong></td>
<td>8.376</td>
</tr>
<tr>
<td><strong>ALDH1A1</strong></td>
<td>-3.315</td>
<td><strong>KRT5</strong></td>
<td>8.308</td>
</tr>
<tr>
<td><strong>PRRX2</strong></td>
<td>-3.227</td>
<td><strong>SCEL</strong></td>
<td>8.207</td>
</tr>
<tr>
<td><strong>ATP8B4</strong></td>
<td>-3.040</td>
<td><strong>SPRR3</strong></td>
<td>7.823</td>
</tr>
<tr>
<td><strong>RSPO3</strong></td>
<td>-2.927</td>
<td><strong>PLD5</strong></td>
<td>7.293</td>
</tr>
<tr>
<td><strong>CXCL3</strong></td>
<td>-2.925</td>
<td><strong>HAPLN1</strong></td>
<td>7.102</td>
</tr>
<tr>
<td><strong>CXCL1</strong></td>
<td>-2.914</td>
<td><strong>L1TD1</strong></td>
<td>6.996</td>
</tr>
</tbody>
</table>

#### 5.4.2 Biological function analysis

**Wound repair and altered cardiovascular function in GDM-CMSCs**

Biological function analysis using DEGs that were identified in all 3 GDM-CMSCs samples was performed with Ingenuity Pathway Analysis (IPA) through two categories: “molecular and cellular functions” and “physiological system development and functions”. The “molecular and cellular functions” most represented in GDM-CMSCs were related to cell death and survival, cellular growth and proliferation, and cellular movement (Figure 5-4).
Figure 5-4. Enriched molecular and cellular function in GDM-CMSCs

Each pair of bars displays the significant state of over-represented functions in GDM-CMSCs compared to H-CMSCs and each colour represents each GDM sample. The p-value, calculated with the Fisher's exact test.
To further identify the altered cellular process of the most represented biological functions, downstream effects analysis was used to understand key biological processes influenced by DEGs. The activation z-score computed by IPA indicated the activation or inhibition state and gene enrichment of each downstream cellular process. A positive z-score indicates increased functional activity in GDM-CMSCs relative to H-CMSCs while a negative z-score indicates a reduction in activity.

As indicated by IPA, genes enriched in GDM-CMSCs were related to enhanced abilities in cell survival, cellular motility, assembly and organization of cytoskeleton, and skin formation, which are critical functions in wound repair and tissue remodelling (Figure 5-5A). The positive associated downstream cellular processes in “molecular and cellular functions” revealed the potential of GDM-CMSCs in wound healing process. Although some negative activation was found in colony formation, proliferation, cellular infiltration, and homing, due to the smaller z-core value it would suggest less significance of gene enrichment and effect.

To gain insight into the gene expression level of GDM and healthy samples, multiple functional gene clusters involved in cell movement and survival (Figure 5-5B), cellular assembly (Figure 5-5C), and development of epithelium (Figure 5-5D) were displayed on the clustering heat maps. The upregulated expressions of these gene sets were demonstrated in GDM-CMSCs associating with an increased function in healing process.
Figure 5-5. Downstream effects in molecular and cellular function

(A) Activation state of top enriched downstream cellular processes in “molecular and cellular functions” using IPA activation z-score to identify the increased (positive z-score) or decreased activity (negative z-score) in GDM-CMSCs compared to H-CMSCs. (B-D) Hierarchical clustering heat maps of DEGs involved in cellular functions related to healing process. Expression levels are represented by log₂ fold change (expression value in each sample vs. mean expression value in H-CMSCs). Colours are according to the scale representing high expression (red) and low expression (green) genes.
In order to explore the development/differentiation potential of GDM-CMSCs, DEGs were used to perform “physiological system development and function” analysis by IPA. The most represented biological function included cardiovascular system development and function, connective tissue development and function, and organ morphology. (Figure 5-6).

Figure 5-6. Enriched physiological system development and function in GDM-CMSCs
The most relevant biological functions in “physiological system development and function” category in GDM-CMSCs were identified by IPA. The p-value, calculated with the Fisher's exact test.
Further in-depth analysis of the downstream functional activation performed in relation to cardiovascular system development showed that cardiogenesis was the most significantly over-represented downstream cellular process with the highest positive z-score. Along with the positive association with development of cardiovascular tissue, it could imply the possibility of GDM-CMSCs giving rise to cardiogenic progenitors and their development into cardiomyocytes (Figure 5-7A). The heat map illustrated a set of genes involved in cardiogenesis that were highly expressed in GDM-CMSCs compared to H-CMSCs, contributing to greater potential in cardiac regeneration (Figure 5-7B).

Cardiogenesis potential is what generates cardiac cells which can replace the loss of cardiomyocytes or insufficient endogenous regeneration of cardiomyocytes in some heart diseases. On the other hand, the ability of stem cells to promote angiogenesis is a reason for successful cell therapies in cardiac regeneration. However, in GDM-CMSCs the cellular processes of vasculogenesis and angiogenesis in cardiovascular development were identified to have decreased activation with negative z-score (Figure 5-7A). The heat map showed that the regulators in vasculogenesis and vasculature development, such as PRRX2, RSPO3, KITLG, and CXCL1, had lower expression in GDM-CMSCs compared with H-CMSCs (Figure 5-7C).

Moreover, other enriched downstream cellular processes in the “physiological system development and function” category included respiratory system development, formation of lung and kidney with positive z-score while development of exocrine gland and connective tissue with negative z-score in GDM-CMSCs (Figure 5-8).
Figure 5-7 Downstream effects in cardiovascular system development

(A) Enriched downstream cellular processes associated with “cardiovascular system development and function” in GDM-CMSCs. Activation state was calculated by IPA activation z-score. (B-C) Heat maps summarized DEGs involved in cardiogenesis and vasculogenesis. Colours indicates high expression (red) and low expression (green)
Figure 5-8. Downstream effects in physiological system development and function
The relevant cellular processes related to development were identified and ranked by the IPA analysis based on DEGs. Activation state was calculated by IPA activation z-score.

5.4.3 Validation of enriched biological functions

*Increased migration ability, wound healing potential, and cardiac development in GDM-CMSCs*

To evaluate microarray data and functional differences between H-CMSCs and GDM-CMSCs, enhanced expression in genes involved in migration, survival, and cellular assembly ability in GDM-CMSCs were validated though real-time PCR analysis. Validated genes were selected mainly based on the significance of increased levels in microarray data and also the importance of the gene in the biological function.
In all 3 GDM-CMSCs microarray data, the highly glycosylated protein CD24 showed more than 10-fold increase. The expression of CD24 has been suggested to regulate cell migration in various cell types\textsuperscript{435, 436}. A microarray study of overexpression and suppression of CD24 in BM-MSCs indicated the regulatory role of CD24 in transforming growth factor (TGF)-β signal\textsuperscript{437} which is known to involve in many cellular functions, including cell growth, survival, and wound healing. Real-time PCR confirmed the significantly upregulated CD24 expression in GDM-CMSCs while the increased level varied from 5 to 15 folds (Figure 5-9A). Approximately 2 times higher expression of $CELSR1$, a membrane of cadherin superfamily involving in regulating adhesion and wound repair signalling, was found in GDM-CMSCs vs H-CMSCs. Filamin B ($FLNB$) and aquaporin 1 ($AQP1$) are involved in cytoskeleton arrangement and cellular assembly which showed a 2-3-fold increase in GDM06 and GDM07 microarray data while GDM08 had 3.7-fold upregulation in $FLNB$ and 40-fold increase in $AQP1$. Real-time PCR verified the increased expression of $FLNB$, $AQP1$, $CELSR1$ in GDM-CMSCs but the relatively high increase in $AQP1$ expression in GDM08 was not detected by real-time PCR analysis (Figure 5-9A).

The selected genes related to skin formation, epithelial development, and healing process included endothelin 1 ($EDN1$) which was evidenced to accelerate wound healing processes\textsuperscript{438}, and several growth factors; transforming growth factor (TGF), heparin-binding EGF-like (HBE)-GF, and connective tissue (CT)-GF which are known to promote wound repair and epithelium growth. The validation of $EDN1$, $HBEGF$, $TGFB2$, $CTGF$ expression was consistent with microarray result, showing significantly upregulated in GDM-CMSCs compared to H-CMSCs (Figure 5-9B).
Figure 5-9. Real-time PCR validated the genes involved in wound healing
Expression level of each gene was normalised to GAPDH expression. Results represent mean ± SEM. Statistical significance was determined by Student’s t-test, *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$. 
To examine biological differences on a functional level in vitro assays were performed to evaluate the migration ability. The Transwell migration assay was used to analyse the motility of single cell to respond toward attractants. H-CMSCs or GDM-CMSCs were placed into the upper compartment of a Transwell in serum free media and the lower compartment was filled with complete growth media containing FBS as an attractant. After allowing migration for 8 hours, enhanced migration ability was observed in GDM-CMSCs with a greater numbers of cells having migrated across the membrane. Cells were continually incubated for 24 hours and both H-CMSCs and GDM-CMSCs were observed to pass through the Transwell filter, where more migrated GDM-CMSCs were observed than H-CMSCs. After either 8 or 24 hours of incubation, GDM-CMSCs had a significant increase in the number of migrated cells vs. H-CMSCs which verified the more mobile state of GDM-CMSCs (Figure 5-10).

Wound healing assay was used to determine the migration ability of cell populations. A wound was created by scratching with a pipette tip through a confluent monolayer of cells and the migration ability determined by wound closure percentage. The result showed that higher numbers of GDM-CMSCs migrated into the wound field at every observed time point (6, 12, 24 hours) than H-CMSCs. The closure percentages were significantly increased, with approximately 30% in GDM-CMSCs and 20% in H-CMSCs after 12 hours and increasing up to 60% in GDM-CMSCs and 40% in H-CMSCs after 24 hours (Figure 5-11). Collectively, both the Transwell migration and wound healing assay validated the enhanced migration ability in GDM-CMSCs.
Figure 5-10. Transwell migration assay
Cell motility was evaluated by Transwell migration assay. Representative images are migrated H-CMSCs and GDM-CMSCs stained with crystal violet after 8 and 24 hours of migration period from 6 H-CMSCs (Healthy03-08) and 6 G-CMSCs (GDM04-09) samples in duplicate. Cell migration ability was calculated by counting migrated cells per field by image J. Results represent mean ± SEM. Statistical significance was determined by Student’s t-test, *p < 0.05, ***p < 0.001.
Figure 5-11. Wound healing assay
Representative images of wound healing assay from 6 H-CMSCs (Healthy03-08) and 6 G-CMSCs (GDM04-09) samples. Images were captured by light microarray after allowing H-CMSCs and GDM-CMSCs to migrate into the middle wound field after 0, 6, 12, 24 hours.
Scale bar, 150 μm. Percentage of wound closure was calculated by measuring the reduction in wound area after incubated for indicated time period. Images were modified (the yellow lines for edges of the wounds) and measured by image J. Numbers shown on the left corner represent the wound area. Statistical significance was determined by Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.
Cardiovascular development was identified as the most enriched biological function in GDM-CMSCs. The related DEGs showed altered expression, especially in cardiogenesis and vasculogenesis. Transcription factor NK2 homeobox 5 (NKX2.5) which has an important role in functioning heart development and formation showed increased in GDM06 and GDM08 microarrays, but a 1.6-fold decrease in GDM07. Validating NKX2.5 expression by real-time PCR, most GDM-CMSCs had a 2-fold upregulation while a more significant increase in NKX2.5 expression could be found in GDM03, GDM08 and GDM10 which showed more than 5-fold upregulated expression. Signalling transduction through platelet-derived growth factor (PDGF)-A and tyrosine kinase receptor mesenchymal epithelial transition factor (MET) is involved in early heart development\textsuperscript{439, 440}. PDGFA and MET expression was consistent with microarray data, showing an average of 2-fold upregulation in GDM-CMSCs vs H-CMSCs. The increased expression of noggin (NOG) was also confirmed by real-time PCR with significant increases from 3-12 fold in GDM-CMSCs compared to H-CMSCs (Figure 5-12A).

The opposite trend was found in vasculogenesis-associated genes, which showed a significantly reduced expression in GDM-CMSCs. R-spondin 3 (RSPO3) and chemokine CXCL12 were two of the top 10 downregulated genes in GDM-CMSCs, both involved in vasculogenesis and angiogenesis. CXCL12 showed 10-fold and greater reduced expression in GDM-CMSCs vs H-CMSCs. The reduction of RSPO3 was not as significant as with microarray data, which had an average of 2-fold decrease in GDM-CMSCs as well as other vasculogenesis regulators; ras interacting protein 1 (RASIP1) and heme oxygenase 1 (HMOX1) (Figure 5-12B).
Figure 5-12 Real-time PCR validated the genes involved in cardiovascular development
Expression level of each gene was normalised to GAPDH expression. Results represent mean ± SEM. Statistical significance was determined by Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.
5.4.4 Canonical pathway analysis

Pathways mediating cardiac development and cell movement are both upregulated in GDM-CMSCs while the majority of downregulated pathways are involved in metabolic processes

IPA canonical pathways analysis was used to evaluate pathways altered in GDM-CMSCs based on DEGs. The canonical pathways refer to the well-characterised cell signalling pathways that present common properties of a particular signalling module or pathway. Positively- and negatively- regulated pathways were identified by IPA with a p value indicating significance and the ratio of the number of DEGs that map to the all known genes in the pathway.

Positively-regulated pathways included growth factors pathways (bone morphogenetic protein (BMP), Wnt/β-catenin, fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF) signalling) and the transcription factor STAT3 pathway. These pathways are all involved in various growth and development processes. Moreover, Rac and Rho protein regulation signalling were also upregulated. Upregulated IL-1 mediated RXR function signalling was involved in the regulation of transport and metabolism of lipid, cholesterol, and bile acid (Figure 5-13A).

Among the down-regulated pathways identified by IPA, most of them were associated with degradation processes, including ethanol degradation, oxidative ethanol degradation, fatty acid α-oxidation as well as the degradation of neurotransmitters (histamine, dopamine, noradrenaline, serotonin) and other molecules (putrescine, tryptophan) (Figure 5-13B).

To elucidate the regulation of altered pathways and biological functions in GDM-CMSCs, we
built the gene regulatory networks of positively-/negatively-regulated pathways. DEGs were used as input nodes and the interaction network was generated according to literature findings and public database.

The enriched biological functions in GDM-CMSCs were associated with upregulated pathways revealed by IPA analysis. STAT3 pathway was most significantly upregulated signalling in GDM-CMSCs, which is imperative for development, cellular homeostasis, and regulating genes in cell growth, proliferation, differentiation in several tissues\(^4\). The transcription factor STAT3 functions as a transducer of several cytokines and growth factors signalling. The upregulated growth factor pathways including BMP signalling, Wnt/β-catenin signalling, and FGF signalling may also function through the activation of STAT3 signalling and regulate various development processes as well as enriched cellular functions in GDM-CMSCs such as cell growth and survival. Hierarchical clustering map illustrated that multiple upregulated DEGs were involved in BMP, Wnt/β-catenin, FGF pathways and leading to increased activities (Figure 5-14A).
Figure 5-13. IPA canonical pathways analysis

IPA canonical pathways analysis of positively- and negatively- regulated pathways in GDM-CMSCs. The x-axis indicates the altered canonical pathways. The left y-axis indicates the statistical significance p value, calculated using the Fisher exact test. The right y-axis represents the ratio of the numbers of genes in our dataset that map to the all known genes in the canonical pathway.
Notably, BMP, Wnt/β-catenin, and FGF are key signalling pathways in heart development. As the cardiac-associated genes, *NKK2.5* and *NOG* are regulated downstream to BMP, Wnt/β-catenin, and FGF pathways, the previously observed upregulation of *NKK2.5* and *NOG* in GDM-CMSCs (Figure 5-12A) may contribute to enhanced cardiogenesis potential via the modulation of BMP, Wnt/β-catenin, and FGF pathways. Other important factors, such as *WNT3/11, LEF1, FZD* in the Wnt/β-catenin signalling pathway, and *FGF1, MAPK, MET* in the FGF signalling pathway also displayed higher expression in GDM-CMSCs than H-CMSCs (Figure 5-14A).

Moreover, IPA pathway analysis identified increased activity of Rho family GTPase signalling in GDM-CMSCs, including Rac, RhoA, Cdc42 signalling. These GTP-binding proteins are activated by growth factors, cytokines and known to regulate cell migration, invasion, morphology, and cytoskeleton organisation which are all critical for tissue repair process. The key component genes of Rho family signalling were upregulated in GDM-CMSCs. Hierarchical clustering map showed increased expression of genes involved in Rho/Rac signalling at a magnitude of log₂ fold changes in all 3 GDM-CMSCs samples normalised to H-CMSCs expression levels (Figure 5-14B). In agreement with IPA biological function analysis and functional validation performed in Figure 5-9 and 5-10, enhanced cell movement capacity in GDM-CMSCs may be associated with the activation through Rho family signalling.
Figure 5-14. Interaction network of positively-regulated pathways

Interaction network was generated by Cytoscape visualization based on DEGs. Heat maps indicated the expression of genes involved in BMP, Wnt/β-catenin, FGF Signaling and Rho family signaling. Each gene is normalised to a mean expression of 3 Healthy-CMSCs samples. Blue shows the genes with below mean expression while red is above mean expression. Numbers indicate the log₂ fold change in each sample.
Significantly reduced expression in ALDH family genes results in negative association with metabolic pathways in GDM-CMSCs

Several pathways associated with degradation processes were significantly downregulated in GDM-CMSCs. Given the dysfunctional metabolic regulation in women with GDM, these pathways are of particular interest for investigating GDM-CMSCs behaviours. Figure 5-15 illustrates the genes associated with these enriched downregulated pathways and showed that the decreased activities of degradation pathways were highly connected to the significant reduction in aldehyde dehydrogenase family gene expression, ALDH1, ALDH2, ALDH3 (Figure 5-15A). Aldehydes can be formed during the metabolism of amino acids, carbohydrates, lipids, vitamins as well as cytotoxic drugs and environmental chemicals. ALDH genes encode the key enzymes regulating cellular detoxification through oxidising endogenous and exogenous aldehydes, and play an important role in many degradation processes.

Notably, ALDH1A1 is one of the most downregulated genes in GDM-CMSCs (Table 5-1). Other genes including ALDH1A2, ALDH2, ALDH3B1 were also significant reduced in GDM microarray data comprising the core molecules in downregulated pathways network. The deficiency of ALDH family genes may lead to insufficient detoxification resulting in aldehydes accumulation and reactive oxygen species (ROS) imbalance. Additionally, a critical pathway for ROS regulation, the Nrf2-mediated oxidative stress response pathway, showed downregulated in GDM-CMSCs, owing to the low expression of important regulators, serine/threonine-protein kinase PRKC and antioxidant enzyme genes (HMOX1, SOD2, AOX1) (Figure 5-15B).

Other down-regulated pathways, such as “IL-6 signalling” and “HGF signalling” regulate multiple molecules involved in angiogenesis (Figure 5-13B). For instance, CEBPB, FOS, ELK1,
CXCL8, which are the important regulators in IL-6 and HGF signalling displayed low expression in GDM-CMSCs. Moreover, the downregulation of “PI3K/AKT signalling” may affect the potent angiogenic factors, IL-6, IL-8, HGF and VEGF signalling transduction through mediating the PI3K/AKT pathway to promote angiogenesis444-446. Biological function analysis identified the downregulated genes in angiogenesis and vasculogenesis that were the downstream components of IL-6, IL-8, HGF pathways, suggesting the regulatory network of reduced angiogenic potential in GDM-CMSCs. Apart from its important role in angiogenesis, PI3K/AKT signalling is also only involved in cell proliferation, growth, and metabolism447.
Figure 5.15. Interaction network of negatively-regulated pathways. ALDH genes were the main molecules in the regulatory network. Networks were generated by Cytoscape visualization based on DEGs. Hierarchical clustering map showed significantly reduced in ALDH family genes expression in GDM-CMSCs and important regulators in Nrf2 pathway.
5.4.5 ALDH expression and function examination

Given that the decreased ALDH family genes expression affected several metabolic pathways and the negative activation of Nrf2-mediated oxidative stress regulation, GDM-CMSCs are likely to have imbalanced cellular ROS regulation. This may lead to increased oxidative stress, which are found in diabetic tissues. The expression of ALDH1A1, ALDH2, ALDH3B1 in GDM-CMSCs and H-CMSCs was validated with real-time PCR, and demonstrated significantly reduced expression levels in GDM-CMSCs (Figure 5-16). In accordance with microarray data, ALDH1A1 was found to have a significantly decreased level of expression in GDM-CMSCs than in H-CMSCs (Figure 5-16A). Both ALDH2 and ALDH3B1 showed around 2-fold reduction in GDM-CMSCs with variation in individual samples (Figure 5-16B and C).

![Figure 5-16. Real-time PCR validation of ALDHs expression](image)

Validation of significantly decreased ALDH1A1, ALDH2, ALDH3B1 expression in GDM-CMSCs. Expression level of each gene was normalised to GAPDH expression. Results represent mean ± SEM. Statistical significance was determined by Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.
Low ALDH family genes expression in GDM-CMSCs may cause insufficient or impaired ALDH enzymatic function in detoxification of endogenous and exogenous aldehydes. To evaluate ALDH enzymatic function, ALDH activity colorimetric assay was performed to measure the generation of nicotinamide adenine dinucleotide (NADH) during ALDH catalytic process for 30 minutes until the absorbance at 450 stop increasing. Acetaldehyde was used as a substrate to induce ALDH enzymatic activity.

In the initial 5 minutes, there was no statistical difference in ALDH activity between H-CMSCs and GDM-CMSCs. H-CMSCs and GDM-CMSCs increased ALDH activity from 0-15 minutes with continually increased catalytic efficiency but gradually declined thereafter in both groups. Of note, significantly lower levels of ALDH activity in GDM-CMSCs were observed at 10, 15, 20, and 25 minutes and the highest level of ALDH activity was seen at 15-min post-stimulation, showing significantly enhanced activity in H-CMSCs (Figure 5-17). The results confirmed that lower express of ALDH in GDM-CMSCs vs. H-CMSCs affected the enzymatic function of ALDH in detoxification.
Figure 5-17. ALDH enzymatic activity
Reduced ALDH enzymatic function was detected in GDM-CMSCs by ALDH activity colorimetric assay measuring the absorbance at 450 nm. The results were obtained from 6 H-CMSCs (Healthy03-08) and 6 G-CMSCs (GDM04-09) samples in duplicate represented as mean ± SEM. Statistical significance was determined by one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001
5.4.6 ROS and oxidative stress

With impaired ALDH activity, accumulation of highly reactive and toxic aldehyde tends to induce ROS formation and increase oxidative stress. A significant reduction of antioxidative enzymes in GDM-CMSCs may lead to a deficiency in antioxidant defences. The detoxification enzymes NAD(P)H quinone dehydrogenase (NQO1) induced by Nrf2 signaling was significantly reduced in GDM-CMSCs (Figure 5-17). Likewise, the expression of superoxide dismutase (SOD2) located in mitochondria regulating antioxidant defences was also significantly downregulated in GDM-CMSCs (Figure 5-17). Owing to the reduction in antioxidative enzyme expression, GDM-CMSCs is therefore likely to have elevated cellular oxidative stress.

Figure 5-18. Real-time PCR validation of antioxidative enzyme expression
The expression of NQO1 and SOD2 involved in Nrf2-mediated oxidative stress pathway were significantly reduced in GDM-CMSCs. Expression level of each gene was normalised to GAPDH expression. Results represent mean ± SEM. Statistical significance was determined by Student’s t-test, *p < 0.05, **p < 0.01
To examine the ROS production, H-CMSCs and GDM-CMSCs were treated with glucose to induce metabolic activity as hyperglycaemia is known to induce ROS levels in diabetes patients. H$_2$O$_2$ treated-cells were used as positive control. ROS production was detected using the cell permeant reagent 2',7'-dichlorofluorescin diacetate (DCFDA) which showed green fluorescence once being oxidised by cellular ROS. After treating with 25 mM glucose for 30 minutes, both H-CMSCs and GDM-CMSCs had increased ROS production without significant difference between two groups. However, higher level of cellular ROS was observed in GDM-CMSCs after 2-hour glucose treatment which showed increased intensity of fluorescence compared to H-CMSCs (Figure 5-19A).

ROS production and changes over a period of time were quantified by measuring fluorescence via a plate reader. Observing the ROS production every 15 minutes, the ROS levels increased for first 45 minutes in both H-CMSCs and GDM-CMSCs following stimulating with glucose. The amount of ROS production was comparable in H-CMSCs and GDM-CMSCs. Between 45 to 90 minutes, ROS level showed significantly higher rates of increase in GDM-CMSCs than H-CMSCs. Notably, H-CMSCs did not produce increased amounts of ROS after 90 minutes and showed slightly reduced ROS generation whereas ROS level in GDM-CMSCs continued to increase and remained elevated from 90 minutes to the end of measured period (Figure 5-19B).
Figure 5-19. Detection of ROS production by DCFDA

(A) ROS production was detected by DCFDA staining (green). Representative fluorescent images were shown from 5 H-CMSCs (Healthy03-07) and 5 G-CMSCs (GDM04-08) samples at different time point and imaged by confocal microscopy. Scale bar, 100 μm. H2O2-treated H-/G- CMSCs were used as positive controls (B) Time-course measurement of ROS levels was determined by fluorescent intensity reading via a plate reader at the wavelengths of Ex/Em = 485/535 nm. The initial fluorescence intensity at 0 min was set at 100%. Data are given as mean ± SEM from at least 6 samples in each group. Statistical significance was determined by one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001
To further elucidate the role of ALDH activity and ROS regulation, the enzymatic function of ALDHs was suppressed by 100 μM of N, N-diethylaminobenzaldehyde (DEAB), a commonly used selective inhibitor of ALDHs. H-CMSCs and GDM-CMSCs were incubated with DEAB for 48 hours and ALDH activity was examined. In the presence of DEAB (ALDH inhibitor) the ALDH activity was significantly suppressed in both H-CMSCs and GDM-CMSCs (Figure 5-20A). Moreover, when the ALDH function was suppressed, the ROS production was significantly increased during glucose-induced metabolic process (Figure 5-20B). DEAB pre-treated H-/GDM- CMSCs produced higher levels of ROS than un-treated H-/GDM- CMSCs. This finding suggested the strong association between the ALDH function and cellular ROS regulation.

Low levels of ROS are detectable in many metabolic processes; however, when ROS production is in excess of the cellular antioxidant capacity, it contributes to cellular damage. This can include DNA, protein, and lipid disruption. In GDM-CMSCs, downregulation of Nrf2-mediated oxidative stress regulation pathway and the impaired function of detoxifying enzymes ALDHs, suggests insufficient capacity to adapt to increased oxidative stress.
Figure 5-20. Inhibition of ALDH function by DEAB
5 H-CMSCs (Healthy03-07) and 5 G-CMSCs (GDM04-08) samples were pre-incubated with 100 mM DEAB for 48 hours. (A) ALDH enzymatic function was detected by ALDH activity colorimetric assay measuring the absorbance at 450 nm. (B) ROS generation was detected by DCFDA and the increasing level was determined by fluorescent intensity reading at the wavelengths of Ex/Em = 485/535 nm. The initial fluorescence intensity at 0 min was set at 100%. Data are given as mean ± SEM. Statistical significance was determined by one-way ANOVA, ***p < 0.001
5.5 Discussion

Overrepresented and underrepresented biological functions in GDM-CMSCs

Microarray revealed that GDM had a number of upregulated genes involved in cell motility, cytoskeleton organization, survival, and together with epithelial development and skin formation. The ability of transplanted cells to mobilise and migrate to injury sites enables them to mediate tissue repair and regeneration\textsuperscript{449}. According to IPA pathway analysis, the upregulation of Rho family GTPase signalling in GDM-CMSCs modulating actin cytoskeletal rearrangement is one of the fundamental migratory pathways\textsuperscript{450}. Recently, a study showed that high glucose promoted human umbilical cord-derived MSCs migration ability and increased migration of transplanted MSCs into wound area in \textit{in vivo} mouse models through the suppression of adhesion molecule, E-cadherin\textsuperscript{451}. Hyperglycaemia induced human induced pluripotent stem cells to express cytoskeleton remodelling regulators and enhanced their migration\textsuperscript{452}. Human umbilical endothelial cells isolated from GDM compared to healthy pregnancies showed increased migration ability although enhanced motility could be reflecting a proangiogenic state of GDM\textsuperscript{453}.

By contrast, the opposite findings such as reduced wound closure ability in perivascular stem cells from GDM women\textsuperscript{454} and impaired migration in GDM umbilical cord-derived endothelial cells were also reported\textsuperscript{455}. The controversial effects of GDM on cell motility may due to different cell sources; for instance, in chapter 3 we demonstrated opposite growth patterns of GDM-AMSCs and GDM-CMSCs compared to their healthy counterparts. Although CMSCs and AMSCs were grown in the same GDM condition, they could show different response to the same environmental factor and have different biological characteristics. Likewise, GDM environment may have different impacts on migration
ability in different placenta-associated cell types. Our results based on microarray analysis of CMSCs demonstrated that AQP1, FLNB, CELSR1, and CD24 playing important roles in cell movement and cytoskeletal remodelling were significantly upregulated in GDM-CMSCs. The finding was further verified by migration assays to confirm the enhanced motility of GDM-CMSCs.

Despite of migration to the wound area, the ability of MSCs to differentiate and promote regeneration accelerates wound repair processes. Several studies have indicated that the multi-lineage differentiation potential of perinatal tissue-derived MSCs enable them to develop into epithelium and promote skin regeneration. Dehydrated placental membranes (amnion and chorion) have been used as skin substitute for burned and ulcerated surfaces for many years. Nowadays, cryopreservation technology is able to maintain the structural and cellular integrity of placental membranes and retain endogenous amniotic and chorionic MSCs vitalisation. The presence of MSCs in cryopreserved placental membranes improved wound-healing therapies.

Microarray analysis identified increased skin regeneration potential in GDM-CMSCs characterised by the upregulation of epithelial development associated genes and regulators (EDN1, KRT14, HBEGF, TGFB2). The in vitro wound healing assays and activation of growth factors signalling (Wnt/β-catenin, BMP) may also contribute to enhanced capacity of GDM-CMSCs in wound repair. In line with a microarray study of BM-MSCs, the expression of genes associated with wound healing was upregulated in BM-MSCs from type 1 diabetes patients although the enhanced wound closure was not observed in their in vitro results.

In addition, activation of growth factors pathways, including Wnt/β-catenin, BMP, FGF, and STAT3 was also positively associated with cardiogenesis in GDM-CMSCs and significant
upregulation of heart development-related genes (NKX2.5, NOG, PDGFA). However, the increased activation of Wnt/β-catenin pathway may be associated with metformin treatment or the activation of insulin signal. One of Wnt pathway effectors is insulin/insulin-like growth factor receptor-dependent activation, which induces phosphorylation of various kinase protein in Wnt pathway\textsuperscript{464}. Metformin were also reported to mediate Wnt/β-catenin signalling in hepatic cells and intestinal cells\textsuperscript{465, 466}. FGF family proteins are involved in the regulation of energy metabolism and hyperglycaemic condition\textsuperscript{467}. FGF-2 was significantly upregulated in diabetic nephropathy and high glucose environment increased FGF-2 mRNA as well as protein synthesis and secretion in human renal fibroblasts\textsuperscript{468}. Thus, the enhanced activation of FGF pathway in G-CMSCs might also reflect the metabolic disorder condition in GDM women.

Cardiovascular development was the most enriched function in GDM-CMSCs; however, the downregulation of angiogenic factors (RASIP1, CXCL12, RSPO3) and angiogenesis inducing pathways (IL-6, IL-8) resulted in reduced vasculogenesis and angiogenesis potential in GDM-CMSCs. The reduced expression of angiogenesis-related genes in GDM-CMSCs might suggest that CMSCs did not contribute to frequently observed hypervascularisation in GDM placentas\textsuperscript{77}. The vasculogenesis and angiogenesis in placenta are regulated by placental endothelial cells which are derived from mesoderm during embryogenesis\textsuperscript{469} while CMSCs arise from extraembryonic tissues. Different origins of placental CMSCs and endothelial cells may result in different biological properties and responses under hyperglycaemic environment. High glucose environment induced endothelial cell dysfunctions leading to abnormal angiogenesis in diabetes patients\textsuperscript{470, 471}. However, enhanced angiogenesis was not found in CMSCs isolated from GDM women. In contrast, G-CMSCs showed reduced potential in angiogenesis. Our findings indicated that G-CMSCs were not directly involved in hyperglycaemia-induced angiogenesis. In line with
a recent study on placental chorionic villi-derived MSCs, the decreased tube formation ability and downregulation of VEGF were observed in GDM vs. healthy pregnancies.\(^{472}\)

**ALDHs activity and ROS regulation**

Pathways associated with several degradation processes were altered in GDM-CMSCs due to the significantly reduced ALDHs expression. As a critical detoxification enzyme, ALDH is highly expressed in various embryonic tissues, stem cells, progenitor cells\(^ {473, 474}\) and protect them against oxidative damages by detoxifying exogenous and endogenous aldehyde.\(^ {475}\) ALDH was also used as an indicator for purifying proangiogenic BM-MSC subset with an enhanced secretory function for vascular regeneration.\(^ {476}\) However, the role of ALDHs in GDM placenta-derived MSCs has yet to be examined. Significantly reduced ALDH family genes in GDM-CMSCs revealed by our microarray data emphasises the impact of pregnancy complication on cellular detoxification. GDM-CMSCs showed significantly lower ALDHs enzymatic activity than H-CMSCs and insufficient capacity to manage increased oxidative stress induced by environmental stimulation with glucose.

The hyperglycaemic environment in GDM pregnancies tends to induce elevated ROS production and oxidative stress.\(^ {477}\) Although ROS can be induced by various molecules undergoing metabolic activities, glucose uptake is one of the major processes that stimulates instant ROS generation.\(^ {478, 479}\) In diabetes patients, hyperglycaemic condition led to ROS imbalance and resulted in ROS-induced cellular damage and cell death.\(^ {480}\) We demonstrated that glucose induced instant ROS production in both H-CMSCs and G-CMSCs whereas the reduction of ROS levels in H-CMSCs after 1.5 hours was not seen in G-CMSCs. It suggested that G-CMSCs showed less capability of adapting to the instant increase in
ROS production than H-CMSCs.

In addition, impaired ALDH activity may exacerbate oxidative stress levels through causing ROS imbalance\textsuperscript{481}. Some studies have reported an association between impaired ALDH function and oxidative stress production. For instance, inhibition of \textit{ALDH1A1} in human lens epithelial cells caused increased oxidative stress and induced mitochondrial damages\textsuperscript{482}. In an \textit{in vivo} study, \textit{ALDH2}-deficient mice showed increased ROS production and enhanced oxidative stress leading to cardiovascular complications\textsuperscript{483}. We found higher levels of ROS was induced in GDM-CMSCs vs. H-CMSCs upon glucose stimulation and increased ROS levels in GDM-CMSCs showed no sign of reduction in our observation period. It is likely that improving ALDH function may enhance detoxification, reduce ROS formation, and therefore protect GDM-CMSCs from oxidative cell damage\textsuperscript{484, 485}. A recent study showed that treating decidual MSCs derived from preeclampsia women with \textit{ALDH1A1} activator restored \textit{ALDH1A1} activity and improved resistance to H$_2$O$_2$-induced oxidative stress in preeclampsia-derived MSCs\textsuperscript{486}. Physiologically harmful environment of oxidative stress in GDM can be improved by antioxidants intake\textsuperscript{487, 488}; however, restoring ALDH function in GDM women might be another therapeutic option and fundamentally improve biological properties of GDM-CMSCs.
5.6 Summary

DNA microarray data provides an understanding of gene profile and biological functions altered in GDM-CMSCs which offers a valuable resource to the regenerative medicine development. To conclude from our findings, the uterine environment during pregnancy could impact on the stem cell biology derived from perinatal tissues. Enhanced migration ability of GDM-CMSCs may have clinical benefits for promoting systemically infused MSCs to migrate to the injured sites. However, detoxification enzyme ALDHs were significantly reduced in GDM-CMSCs leading to downregulation of several degradation pathways. Decreased ALDH activity in GDM-CMSCs was also associated with impaired ability to respond to oxidative stress with the evidence of elevated ROS production after glucose stimulation. The information based on microarray can be useful for exploring suitable clinical use of CMSCs from GDM and healthy pregnancies.

<table>
<thead>
<tr>
<th>Advantages of G-CMSCs vs H-CMSCs</th>
<th>Disadvantages of G-CMSCs vs H-CMSCs</th>
</tr>
</thead>
<tbody>
<tr>
<td>a) Enhanced migration ability with increased cytoskeleton organisation gene expression</td>
<td>a) Reduced proliferation and colony formation ability</td>
</tr>
<tr>
<td>b) Potential in promoting wound healing with skin formation and epithelium development</td>
<td>b) Low expression in vasculogenesis-associated genes</td>
</tr>
<tr>
<td>c) Increased cardiogenesis-associated gene expression</td>
<td>c) Impaired ALDH enzymatic function</td>
</tr>
<tr>
<td>d) Increased activity in growth factor pathway - BMP, Wnt/β-catenin, and FGF pathways</td>
<td>d) Poor response to glucose-induced ROS</td>
</tr>
</tbody>
</table>
Chapter 6

Discussion, Conclusion and Future Work
6.1 Summative discussion and conclusion

6.1.1 Human placenta – an attractive source of MSCs

Regenerative medicine based on MSCs is aimed at enhancing tissue regeneration, restoring and maintaining the normal function of tissues or organs and also intended to assist in the treatment of many life-threatening or chronic, lifelong disease. Although bone marrow MSCs are the most popular and widely studied MSCs for many years, concerns about BM-MSCs such as decreased numbers and stemness with donor’s age, invasive isolation procedure, and allogeneic transplant rejection have encouraged researchers to explore new sources of MSCs. Nowadays, stem cells have been found in various adult tissues, neonatal-related tissues, and also induced pluripotent stem cells.

Placenta, developing during pregnancy and playing a pivotal role in embryogenesis, contains plentiful undifferentiated stem cells. As being a part of extra-embryonic tissues without the need for invasive procedures during cell extraction or ethical concerns, placenta has many advantages for MSCs therapy. The opportunity of storing perinatal stem cell in biobanks, including cord blood stem cells and placental stem cells, makes them rapidly available and become promising autologous sources for clinical applications.

There is no doubt that placental MSCs hold a great therapeutic potential; however, these MSCs emerge during pregnancies and only accessible postpartum whether biological properties of placental MSCs altered by pregnancy complications is unclear. Little is known about the effects of GDM on placenta-derived amniotic and chorionic MSCs.

In this study, cells were isolated from human placentas. To confirm their MSCs phenotype, firstly, cells derived from amniotic and chorionic membrane displayed attached fibroblast-
like morphology, which is normally observed in MSCs culture. Secondly, cells were
examined for surface markers expression by flow cytometry to meet the minimal
definition criteria for MSCs according to the International Society for Cellular Therapy.\footnote{109}
H-/G- CMSCs/AMSCs showed positive expression of CD73, CD90, CD105 and lacked the
expression of CD14, CD19, CD34, CD45 and HLA-DR. Thirdly, these cells demonstrated
differentiation ability towards mesenchymal lineage, such as osteogenesis, adipogenesis,
and chondrogenesis.

Characterisation of CMSCs and AMSCs from GDM and healthy placentas demonstrated
significantly fundamental differences between CMSCs and AMSCs and evidenced the
altered proliferative, adipogenic, immunomodulatory potential in CMSCs/AMSCs derived
from GDM placentas. CMSCs and AMSCs were isolated from different layers of placental
membrane - chorion and amnion. Two layers are connected together acting as a protective
barrier during fetal development and MSCs derived from both chorion and amnion are
thought to have the same origin; however, they were found displaying distinct
characteristics in our study. CMSCs showed enhanced proliferation and tri-lineage
differentiation potential compared with AMSCs regardless of deriving from GDM or
healthy placenta. Secretome of both CMSCs and AMSCs displayed immunomodulatory
capacity in regulating T-cell proliferation and macrophage polarisation but more profound
effects were found in CMSCs.

GDM is a temporary condition that usually disappears after pregnancy but it has long-term
impacts on maternal health and fetal development. Embryonic stem cells and MSCs
emerging during pregnancies are likely to be compromised by pregnancy complications.
We found that GDM had distinct effect on CMSCs and AMSCs, for instance, altered
proliferation ability was found in G-CMSCs and G-AMSCs vs. their healthy counterparts
while GDM affected CMSCs and AMSCs proliferation in an opposite manner. Likewise, adipogenic potential showed significantly enhanced in GDM-CMSC but not in GDM-AMSCs. Some studies have also demonstrated the influence of GDM on umbilical cord cell. Umbilical vein endothelial cells (HUVECs) and Wharton’s jelly derived MSCs (WJ-MSCs) from GDM pregnancies showed decreased glucose uptake and mitochondrial oxygen consumption, increased generation of ROS, reflecting a metabolic disorder state in GDM women. These alterations might be associated with endothelial dysfunction leading to adverse vascular functions in infants. A study indicated that mitochondrial transcription and biogenesis gene expressions were altered in GDM-WJ-MSCs which contributed to impaired mitochondrial functions and may play a role in impaired insulin release and glucose sensitivity.

Umbilical cord MSCs (UC-MSCs) isolated from obese pregnancies demonstrated greater adipogenesis tendency and less potential for myogenesis through the regulation of Wnt/glycogen synthase kinase (GSK)-3β/β-catenin pathway. In correspondence to the clinical finding that fetuses development in obese women have higher infant adiposity. In chapter 3, we also found that CMSCs derived from GDM placenta showed enhanced adipogenic commitment with higher basal level of adipogenic-related gene expression and more responsive to the stimulation of adipogenesis differentiation media leading to enhanced adipocytes generation. Obese and GDM pregnancies have similar intrauterine environment - high levels of glucose and placental hormones, and this environment is usually found to have increased amount of adipocytes. One of the hormones shows significantly increased in many obese and GDM pregnancies is insulin, which is a common inducer for adipogenesis used in differentiation media. High glucose condition was also reported to induce adipocyte-associated gene expression, such as proliferators activated receptor gamma (PPARγ), lipoprotein lipase (LPL), and adiponectin, and might
be a potent inducer for adipogenic commitment\textsuperscript{506, 507}.

Immunosuppressive capacity of MSCs contributes to significant therapeutic outcomes of cell therapy. Little is known about the effects of GDM environment on immunomodulatory ability in either placenta-derived MSCs or umbilical cord-derived MSCs. A study examining UC-MSCs from obese/diabetic women indicated that the expression of genes involved in MSCs immunomodulatory ability, such as HLA-G was detected at passaged 2 and reduced in subsequent passages while the reduction was not observed in healthy UC-MSCs. However, except for HLA-G gene examination by PCR, there was insufficient evidence of the altered immunomodulatory function in MSCs derived from obese/diabetic samples\textsuperscript{508}. Therefore, our study investigated the immunomodulation in both H-MSCs and GDM-MSCs through secretome regulation on T-cell proliferation and activation as well as macrophage polarisation by co-culture system. The findings suggested that GDM- and H- CMSCs provided an equivalent immunoregulatory effect on T-cells while GDM-CMSCs had a reduced effect on macrophage regulation. However, both H- and GDM- CMSCs displayed a superior immunomodulatory capacity in regulation of both T-cells and macrophages than AMSCs.

Although some degrees of alterations were observed in GDM-CMSCs/AMSCs, the differentiation potential (osteogenesis, chondrogenesis), immunophenotype, and immunosuppressive ability were not significantly hampered by GDM environment. Most of the characteristics of GDM-CMSCs investigated in chapter 3 were comparable with H-CMSCs and same as GDM-AMSCs vs. H-AMSCs.

6.1.2 IPC generation – an application of autologous MSCs for diabetes therapy

Women with GDM during pregnancy carry a lifetime risk of developing type 2 diabetes of
up to 50-60%\textsuperscript{509}. Infants born to GDM pregnancy are also at risk of type 2 diabetes in early adulthood. Exploring the regenerative potential of placental MSCs from GDM women provides a promising possibility of using autologous MSCs in future diabetes therapy. Differentiating autologous stem cells \textit{in vitro} and then transplanting to the patients themselves eliminates the complications of graft rejection or requirements of immune suppression regimen in transplantation\textsuperscript{510}. A clinical study of diabetic patients on insulin injection receiving autologous bone-marrow stem cells transplantation showed an improvement of more than 50% reduction in insulin requirement\textsuperscript{511}. However, in that study, the cell population used was a mixture of bone marrow HSCs and MSCs, and there was no complete follow-up study or the understanding of regulatory functions of transplanted cells in disease management. On the other hand, BM-MSCs from diabetic patients were generally thought to have been influenced under a prolonged diabetic environment. In diabetic mice models, a reduction in the numbers of endogenous BM-MSCs, impaired proliferation, survival, differentiation ability of BM-MSCs were reported\textsuperscript{512,513}.

BM-MSCs from diabetic patients may be significantly influenced by prolonged exposure to hyperglycaemic and inflammatory environment for several years, while placental MSCs only emerge during pregnancy and could be more pluripotent than BM-MSCs. GDM environment affects some biological properties of CMSCs/AMSCs but does not entirely hamper their differentiation capacities. Through characterisation in chapter 3, we evidenced that GDM-CMSCs and AMSCs were able to demonstrate their stem cell functions via differentiation and immunomodulation; thus we sought to further investigate their therapeutic potential in diabetes cell therapy.

MSCs are known to have potential in pancreatic islets regeneration and insulin resistance
amelioration\textsuperscript{202}; however, transplanted MSCs were not found to spontaneously convert to beta-cells or secrete insulin\textsuperscript{514-516}. There are also some concerns regarding teratoma formation and the promotion of tumour growth by transplanting undifferentiated MSCs\textsuperscript{517-519}. Therefore, generating insulin-producing cells (IPCs) or engineered islet-like clusters from MSCs, progenitor cells, or genetically modified cells have offered an alternative approach for diabetes therapy. In order to induce IPC generation from MSCs, several growth factors and small molecules were used to mimic beta-cell development environment, while cell responses to these stimulations varies in different tissue-derived MSCs.

We optimised a feasible approach for generating IPC from GDM-CMSCs and H-CMSCs with the ability to respond to glucose challenge and secrete insulin. GDM-CMSCs and H-CMSCs derived IPCs were functionally indistinguishable with similar morphology, comparable levels of beta-cell markers expression, and insulin secretion ability. However, IPCs differentiation method for GDM- and Healthy- AMSCs requires further optimisation. Although our study identified betacellulin as a potent inducer for insulin expression in AMSCs, insulin secretion function was not therefore improved. Insulin secretion is regulated by several internal or external factors, including insulin synthesis, insulin exocytosis, glucose sensing, functional structure formation, and environmental stimulation\textsuperscript{520-522}. The insufficient insulin secretion of AMSC-IPCs in our study requires further investigation. Overall, our findings conclude that for the efficiency of autologous therapies for GDM women, endogenous CMSCs is a potential therapeutic target which could be clinically applicable to diabetes treatment in the future.

While the advances of generating mature and glucose responsive IPCs from stem cells have brought a new strategy for diabetes treatment, the application in clinical practice
remains challenging. By stimulating with various compounds to induce IPC differentiation, the effective concentrations are inconsistent in different studies even though some studies used the same MSC source. Identifying specific cell surface markers for each stage of beta-cell regeneration may improve current IPC generation protocols. Additionally, the intensively laboratory process of IPC production has reduced the willingness of investments in clinical research. Moreover, although research has showed that MSC-generated IPCs were able to secrete adequate amount of insulin in preclinical models, scientists are still struggling to find well-defined and reproducible condition of MSC-derived IPCs and mass production of mature beta-cells to meet clinical needs. In present study, we evaluated the potential of using autologous CMSCs from GDM women for clinical application to diabetes treatment in the future. The IPC differentiation approach can be successfully applied to both H-CMSCs and GDM-CMSCs; however, differentiation method for AMSCs requires further optimisation and the long-term outcomes of using autologous MSC-derived IPCs needs to be investigated.

### 6.1.3 Microarray – insights of gene profile to functional molecular levels

Microarray technology allows scientists to study expression levels of a large number of genes at the same time. The large amount of data provided by microarrays requires computational analysis through bioinformatics approaches to explore biological meaningful hypothesis. We performed DNA microarray to further understand the characteristics of H-CMSCs and GDM-CMSCs. However, the limitation in present study was low sample sizes. In microarray data, gene profiles of 3 GDM-CMSCS samples showed variable expression with certain degrees of variability between each other while 3 H-CMSCS samples were relatively consistent. The scatter plot shown in Figure 6-1 demonstrated the relationship of expression patterns and variability in two experiments.
Gene with similar expression levels in two samples appeared a smooth linear curve while a non-linear indicates variation between two samples. An ideal experimental group with low variation should have a linear curve in the comparison of two independent samples within the same group. In Figure 6, three H-CMSCs samples showed high level of similarity while three G-CMSCs samples demonstrated some degrees of variation. Given that three G-CMSCs samples were collected from women received different treatments, it could have impact on their gene expression patterns and cause the variation. It is likely that increasing GDM sample sizes and analysing gene expression patterns based on different GDM treatments would provide more information regarding GDM-CMSCs transcriptional profile and reduce the variations.

**Figure 6-1. Scatter plot matrix of microarray data**
(A) Three GDM-CMSCs (GDM06, 07, 08) and (B) three H-CMSCs (H03, 07, 08) used for microarray experiment. A scatter plot is used to examine each microarray chip that has unusual/similar expression patterns compared to other microarray chips during fluorescent intensity detection. It can be used to visualise variations in gene expression between two arrays. Gene with similar expression levels in two samples appeared a smooth linear curve. In contrast, a non-linear curve indicates variations between two samples. The X and Y axes are the normalised intensity for the samples (log2 scaled), normalised to RNA control (poly A+ RNA with Spike-IN, Figure 5-1) and experimental control (healthy group), respectively.
Importantly, we validated gene expression by real-time PCR with 10 healthy and 11 GDM samples in order to verify the microarray results. The PCR is commonly used for microarray validation but some non-agreeing results of microarray and real-time PCR has been discussed, such as the difference in expression fold changes. In our study, although expression fold changes of some validated genes were found to have different expression levels between microarray and real-time PCR results, the up- or down- regulated states were all in agreement with microarray data.

To gain insight into the biological characteristics of GDM-CMSCs, co-upregulated and co-downregulated genes in all 3 GDM samples were identified and used for biological functions and pathways analysis. Furthermore, gene regulatory networks reveal the alterations in a set of genes and pathways that regulate biological processes instead of simple activation or inhibition of a single gene or signaling. Following microarray analysis with IPA software, functional assays confirmed the overrepresented or underrepresented biological functions in GDM-CMSCs, including enhanced cell migration and spreading ability but an impairment in ALDHs enzymatic function and ROS regulation. The validation and investigation of the most represented biological functions in GDM-CMSCs was discussed in chapter 5 while the information obtained from microarray data may also be useful in many other aspects. Microarray results, containing the expression of thousands of genes, can be used to study the drug target for GDM, association between GDM and the risk of type 2 diabetes, gene correlation with GDM progression, as well as transcriptional signature of GDM-CMSCs. For instance, *PTAFR* (platelet activating factor receptor), *CMYA5* (cardiomyopathy associated 5), and *CCR7* (C-C Motif chemokine receptor 7) were detected in H-CMSCs but absent in GDM-CMSCs while *PROM2* (prominin 2) and *GDF6* (growth differentiation factor 6) were only detectable in GDM-CMSCs. The presence or absence of these genes could be meaningful in some
biological properties of H-CMSCs and GDM-CMSCs. Undoubtedly, there is still a lot remained to be explored in our microarray data.

The main aim of this study is to determine the potential of GDM-MSCs in regenerative medicine. Through characterisation in chapter 3, we investigated stem cells properties and showed that both Healthy- and GDM- CMSCs/AMSCs were able to grow, proliferate, differentiate, and regulate immune cells in vitro. Moreover, GDM-CMSCs could be successfully differentiated into IPCs and display comparable functions with H-CMSCs derived IPCs, suggesting a promising potential for diabetes therapy in the future. Through microarray transcriptional profiling and bioinformatics, we were able to identify the enhanced and impaired biological functions in GDM-CMSCs based on their genome profile and this information would be valuable for developing potential application of GDM-MSCs in clinical practice.

The increasing incidence of metabolic diseases during pregnancy affects the physiology of several maternal and fetal organ developments\textsuperscript{531}. Maternal nutrients and metabolic activities significantly link to fetal programming and the later development of metabolic disorders in mothers and their children\textsuperscript{532, 533}. GDM environment affected the epigenetic signature of cord blood\textsuperscript{534} and newborns exposed to GDM were more likely to have epigenetic differences in metabolic pathways\textsuperscript{535}. We demonstrated that biological properties of CMSCs/AMSCs were altered in GDM pregnancy, including the increased adipogenic potential, immature senescence under high glucose culture, decreased metabolic enzyme (ALDHs) activities, and down regulation in metabolic pathways activation. These findings reflect the influence of GDM on cell biological properties and the altered features in GDM-CMSCs/AMSCs might be associated with the long-term risk of type 2 diabetes development. For instance, increased adipocyte formation and
accumulation were found in many obese diabetes patients; senescence-associated secretory phenotypes (SASP) that secreted proinflammatory cytokines and exacerbated insulin resistance were frequently seen in type 2 diabetes patients. The study of GDM-CMSCs/AMSCs would provide further understanding of the fetal and maternal metabolic disorder development.

The findings in our study were obtained by using H-CMSCs, H-AMSCs, G-CMSCs, and G-AMSCs as a single experimental group. However, the individual differences within each group may cause variabilities in some results. For example, the severity of GDM and different treatment methods may have direct impact on biological characteristics in individual samples. At this stage, we were unable to collect more GDM placentas for further analysis, but in future study, treatment methods and blood glucose levels of each patient should be taken into account. Increasing sample size and experimental groups such as high-BMI GDM, low-BMI GDM, metformin-treated GDM, or insulin-treated GDM would reduce variabilities and provide further understating about GDM-MSCs.
6.2 Future work

Our study has raised a number of considerations for future work. First, as autologous cell transplant is aimed at personalised medicine, variation in individual donor condition correlating to the CMSCs/AMSCs differentiation and characterisation result should be taken into account. For future study of GDM-MSCs, considering the individual differences during analysis, including glycaemic control and medical condition in each patient would provide more detailed understanding of GDM-MSC biological properties.

In this study, all gene expressions were examined by SYBR-Green based real-time PCR, which is a highly specific, double-stranded DNA binding dye. However, genes with low expression levels are difficult to be detected by SYBR-Green dye and the small gene copy variations between samples are likely to be neglected. Thus, future study using TaqMan-based PCR via a fluorogenic probe will allow the detection of small gene copy variations and provide more accurate gene expression results than SYBR-Green based method.

To apply autologous MSC-generated IPCs in clinical practice the safety and efficacy of these IPCs for cell therapy need to be investigated. By using in vivo models, it would provide further understanding of the maturity, function, and survival of IPCs in a physically relevant situation. Although some functional features of IPCs were similar to beta-cells, the comprehensive comparison would require, such as the amount of insulin release and cell behaviours between lab-grown IPCs and mature beta-cells in human body. More importantly, whether islet-like clusters generated in our protocol are pure beta-cells or composed of heterogeneous population remains unknown.

Microarray data also raises some questions and opportunities for future study. The pathways analysis revealed the upregulation of several growth factors pathways (BMP,
Wnt, FGF). Although these pathways have critical roles in regulating cardiac regeneration, they are also involved in many cellular functions. The exact relationship of upregulated pathways and cardiogenesis potential in GDM-CMSCs requires further elucidation. The potential of GDM-CMSCs in wound healing was identified by IPA analysis and the expression of genes associated with healing process as well as migration ability were validated through in vitro assays. However, wound healing assay is a simple experiment but the wound repair process is complicated. In vivo models would provide more convincing evidence for wound healing studies. In addition, there are many freely available and commercial platforms for microarray data processing. In present study, IPA software (Qiagen) was used to perform biological functions and pathways analysis based on Ingenuity Knowledge Base (Qiagen), while with other bioinformatics software based on different database, it might provide some undiscovered findings in our microarray data. However, IPA is a powerful software for microarray analysis that can also be used to predict upstream regulators, biomarkers, comparison and interaction networks which have not yet been discovered with our GDM and healthy CMSCs microarray data.
Chapter 7

References


36. Daly, B, Toulis, KA, Thomas, N, Gokhale, K, Martin, J, Webber, J, *et al.* (2018). Increased risk of ischemic heart disease, hypertension, and


77. Huynh, J, Dawson, D, Roberts, D, and Bentley-Lewis, R (2015). A


102. Prusa, AR, and Hengstschlager, M (2002). Amniotic fluid cells and


125. Jones, GN, Moschidou, D, Puga-Iglesias, TI, Kuleszewicz, K, Vanleene,


229. Riss, TL, Moravec, RA, Niles, AL, Duellman, S, Benink, HA, Worzella, TJ,


trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev 17: 929-940.


287. Glennie, S, Soeiro, I, Dyson, PJ, Lam, EWF, and Dazzi, F (2005). Bone marrow mesenchymal stem cells induce division arrest anergy of


298. Spaggiari, GM, Abdelrazik, H, Becchetti, F, and Moretta, L (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-


endoderm from human embryonic stem cells only when phosphatidylinositol 3-kinase signaling is suppressed. Stem Cells 25: 29-38.


cells obtained from murine bone marrow. *Diabetes* **53**: 1721-1732.


368. Komatsu, M, Sato, Y, Yamada, S, Yamauchi, K, Hashizume, K, and Aizawa, T (2002). Triggering of insulin release by a combination of cAMP signal...


380. Oh, SH, Muzzonigro, TM, Bae, SH, LaPlante, JM, Hatch, HM, and


401. Oliver-Krasinski, JM, Kasner, MT, Yang, J, Crutchlow, MF, Rustgi, AK, Kaestner, KH, et al. (2009). The diabetes gene Pdx1 regulates the


8.
484. Lappas, M, Hiden, U, Desoye, G, Froehlich, J, Hauguel-de Mouzon, S,


Qi, H, Yang, YL, Xie, HB, Zhou, HX, Deng, CY, and Li, FR (2011). Teratoma
Derived From Bone Marrow Mesenchymal Stem Cells in a Diabetic Microenvironment. *Pancreas* **40**: 981-983.


524. Dayan, N (2014). Making insulin producing beta cells from stem cells-how close are we?


532. Godfrey, KM (2002). The role of the placenta in fetal programming-a


Appendix – Ethical approval

University Hospitals of North Midlands NHS Trust

RESEARCH AND DEVELOPMENT DEPARTMENT
Academic Research Unit
Courtyard Annexe – C Block
Newcastle Road
Stoke-on-Trent
ST4 6QG
Telephone: 01782 675387
Fax: 01782 675399
Email: Darren.Clement@uhnhs.nhs.uk
research.governance@uhnhs.nhs.uk

Ref: DC/CR

26th June 2016

Dr Pensee Wu
Consultant in Maternal Foetal Medicine
University Hospitals of North Midlands NHS Trust
Maternity Department
The Royal Stoke University Hospital
Newcastle Road
Stoke-on-Trent
ST4 6QG

Dear Dr Wu

Re: PERsonalised approach to FEtal stem Cell bank Use – do pregnancy complications affect stem cell behaviour for autologous use? – PERFEC-U
Chief Investigator: Dr Pensee Wu
Sponsor/Co-Sponsor: University Hospitals of North Midlands NHS Trust
SSI Submission Date: 17/03/2016

I can confirm that the above project has been given NHS Permission for Research by the Research & Development Department for the University Hospitals of North Midlands NHS Trust and the details entered on to the R&D database.

I note that this research project has been approved by West Midlands – Solihull
Research Ethics Committee reference: 15/WM/0342

NHS permission for the above research has been granted on the basis described in the application form, protocol and supporting documentation. The documents reviewed were:

<table>
<thead>
<tr>
<th>Document</th>
<th>Version Number</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol</td>
<td>2.1</td>
<td>03/03/16</td>
</tr>
<tr>
<td>PIS (C)</td>
<td>1.1</td>
<td>15/12/15</td>
</tr>
<tr>
<td>PIS (G)</td>
<td>1.1</td>
<td>15/12/15</td>
</tr>
<tr>
<td>PIS (P)</td>
<td>1.1</td>
<td>15/12/15</td>
</tr>
<tr>
<td>Consent Form (C)</td>
<td>1.1</td>
<td>15/12/15</td>
</tr>
<tr>
<td>Consent Form (G)</td>
<td>1.1</td>
<td>15/12/15</td>
</tr>
</tbody>
</table>

R&D ID: 1126 UKCRN ID: n/a CSP ID: n/a REC REF: 15/WM/0342
The research sponsor or the Chief Investigator, or the local Principal Investigator at a research site, may take appropriate urgent safety measures in order to protect research participants against any immediate hazard to their health or safety. The R&D office should be notified that such measures have been taken. The notification should also include the reasons why the measures were taken and the plan for further action. The R&D office should be notified within the same time frame of notifying the REC and any other regulatory bodies.

Approval by the R&D Dept therefore assumes that you have read, understand and agree to comply with the:

- Data Protection Act
- Health and Safety Act
- ICH Guidelines on good clinical practice
- All applicable Trust policies & procedures

In line with these requirements may I draw your attention to the need for you to provide the following documentation/notifications to the R&D Department throughout the course of the study and that all amendments (including changes to the local research team) need to be submitted to R&D in accordance with guidance in IRAS:-

- Annual Progress Report Form (sent to you by this department)
- End of Study Declaration Form (available on IRAS website)
- Changes to study start and end dates
- Changes in study personnel

Please note that the NHS organisation is required to monitor research to ensure compliance with the Research Governance Framework and other legal and regulatory requirements. This will be achieved by random audit by our department.

I would like to take this opportunity to wish you well with your research. If you need any further advice or guidance please do not hesitate to contact us.

Yours sincerely

Dr Darren Clement
R&D Manager – University Hospitals of North Midlands NHS Trust

Cc  Fidelma O’Mahony – Clinical Director Maternity, UHNM
Darren Clement – Guy Hilton Research Centre, UHNM
Li-Yun Chen – Student Researcher, Keele University
Zara Richards – Postgraduate Research Administrator, Keele University
Jill Stacey – Professional Head for Research Nursing, UHNM
Helen Grocott – Information Governance Manager, UHNM
Laura Longshaw – R&D Auditor & Monitor, UHNM
Dawn Sirdefield – R&D Auditor & Monitor, UHNM

R&D ID: 1125  UKCRN ID: n/a  CSP ID: n/a  REC REF: 16WM/0542